6㧚 ⎇ⓥᵴേާಽሶ࡮᭴ㅧቇ⻠ᐳި
㧔1㧕⚦⢩ᖱႎቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ၮ␆කቇ♽ߪੱຬ߇㒢ࠄࠇߡ޿ࠆߚ߼ߦ㧘⣖␹⚻ᄖ⑼ቇ㧘⣲≌ᄖ⑼ቇߥߤߩ⥃ᐥಽ㊁߆ࠄੱ⊛ᡰេࠍฃߌߥ߇ࠄ㧘⎇ⓥࠍ⛯ߌߡ߈ߚ‫⚦ޕ‬⢩ౝᖱႎવ㆐㧘ߥ߆ߢ߽⚦⢩ߩ↢ߣᱫߩ೙ᓮࡔࠞ࠾࠭ࡓࠍਥߚࠆ࠹࡯ࡑ
ߣߒߡ⎇ⓥࠍⴕߞߡ߈ߚ‫⎇ޕ‬ⓥኻ⽎ߣߒߡߪਥߣߒߡ␹⚻♽㧘ⴊ▤♽㧘߇ࠎࠍᛒߞߡ޿ࠆ‫⚦ࠎ߇ޕ‬⢩ߢߪࠕࡐ࠻࡯ࠪࠬࠍല₸ࠃߊ⺃ዉߔࠆߎߣ߇㧘৻ᣇ⣖᪪Ⴇߥߤߩ⯯ⴊㇱ૏ߢߪࠕࡐ࠻࡯ࠪࠬࠍᛥ೙ߔࠆߎߣ߇
੍㒐߿ᴦ≮ߦߟߥ߇ࠆ‫ߚ߹ޕ‬㧘ⴊ▤ߐࠄߦ⚵❱ౣ↢ߦߟ޿ߡߩ⎇ⓥ߽ㅴⴕਛߢ޽ࠆ‫ޕ‬⣖᪪Ⴇᓟߩ⚵❱㓚ኂߩシᷫ㧘߅ࠃ߮ⴊ▤࡮␹⚻⚵❱ౣ↢ߩ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘േ⣂⎬ൻߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮ߦࠃࠆⴊ▤ౝ⊹⚦⢩ߩ㓚ኂࡔࠞ࠾࠭ࡓߣߘߩ੍㒐ߦߟ޿ߡ߽㧘৻ቯߩᚑᨐࠍ਄ߍߡ޿ࠆ‫⚵࡮ེ⤳ߩߡߴߔߪ▤ⴊޕ‬❱߇ᚑ┙ߔࠆߚ߼ߩ㊀ⷐߥၮᧄන૏ߢ޽ࠅ㧘ࡐࠬ࠻ࠥࡁࡓᤨઍߩ㊀ⷐߥ⎇ⓥ࠹࡯ࡑߩ߭ߣߟߢ޽ࠆ‫ޕ‬࿖┙ᚑ⢒ක≮࠮ࡦ࠲࡯ߣߩ౒ห⎇ⓥߢ㧘ⴊ▤ߩ⊒↢࡮ౣ↢ߦ㊀ⷐߥㆮવሶࠍหቯߒߡ߅ࠅ㧘⹦⚦ߥᯏ⢻⸃ᨆࠍⴕߞߡ޿ࠆ‫ߦࠄߐޕ‬㧘߽߁৻ߟߩ⣂▤♽ߢ޽ࠆ࡝ࡦࡄ▤ߩ⊒↢㧘ౣ↢ᯏ᭴ߦߟ޿ߡ߽⎇ⓥࠍ㐿ᆎߒߚ‫ޕ‬
2㧚ฬ★
ਛፉ ⨃
ᢎ᝼㧦
ಎᢎ᝼㧦 ဈ㊁༑ሶᨋ⌀৻㇢ഥᢎ㧦

Shigeru Nakashima
Yoshiko Banno
Shin-ichiro Hayashi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਛፉ ⨃. ᄢፉᵏ㇢, ㋈ᧁ⚔৻, ⣄ጊᵗฝ, ᣂ੗ᵗ↱, ⍹ᶆ┨৻, ᄢ㓈⦟ౖ, ጯᧄஜ㓶, ᱜᧁᤐᒾ, ጊᧄ৻ᄦ✬㧚↢ൻቇ੐ౖ ╙ 4 , ᧲੩㧦᧲੩ൻቇหੱ㧧2007 ᐕ㧚
2㧕 ᨋ⌀৻㇢, ศ᧛⚩৻㧚᫪ਅ┥৻✬. ⯯ⴊᕈ⣖ⴊ▤∔ᖚߩౣ↢ᴦ≮㧔⚦⢩ᴦ≮㧕㧦ⴊ▤ߩౣ↢̅ⴊ▤ౣ↢කቇߩᄛ᣿ߌгㄭߠߊታ↪ൻг, ᧲੩㧦⌀⥝੤ᤃ㧔ᩣ㧕කᦠ಴ ㇱ㧧 2008 ᐕ㧦155㧙161㧚
3㧕 ਛፉ ⨃, ጟ㊁ᐘ㓶㧚৻ἑ⊕Ꮲ, ㋈ᧁብᴦ✬. ⚦⢩ౝࠪࠣ࠽࡞વ㆐ᯏ᭴㧦࿑⺑ಽሶ∛ᘒቇ ╙㧠 , ᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦46㧙49㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Yamada Y, Banno Y, Yoshida H, Kikuchi R, Akao Y, Murate T, Nozawa Y. Catalytic inactivation ofhuman phospholipase D2 by a naturally occurring Gly901Asp mutation. Arch Med Res.
2006;37:696-699.
2㧕 Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y. High expressionof sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and theircamptothecin-induced up-regulation. Biochem Biophys Res Commun. 2006;342:1284-1290.
3㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K, Fan DG, Ohno T, Miyazawa K, Liu N, Shimizu
K. -Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Biophys Res Commun. 2006;343:937-942.
4㧕 Ohguchi K, Banno Y, Akao Y, Nozawa Y. Involvement of phospholipase D1 in collagen type I
production of human dermal fibroblasts. Biochem Biophys Res Commun. 2006;348:1398-1402.
5㧕 Akutagawa A, Fukami K, Banno Y, Takenawa T, Kannagi R, Yokoyama Y, Oda K, Nagino M, Nimura Y,
Yoshida S, Tamiya-Koizumi, K. Disruption of phospholipase CG4 gene modulates the liver㧙㧙

IF 1.772

IF 2.749

IF 2.749
IF 2.749

regeneration in cooperation with nuclear protein kinase C. J Biochem. 2006;140:619-625.
6㧕 Raymond MN, Bole-Feysot F, Banno Y, Tanfin Z, Robin P. Endothelin-1 inhibits apoptosis through asphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology.
2006;147:5873-5882.
7㧕 Sobue S, Iwasaki T, Sugisaki C, Nagata A, Kikuchi R, Murakami M, Takagi A, Kojima T, Banno Y,
Akao Y, Nozawa Y, Kannagi R, Suzuki M, Abe A, Naoe T, Murate T. Quantitative RT-PCR analysis ofsphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leuchemia.
2006;20:2042-2046.
8㧕 Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator ofosteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 2006;25:5840-5851.
9㧕 Masuda H, Kalka C, Takahashi T, Yoshida M, Wada M, Kobori M, Itoh R, Iwaguro H, Eguchi M, Iwami
Y, Tanaka R, Nakagawa Y, Sugimoto A, Ninomiya S, Hayashi S, Kato S, Asahara T. Estrogen-mediatedendothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. Circ Res.
2007;101:598-606.
10㧕 You F, Osawa Y, Hayashi S, Nakashima S. Immediate early gene IEX-1 induces astrocytic
differentiation of U87-MG human glioma cells. J Cell Biochem. 2007;100:256-265.
11㧕 Leiber D, Banno Y, Tanfin Z. Exogenous sphingosine-1 phosphate and sphingosine kinase activated byendothelin-1 induced myometrial contraction through differential mechanisms. Am J Physiol Cell
Physiol. 2007;292:C240-C250.
12㧕 Jung ID, Lee JS, Kim YJ, Jeong YI, Lee CM, Baumruker T, Billlich A, Banno Y, Lee MG, Ahn SC, Park
WS, Han J, Park YM. Sphingosine kinase inhibitor suppresses a Th1 polarization via the inhibition of
immunostimulatory activity in murine bone marrow-derived dendritic cells. Int Immunol.
2007;19:411-426.
13㧕 Mizoguchi H, Yamada K, Niwa M, Mouri A, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y,
Nabeshima T. Reduction of methamphetamine-induced sensitization and reward in matrix
metalloproteinase-2 and -9 deficient mice. J Neurochem. 2007;100:1579-1588.
14㧕 Kikuchi R, Murakami M, Sobue S, Iwasaki T, Hagiwara K, Takagi A, Kojima T, Asano H, Suzuki M,
Banno Y, Nozawa Y, Murate T. Ewing’s sarcoma fusion protein, EWS/Fli-1and Fli-1 protein induce
PLD-2 but not PLD-1 gene expression by binding to an ETS domain of 5’ promoter. Oncogene
2007;26:1802-1810.
15㧕 Kikuchi R, Sobue S, Murakami M, Ito H, Kimura A, Iwasaki T, Shibayama S, Takagi A, Kojima T,
Suzuki M, Banno Y, Nozawa Y, Murrate T. The regulatory mechanism of Vitamine D3 induced increaseof PLD1 transcription of a human keratinocyte cell line, HaCaT. FEBS Lett. 2007;581:1800-1804.
16㧕 Mizoguchi H, Yamada K, Mouri A, Niwa M, Mizuno T, Noda Y, Nitta A, Itohara S, Banno Y,
Nabeshima T. Role of matrix metalloproteinase and tissue inhibitor of MMP in
methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor
down-regulation and dopamine release. J Neurochem. 2007;102:1548-1560.
17㧕 Murakami M, Ichihara M, Sobue S, Kikuchi R, Ito H, Kimura A, Iwasaki T, Takagi A, Kojima T,
Takahashi M, Suzuki M, Banno Y, Nozawa Y, Murate T. RET signaling-induced SPHK1 gene
expression plays a role in both GDNF-induced differentiation and MEN2-type oncogenesis. J
Neurochem. 2007;102:1585-1594.
18㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 downregulates
TNF-D-induced production of matrix metalloproteinase-1 in HCS-2/8 chondrocytes by inhibiting
Raf-1/MEK/ERK cascade through EP4 prostanoid receptor activation. J Cell Biochem.
2007;100:783-793.
19㧕 Yamashita K, Kotani Y, Nakajima Y, Shimozawa M, Yoshimura S, Nakashima S, Iwama T, Hara H.
Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitoro and invivo by acting directly on neurons. Brain Res. 2007;1154:215-224.
20㧕 Banno Y, Nemoto S, Murakami M, Kimura M, Ueno, Y, Ohguchi K, Hara A, Okano Y, Kitade Y, Onozuka
M, Murate T, Nozawa Y. Depolarization-induced differentiation of PC12 cells is mediated byphospholipase D2 through the transcription factor CREB pathway. J Neurochem. 2008;104:1372-1386.
21㧕 Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T,
Nakamura M, Ito Y, Suzuki M, Banno Y, Nozawa Y, Murate T. Implications of sphingosine kinase 1
expression level for the cellular sphingolipid rheostat -Relevance as a marker for daunorubicin
sensitivity of leukemia cells. Int J Hematol. 2008;87:266-275.
22㧕 Sobue S, Murakami M, Banno Y, Ito Y, Kimura A, Furuhata A, Gao S, Takagi A, Kojima T, Suzuki M,
Akao Y, Nozawa Y, Murate T. V-src oncogene increases sphingosine kinase 1 expression through its
mRNA stabilization -Alteration of AU-rich element binding proteins. Oncogene. 2008;27:6023-6033.
23㧕 Niinomi K, Banno Y, Iida H, Dohi S. Nicorandil, an adenosine triphosphate-sensitive potassiumchannel opener, inhibits muscarinic acetylcholine receptor-mediated activation of extracellularsignal-regulated kinases in PC12 cells. Anesth Analg. 2008;107:1892-1898.
24㧕 Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, Yoshimura S, Nakashima S, Kunisada T, Iwama T.
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.

㧙㧙

IF 2.020

IF 5.045

IF 6.612
IF 8.662

IF 9.721
IF 3.409

IF 4.230

IF 3.290

IF 4.451

IF 6.440

IF 3.263

IF 4.451

IF 4.451

IF 3.409

IF 2.212

IF 4.451

IF 1.491

IF 6.440

IF 2.214J Biol Chem. 2008;283:10958-10966.

IF 5.581

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠬࡈࠖࡦࠧ⢽⾰ઍ⻢㉂⚛ߦࠃࠆ⚦⢩Ⴧᱺ࡮↢ሽߩ೙ᓮᯏ᭴⸃᣿㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,600 ජ౞(2,000㧦1,600 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ᧃ᪳ⴊ▤ౝ⊹․⇣⊒⃻࿃ሶߩหቯ߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 17 ᐕᐲ㧧1,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᬢ 㚊⪇㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࡅ࠻ࠣ࡝ࠝ࡯ࡑ⚦⢩ߩᱫߣಽൻߩࠬࠗ࠶࠴ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 17 ᐕᐲ㧧500 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧧ⴊ▤ౝ⊹೨㚟⚦⢩ߩേ㕒⣂ⴊ▤߳ߩಽൻ೙ᓮ
߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧔ಽ㊁ࠍߎ߃ߚ౒ห⎇ⓥ㧕㧧⣖⯯ⴊߣ␹⚻ᄌᕈ∔ᖚߩᣂߒ޿ᴦ≮ᴺߩ㐿⊒ߦะߌߚၮ␆⎇ⓥ㧔⣖⯯ⴊߦ߅ߌࠆ⚵❱ᐙ⚦⢩ߩಽൻ೙ᓮࠍ੺ߒߚ␹⚻ⴊ▤ୃᓳᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ᬢ 㚊⪇㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࠟࡦ⚦⢩ߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬߣࠝ࡯࠻ࡈࠔࠫ࡯ߩࡃ࡜ࡦࠬ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦೨ፉ㓷⟤㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧧ࠟࡦ⚦⢩ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯⺃ዉߣࠪࠣ࠽࡞વ㆐ᯏ᭴㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦ⴊ▤␹⚻૞േ EphrinB ࡝ࠟࡦ࠼ࠍ೑↪ߒߚࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ∛ᘒ⸃᣿߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦᧛ᚻ㓉 (ฬฎደᄢቇකቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ᖡᕈ⣲≌, ␹⚻ᄌᕈ∔ᖚߢߩࠬࡈࠖࡦࠧࠪࡦࠠ࠽࡯࠯ߩ⊒⃻⇣Ᏹߩ⸃ᨆߣ∛ᘒߢߩᗧ⟵㧧ᐔᚑ 18㧙
19 ᐕᐲ㧧4,050 ජ౞(2,200㧦1,850 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ဈ㊁༑ሶ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦᛫≸೷⠴ᕈߩ↢ℂᵴᕈ⢽⾰ߦࠃࠆ⺞▵ᯏ᭴ߣࠤࡕ࠹࡜ࡇ࡯ߦ߅ߌࠆᜰᮡߩ⏕┙㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ਛፉ ⨃㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧦⢽⢌⚵❱↱᧪㑆⪲♽ᐙ⚦⢩ߣ␹⚻ᩕ㙃࿃ሶࠍ↪޿ߚᣂߒ޿␹⚻∔ᖚᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧100 ජ౞12㧕 ⎇ⓥઍ⴫⠪㧦਄↰ ᶈ (ጘ㒂ᄢቇᎿቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ᣂⷙEJଐሽᕈ RhoGEF ߣ⋧੕૞↪ߔࠆ↢૕ಽሶߩหቯߣߘߩ↢ℂᯏ⢻ߩ⸃᣿㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
4,200 ජ౞(1,400㧦1,400㧦1,400 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦਄↰ ᶈ (ጘ㒂ᄢቇᎿቇㇱ), ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ⎇ⓥ‫ޟ‬G࠲ࡦࡄࠢ⾰‫ޠ‬㧦ੑߟߩ G ࠨࠗࠢ࡞ࠍ⚿߱ᣂⷙਃ㊂૕ G Ⱞ⊕⾰ࠪࠣ࠽࡞ଐሽᕈ RhoGEF ⟲ߩᯏ⢻⸃ᨆ㧧
ᐔᚑ 20㧙21 ᐕᐲ㧧5,200 ජ౞(2,600㧦2,600 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛శᶈ㧔ጘ㒂⮎⑼ᄢቇ㧕, ⎇ⓥಽᜂ⠪㧦ဈ㊁༑ሶ㧧⑼ቇᛛⴚᝄ⥝ᯏ᭴ࠪ࡯࠭⊒ជ⹜㛎⎇ⓥ㧦⢽⾰ࡔ࠲ࡏࡠࡒ࠶ࠢࠬߦࠃࠆൻቇ≮ᴺࡃࠗࠝࡑ࡯ࠞ࡯ߩᬌ⚝ߣᬌ⸽㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞
15㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦ⴊ▤␹⚻૞േ EphrinB ࡝ࠟࡦ࠼ࠍ೑↪ߒߚࠕ࡞࠷ࡂࠗࡑ࡯∛ߩ∛ᘒ⸃᣿߅ࠃ߮ᴦ≮ᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,060 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ:ᶖൻེ⣲≌ߦ߅ߌࠆ࡝ࡦࡄ▤ᣂ↢ߩࡔࠞ࠾࠭ࡓ⸃᣿߅ࠃ߮࡝ࡦࡄ▤ࠍ࠲࡯ࠥ࠶࠻ߣߒߚᴦ≮ᔕ↪㧧ᐔᚑ 20
ᐕᐲ㧧500 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ᳰ੉↱㚅, ಽᜂ⠪㧦ᨋ⌀৻㇢㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ߩ⎇ⓥᵴᕈൻ㧔ක㧕ߩߚ߼ߩᡰេ੐ᬺ㧦ANGPT1 ߣ⚵❱ᐙ⚦⢩ࠍ೑↪ߒߚ⯯ⴊᕈ⣖ⴊ▤∔ᖚߦኻߔࠆᣂߒ޿ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᨋ⌀৻㇢㧘ਛፉ⨃㧦ⴊ▤ౝ⊹ౣ↢ߦ߅ߌࠆ PDE3 㒖ኂ೷㧔ࠪࡠࠬ࠲࠱࡯࡞㧕ߩᓎഀ㧧ᐔᚑ 19 ᐕᐲ㧧
1,000 ජ౞㧦ᄢႦ⵾⮎㧔ᩣ㧕
2㧕 ဈ㊁༑ሶ㧦⊹⤏߅ࠃ߮⊹⤏⚦⢩ߩ࠮࡜ࡒ࠼േᘒߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧500 ජ౞㧦ࠦ࡯࠮࡯㧔ᩣ㧕㧙㧙

5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᨋ⌀৻㇢㧦Alzheimer ∛㑐ㅪ࠲ࡦࡄࠢ, Amyloid-E (AE-40)ߩⴊ▤ౣ↢㒖ኂ૞↪㧧࿖㓙౏㐿⇟ภ
㧔WO2006/05977㧕
6㧚ቇળᵴേ
1㧕ቇળᓎຬਛፉ ⨃㧦
1㧕 ᣣᧄ↢ൻቇળ⹏⼏ຬ࡮ෳਈ(㨪⃻࿷)2㧕 ᣣᧄ↢ൻቇળ ක⑼↢ൻቇ࡮ಽሶ↢‛ቇᢎ⢒ද⼏ળᆔຬ(㨪ᐔᚑ 19 ᐕ 8 ᦬)
3㧕 ╙ 20 ࿁࿖㓙↢ൻቇ࡮ಽሶ↢‛ቇળ⼏⊓㍳ផㅴᆔຬળᆔຬ(㨪ᐔᚑ 18 ᐕ 6 ᦬)
ဈ㊁༑ሶ㧦1㧕 ᣣᧄ↢ൻቇળਛㇱᡰㇱᐙ੐(ᐔᚑ 18 ᐕ 9 ᦬㨪ᐔᚑ 20 ᐕ 8 ᦬)
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਛፉ ⨃㧦
1㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬, ጘ㒂, ᐳ㐳)2㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 1 ᦬, ጘ㒂, ᐳ㐳)3㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬, ጘ㒂, ᐳ㐳)4㧕 ጘ㒂㜞ⴊ࿶∝ᴦ≮࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬, ጘ㒂, ᐳ㐳)ဈ㊁༑ሶ㧦
1㧕 ╙㧝࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬, ☨ሶ, Ṷ⠪)2㧕 ╙ 2 ࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 19 ᐕ 5 ᦬, ☨ሶ, Ṷ⠪)
3㧕 ╙ 3 ࿁ࠬࡈࠖࡦࠧ࠹࡜ࡇ࡯(STC)⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬, ☨ሶ, Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേਛፉ ⨃㧦
1㧕 TIMA Foundation (Liechtenstein)

Adviser (㨪⃻࿷)ဈ㊁༑ሶ㧦
1㧕 ᣣᧄቇⴚᝄ⥝⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ)ᨋ ⌀৻㇢㧦1㧕 ᣣᧄ૕⢒දળࠬࡐ࡯࠷࠼ࠢ࠲࡯(౓ᐶᡰㇱ)(ᐔᚑ 19 ᐕ 10 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ဈ㊁༑ሶ㧦ࠬࡈࠖࡦࠧ⢽⾰ઍ⻢㉂⚛ߦࠃࠆ⚦⢩Ⴧᱺ࡮↢ሽߩ೙ᓮᯏ᭴ߩ⸃᣿㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕ
ᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 5 ᦬)
11㧚ႎ㆏
ဈ㊁༑ሶ㧦
1㧕 ⚦⢩ߩ↢ᱫ⺞▵ᯏ᭴ࠍតࠆ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 13 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥߦߟ޿ߡߪ೙㒢ߐࠇߚࡑࡦࡄࡢ࡯߿੍▚ߩਛߢ㊂ࠃࠅ߽⾰ߦߎߛࠊࠅ㧘߈ߜࠎߣ⹏ଔߐࠇࠆ⎇ⓥ
ࠍ⋡ᜰߒߡ߈ߚ‫߁߽ޕ‬ዋߒߢ⊒⴫ߢ߈ࠆ⎇ⓥᚑᨐ߽ᄙᢙ᦭ࠅ㧘৻ቯߩᚑᨐࠍ਄ߍࠆߎߣ߇ߢ߈ߚߣᕁ߁‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ၮ␆♽ಽ㊁౒ㅢߩ໧㗴ߢ޽ࠆᄢቇ㒮↢ߩ⏕଻ߪ㧘ೋᦼ⎇ୃߩ⟵ോൻߩታᣉߦࠃࠅ߹ߔ߹ߔ࿎㔍ߣߥߞߚ‫ୃ⎇ޕ‬කߩᄢㇺᏒ㓸ਛߪᣣᧄో૕ߩ໧㗴ߢ߽޽ࠆ߇㧘ᣧᕆߥኻ╷߇ߥߐࠇߥߌࠇ߫㧘ᣧ᥅㧘࿾ᣇߩක≮૕೙㧘߭޿ߡߪ࿾ᣇᄢቇߩၮ␆කቇ⎇ⓥߪੱ᧚⊛ߦ፣უߩෂᯏࠍㄫ߃ࠆߢ޽ࠈ߁‫ޕ‬ಽ㊁୘‫ߩޘ‬ദജߣߒߡ㧘ቇ↢߳ߩ௛߈߆ߌߩᒝൻߣ㧘⥃ᐥಽ㊁ߣߩ౒ห⎇ⓥ߇੹ᓟ߹ߔ߹ߔ㊀ⷐߦߥࠆߣᕁࠊࠇࠆ‫⊒ޕ‬ᗐߩᨵエߥ⧯ᚻ⎇ⓥ⠪ࠍ⏕଻ߔࠆᗧ๧ߢ߽㧘৻ಽ㊁ߩ⺖㗴ߢߥߊකቇ⎇ⓥ⑼ో૕ߢᣧᕆߦขࠅ⚵߻ߴ߈໧㗴ߢ޽ࠅ㧘ࠬࠞ࡜࡯ࠪ࠶ࡊߩഃ⸳ߪ㜞ߊ⹏ଔߢ߈ࠆ‫ߪࠄ߆ࠇߎޕ‬ฦಽ㊁߇੹એ਄ߦ⎇ⓥᬺ❣ࠍౝᄖߦࠕ
ࡇ࡯࡞ߒ㧘ቇ↢㆐ߦ⎇ⓥߩ㊀ⷐᕈ߿߅߽ߒࠈߐࠍ໪⫥ߒߡ޿ߊߎߣ߇㊀ⷐߦߥࠆߢ޽ࠈ߁‫ޕ‬කቇ⎇ⓥ⑼ో૕ߢߩ⎇ⓥ૕೙ߩᣧᕆߥౣᬌ⸛߇ᦸ߹ࠇࠆ‫ޕ‬ቇㇱቇ↢ࠍߺߡ޿ࠆߣ㧘ℂ♽ߦ߽߆߆ࠊࠄߕታ㛎߿⎇ⓥߦ⥝๧ࠍ␜ߐߥ޿߽ߩ߇ᕆჇߒߡ޿ࠆࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬ീᒝળࠍડ↹ߒߡ߽ෳട⠪߇㓸߹ࠄߥ޿ߒ㧘ቇᬺᚑ❣ߣߒߡ⹏ଔߐࠇࠆߎߣએᄖߦߪ૛ࠅ⥝๧ࠍ␜ߐߕ㧘ᄞߣ߆Ꮧᦸߣ޿߁⸒⪲߇ᗵߓࠄࠇߥ޿ቇ↢߇ᕆჇߒߡ޿ࠆࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬ᄢቇ౉ቇએ೨ߩኅᐸ޽ࠆ޿ߪቇᩞᢎ⢒ࠍ߈ߜࠎߣ⷗⋥ߒߡ޿߆ߥߌࠇ߫㧘කቇㇱ౉ቇቯຬࠍ޿ߊࠄჇ߿ߒߡ߽㧘ᧄᒰߦ₂り⊛ߥ௛߈ࠍߒߡߊࠇࠆකᏧࠍ⢒ߡࠆߩߪ૛ࠅᦼᓙߢ߈
ߥ޿ߩߢߪߥ޿߆ߣ޿߁ෂᯏᗵࠍᒝߊᗵߓߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⚦⢩ߩ↢ߣᱫߩ೙ᓮᯏ᭴߅ࠃ߮⚦⢩ߩಽൻࡔࠞ࠾࠭ࡓߩ⸃᣿ߪ㧘߇ࠎߩᴦ≮߿⚵❱ߩᒻᚑ࡮ౣ↢ߩၮ␆ߣߥࠅᓧࠆ⎇ⓥߢ޽ࠆ‫ߚ߹ޕ‬㧘ⴊ▤ߪ⤳ེ࡮⚵❱ߩ⛽ᜬߦᰳ߆ߖߥ޿㊀ⷐߥⷐ⚛ߢ޽ࠅ㧘ߘߩᒻᚑ࡮
ౣ↢ߪ↢૕ߩᯏ⢻⛽ᜬߦ⋥⚿ߒߡ޿ࠆ‫ߩߎޕ‬ਔ⎇ⓥ࠹࡯ࡑߪߔߴߡߩ⥃ᐥಽ㊁ߦ߽౒ㅢߒߚ໧㗴ߢ޽ࠅ㧘੹ᓟᧄቇ⥃ᐥ♽ಽ㊁ࠍߪߓ߼ߣߔࠆ౒ห⎇ⓥᯏ㑐ߣߩㅪ៤ࠍࠃࠅ৻ጀᷓ߼ߡ㧘ߎࠇࠄߩ⎇ⓥࠍߐࠄߦㅴ
߼ߡ޿߈ߚ޿ߣ⠨߃ߡ޿ࠆ‫⎇ߩࠄࠇߎޕ‬ⓥߩߐࠄߥࠆ⊒ዷࠍ߼ߑߒ㧘ක≮ᔕ↪ߩၮ␆⎇ⓥߣߥࠆߎߣࠍ
⋡ᮡߣߒߚ޿‫ޕ‬㧙㧙㧔2㧕ಽሶ↢ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
1㧕Ⱞ⊕⾰ߩ㜞ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ‛ℂൻቇ⊛⎇ⓥࡐࠬ࠻ࠥࡁࡓߦ⛯ߊ⎇ⓥ㗔ၞߪ‫ᤨߩ⾰⊕Ⱞޟ‬ઍ‫߇ࠆ޿ߡࠇࠊ⸒߽ߣޠ‬㧘ㆮવᖱႎߩ⠡⸶ߦࠃߞߡⰮ⊕⾰߇↢วᚑߐࠇߡߘߩᯏ⢻ࠍ⊒ើߔࠆ߹ߢߦ㧘Ⱞ⊕⾰ߪ㜞ᰴ᭴ㅧࠍᒻᚑߒߚᓟߦߐ߹ߑ߹ߥ⠡⸶ᓟୃ㘼
㧔post translational modification㧕ࠍฃߌࠆ‫ޕ‬ᢙ޽ࠆⰮ⊕⾰ߩਛߢࠕ࡞ࡉࡒࡦಽሶࠍ଀ߦߒߡ㧘ߐ߹ߑ߹ߥ⠡⸶ᓟୃ㘼߇ࠕ࡞ࡉࡒࡦߩ↢ℂᯏ⢻㧘ߚߣ߃߫࡝ࠟࡦ࠼⚿ว⢻ߥߤߦߤߩࠃ߁ߥᓇ㗀ࠍ෸߷ߔ߆ߣ޿
ߞߚ⎇ⓥࠍⴕ޿㧘∔ᖚߣߩ㑐ㅪᕈߦߟ޿ߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬2㧕Ⱞ⊕⾰࡮ࡍࡊ࠴࠼ߩ⇣Ᏹಝ㓸૕ᒻᚑߩಽሶࡔࠞ࠾࠭ࡓ
Ⱞ⊕⾰ߩ┙૕᭴ㅧ㧔ࠦࡦࡈࠜࡔ࡯࡚ࠪࡦ㧕⇣Ᏹߦ⿠࿃ߔࠆ∔ᖚߣߒߡ㧘ࠕ࡞࠷ࡂࠗࡑ࡯∛߿ࡊ࡝ࠝࡦ∛߇ᵈ⋡ߐࠇߡ޿ࠆ‫․ߩߘޕ‬ᓽߣߒߡ㧘․ቯߩⰮ⊕⾰߇㐳޿ᤨ㑆߆߆ߞߡ⇣Ᏹߥಝ㓸૕ࠍᒻᚑߒߡ⚵❱ౝߦᴉ⌕ߒ㧘ᱜᏱ⚦⢩ߩᯏ⢻⇣Ᏹࠍ߈ߚߔߩߢ㧘ߎࠇࠄߩ∔ᖚࠍ✚⒓ߒߡ‫ߣޠ∛ࡦ࡚ࠪ࡯ࡔࠜࡈࡦࠦޟ‬๭ࠎߢ޿ࠆ‫ޕ‬਄⸥㧔1㧕ߩ⎇ⓥߦ㑐ㅪߒߡ㧘ߤߩࠃ߁ߥṁᇦ᧦ઙਅߢⰮ⊕⾰ߩ⇣Ᏹߥಝ㓸૕߇⊒↢ߔࠆ߆㧘޽ࠆ޿ߪಝ㓸૕⊒↢ࠍ㒐ߋߦߪߤߩࠃ߁ߦߒߚࠄࠃ޿߆㧘੹ᓟ‫∔ޟ‬ᖚ㑐ㅪⰮ⊕⾰‫ࠍޠ‬ኻ⽎ߣߒߡ⎇ⓥࠍㅴ߼ࠆ੍ቯ
ߢ޽ࠆ‫ޕ‬
3㧕↢૕ౝ㉄ൻࠬ࠻࡟ࠬߣ࡟࠼࠶ࠢࠬᔕ╵↢૕ߪߐ߹ߑ߹ߥᄖㇱⅣႺⷐ࿃ߦࠃߞߡߐ߹ߑ߹ߥࠬ࠻࡟ࠬࠍฃኈߒߡ޿ࠆ‫㉄ߦߊߣޕ‬ൻࠬ࠻࡟ࠬߪ⠧ൻ߿≸ൻߦኒធߦ㑐ㅪߒߡ޿ࠆ‫ޕ‬ⴊᷡࠕ࡞ࡉࡒࡦߪ↢૕ౝߢ߽ߞߣ߽ᄙ㊂ߦሽ࿷ߔࠆ໑৻ߩ SH ၮ฽᦭Ⱞ⊕⾰ߢ㧘⚦⢩ᄖ㉄ൻㆶర✭ⴣᯏ⢻ࠍ᦭ߒߡ޿ࠆ‫⚦ޕ‬⢩ᄖᶧ㧘ߣߊߦᓸዊⓨ㑆ౝߦሽ࿷ߔࠆࠕ࡞ࡉࡒࡦߩ㉄ൻㆶర⁁ᘒࠍ᷹ቯߔࠆߎߣߦࠃ
ߞߡ㧘୘૕ో૕ߣߒߡߩ࡟࠼࠶ࠢࠬᔕ╵ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬4㧕Ⱞ⊕⾰ߣ᳓ಽሶ㑆⋧੕૞↪ߩಽሶࡔࠞ࠾࠭ࡓ
᳓ߪ↢૕ߩ⚂ 60㧑ࠍභ߼ࠆಽሶ㓸࿅ߢ㧘ߐ߹ߑ߹ߥ↢૕㜞ಽሶߦߘߩᵴേߩ႐ࠍឭଏߒߡ޿ࠆ‫ޕ‬NMR
ߣ޿߁⎇ⓥᚻᲑߦࠃߞߡ㧘Ⱞ⊕⾰๟ㄝߩ᳓ಽሶ㓸࿅ߩേ⊛᜼േ㧘ߔߥࠊߜⰮ⊕⾰̆᳓ಽሶ㑆⋧੕૞↪߇ᬌ಴ߐࠇ㧘ᧄ⎇ⓥ⺖㗴ߪ޽ࠄߚߦ‫ޟ‬ಽሶ࡮⚦⢩ࠗࡔ࡯ࠫࡦࠣᴺ‫ߩ┙⏕ޠ‬ၮ␆ߣߥࠅᓧࠆน⢻ᕈ߇ត⚝ߐࠇߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦

ᕺ⦟⡛৻
ኹ↰⍮ᣂ
᧛ጊᐘ৻

Seiichi Era
Tomoyoshi Terada
Koichi Murayama

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᕺ⦟⡛৻㧚ᣣᧄ↢ℂቇળᢎ⢒ᆔຬળ✬, CBT Ḱ᜚ MCQ ߦࠃࠆ↢ℂቇ໧㗴㓸㧚᧲੩㧦ᢥశၴ㧧2006 ᐕ.
2㧕 ᕺ⦟⡛৻㧚ⴊᷡ࠲ࡦࡄࠢ⾰㧔ⴊᷡࠕ࡞ࡉࡒࡦߩࠢ࡜ࠬ࠲࡯ᒻᚑ㧕㧚ᣣᧄ࡟ࠝࡠࠫ࡯ቇળ✬, ࡟ࠝࡠࠫ࡯࠺࡯
࠲ࡂࡦ࠼ࡉ࠶ࠢ, ᧲੩㧦ਣༀ㧧2006 ᐕ㧦392㧙394㧚
3㧕 ㋈ᧁ␽ผ㧘᧻ጊᐘᨑ㧘ᕺ⦟⡛৻㧘೽ፉᤘౖ㧚⣢ᯏ⢻ૐਅߦࠃࠆⴊẏ albumin ߩㆶర₸ߩૐਅ—⛽ᜬㅘᨆ଀ߣߩᲧセ㧦㕍ᩉ৻ᱜ㧘⪉↰ ᣿ ⋙ୃ㧚⣢ߣࡈ࡝࡯࡜ࠫࠞ࡞ ╙ 9 㓸㧘᧲੩㧦᧲੩ᢎቇ␠㧧2008 ᐕ㧦149
㧙153.
4㧕 ኹ⣁ඳਯ㧘ਛጊ᣽᣿㧘᧻ጊᐘᨑ㧘ችỈ♿ሶ㧘ਛጊᕺテ㧘⚦⼱㦖㓶㧘ᕺ⦟⡛৻㧘દ⮮⽵ཅ㧚ᘟᕈ⣢ਇోᖚ⠪ߦ߅ߌࠆ㉄ൻࠬ࠻࡟ࠬ㧦ࠕ࡞ࡉࡒࡦ㉄ൻㆶరᲧࠍᜰᮡߣߒߚᬌ⸛㧦㕍ᩉ৻ᱜ㧘⪉↰ ᣿ ⋙ୃ㧚⣢ߣࡈ࡝࡯࡜ࠫࠞ࡞ ╙ 9 㓸㧘᧲੩㧦᧲੩ᢎቇ␠㧧2008 ᐕ㧦154㧙158.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᦥᚒ⟤ ൎ, ᕺ⦟⡛৻, ᐔ᧻ብ৻, ᧛਄᡽㓉, ἑየ⧐ノ, ട⮮৻ᄦ, ⮮ᧄ ቞㧚↢ℂ⃻⽎ߣ㜞ಽሶឃ㒰૕Ⓧല
ᨐ㧔excluded volume effect㧕㧙㜞ಽሶᵴ㊂ଥᢙ㧔Σ㧕ᣣᧄ↢ℂቇ㔀⹹ 2006 ᐕ㧧68 Ꮞ㧦4㧙14㧚
2㧕 ᦥᚒ⟤ ൎ, ᕺ⦟⡛৻, ᐔ᧻ብ৻, ᧛਄᡽㓉, ἑየ⧐ノ, ട⮮৻ᄦ, ⮮ᧄ ቞㧚↢ℂ⃻⽎ߣ㜞ಽሶឃ㒰૕Ⓧല
ᨐ㧔excluded volume effect㧕㧙㜞ಽሶᵴ㊂ଥᢙ㧔Τ㧕ᣣᧄ↢ℂቇ㔀⹹ 2006 ᐕ㧧68 Ꮞ㧦47㧙57㧚
3㧕 ᕺ⦟⡛৻㧚ฦ⒳∔ᖚߦ߅ߌࠆ㉄ൻဳ࡮ㆶరဳࠕ࡞ࡉࡒࡦߩᄌേ㧔․㓸—ⴊᷡࠕ࡞ࡉࡒࡦࠍᎼࠆᦨㄭߩ⹤㗴㧕㧘ᩕ㙃⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦139㧙143㧚㧙㧙4㧕 ᕺ⦟⡛৻㧚↢૕♽ߩ᳓ߩ✭๺ᤨ㑆㧙㜞ಽሶሽ࿷ਅߢߩ✭๺㧘ᣣ⏛ක⹹ 2008 ᐕ㧧28 Ꮞ㧦1㧙9㧚
5㧕 ኹਅᢘᰴ㇢, ᧛ጊᐘᏒ, ਭ↰ᶈผ, ⪭ว๟ศ㧚ㄭ⿒ᄖൻቇࠗࡔ࡯ࠫࡦࠣᴺ߅ࠃ߮࡟࡯ࠩ࡯ࡉ࡟࡯ࠢ࠳࠙ࡦಽ
శᴺߦࠃࠆ㍤೷᭴ᚑ☸ሶߩಽᢔᕈ⹏ଔ㧘ࡈࠔ࡯ࡓ࠹࠶ࠢࠫࡖࡄࡦ 2008 ᐕ㧧24 Ꮞ㧦1587㧙1595㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ੹੗ ৻㧘ᕺ⦟⡛৻㧘ᴡᧄᢅ᣿㧚೶㆏ᒝൻวኋߦ߅ߌࠆᾫᚑ໊ㄆሶ៨ขߩᓇ㗀㧘ᢎ⢒කቇ 2007 ᐕ㧧53
Ꮞ㧦40㧙41㧚
2㧕 ㋈ᧁ␽ผ㧘㕍ᧁఝሶ㧘᧻ጊᐘᨑ㧘㐳⼱Ꮉ ᒄ㧘◉ේ૫ᒾ㧘ᯅᧄ㓉↵㧘ᕺ⦟⡛৻㧘೽ፉᤘౖ㧚⣢ᯏ⢻㓚ኂߦࠃࠆⴊẏࠕ࡞ࡉࡒࡦߩㆶరൻ₸ߩૐਅߣߘߩᯏᐨ଻ሽᦼ⣢ਇో଀ߣ⛽ᜬⴊᶧㅘᨆ଀ߩᲧセ㧘ᣣ⣢ળ⹹
2008 ᐕ 50 Ꮞ㧦513㧙520㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Suda K, Kato J, Nozawa M, Komabayashi T, Imai H, Era S. ANP content in rat myocardium during
and after swimming. Adv Exerc Sports Physiol. 2006;12:121-125.
2㧕 Negawa T, Murayama K, Ozaki Y, Hayashi T, Era S. Near-infrared spectroscopy study of heat-induced
gelation and hydration of bovine serum albumin in aqueous solution. ITE Lett Batt New Tech Med.
2006;7:42-48.
3㧕 Murayama K, Tomida M, Ootake Y, Mizuno T, Ishimaru J. Principal discriminant variate analysis fordiagnosis of temporomandibular joint disorders using capillary near-infrared spectroscopy of one dropof human temporomandibular joint synovial fluid. ITE Lett Batt New Tech Med. 2006;7:49-52.
4㧕 Murayama K, Tomida M, Hayashi M, Kawakami Y. Abnormal crystal growth of rat teeth by excessive
gamma knife irradiation of brain: microscope ATR/FT-IR spectroscopy study. ITE Lett Batt New TechMed. 2006;7:84-86.
5㧕 Tomida M, Hayashi M, Kawakami Y, Katayama Y, Kouyama N, Murayama K, Ando H, Asanuma N.
The sensitivity of the rat sciatic nerve after gamma knife irradiation. ITE Lett Batt New Tech Med.
2006;7:87-91.
6㧕 Terawaki H, Matsuyama Y, Era S, Matsuo N, Ikeda M, Ogura M, Yokoyama K, Yamamoto T, Hosoya T,
Nakayama M. Elevated oxidative stress measured as albumin redox state in continuous ambulatory
peritoneal dialysis patients correlates with small uraemic solutes. Nephrol Dial Transpl. 2007;22:968.
7㧕 Terawaki H, Nakayama K, Matsuyama Y, Nakayama M, Sato T, Hosoya T, Era S, Ito S. Dialyzable
uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients.
Blood Purif. 2007;25:274-279.
8㧕 Fukushima H, Miwa Y, Shiraki M, Gomi I, Toda K, Kuriyama S, Nakamura H, Wakahara T, Era S,
Moriwaki H. Oral branched-chain amino acid supplementation improves the oxidized/reduced
albumin ratio in patients with liver cirrhosis. Hepatol Res. 2007;37:765-770.
9㧕 Terada T, Murayama K, Ra C. Structural study of mutated FcǭRI Ǫ chain ITAM by circulardichroism spectroscopy. ITE Lett Batt New Tech Med. 2007;8:65-68.
10㧕 Terada T, Murayama K, Ra C. Structural study of FcǭRI Ǫ chain polymorphism by circulardichroism spectroscopy. ITE Lett Batt New Tech Med. 2007;8:84-87.
11㧕 Bo Y, Murayama, K, Yan, H. Study of thermal dynamics of defatted bovine serum albumin in D2O solution
by Fourier transform infrared spectra and evolving factor analysis. Appl Spectrosc. 2007; 61:921-927.
12㧕 Matsushima S, Nishiofuku H, Iwata H, Era S, Inaba Y, Kinosada Y. Equivalent cross-relaxation rate
imaging of axillary lymph nodes in breast cancer. J Magn Reson Imaging. 2008;27:1278-1283.
13㧕 Era S, Matsuyama Y, Terada T, Minami T. Heterogeneity of the redox state of commercial humanserum albumin products. FEBS J. 2008;275:209.
14㧕 Iwai I, Ikuta K, Murayama K, Hirao T. Change in optical properties of stratum corneum induced byprotein carbonylation in vitro. Int J Cosmet Sci. 2008;30:41-46.

IF 3.154

IF 1.493

IF 1.255

IF 1.531
IF 2.209
IF 3.396

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦೽ፉᤘౖ, ⎇ⓥಽᜂ⠪㧦ᕺ⦟⡛৻㧧ⅣႺౣ↢଻ోᯏ᭴㧦㊀㊄ዻ╬ߩஜᐽᓇ㗀ߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧4,000 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦೽ፉᤘౖ㧘⎇ⓥಽᜂ⠪㧦ᕺ⦟⡛৻㧧ⅣႺ⋭⎇ⓥ⾌⵬ഥ㊄㧦㊀㊄ዻ╬ߩஜᐽᓇ㗀ߦ㑐ߔࠆ✚ว⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧4,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ኹ↰⍮ᣂ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦㜞ⷫ๺ᕈ IgE ฃኈ૕  ㎮ߩᯏ⢻⸃ᨆߣࠪࠣ࠽࡞વ㆐ߩ⸃᣿㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᕺ⦟⡛৻㧘⎇ⓥಽᜂ⠪㧦᧻ፉ ⑲㧘♿ࡁቯ଻⤿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦⏛᳇౒㡆ᴺߦࠃࠆ↢૕⚵❱∛ᄌᬌ಴ߩߚ߼ߩಽሶࠗࡔ࡯ࠫࡦࠣߩ㐿⊒ߣ⥃ᐥᔕ↪㧧ᐔᚑ㧙㧙

19㧙20 ᐕᐲ㧧3,570 ජ౞(2,470㧦1,100 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᕺ⦟⡛৻㧦ᾫᚑ໊ㄆሶࠍࡅ࠻ߦᛩਈߒߚ㓙ߩ᛫㉄ൻ૞↪ߩ್ቯ㧔੍஻ታ㛎㧕㧧ᐔᚑ 18 ᐕᐲ㧧220 ජ౞㧦㘧㛗໊ㄆᎿᚱ㧔ᩣ㧕
2㧕 ᕺ⦟⡛৻㧦ࡅ࠻ߦኻߔࠆᾫᚑ໊ㄆሶߩ᛫㉄ൻലᨐߩᬌ⸛㧔ᧄታ㛎㧕㧧ᐔᚑ 18 ᐕᐲ㧧220 ජ౞㧦㘧㛗໊ㄆᎿᚱ㧔ᩣ㧕
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᕺ⦟⡛৻㧘⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧦㉄ൻဳࠕ࡞ࡉࡒࡦૐਅ೷㧔⊒᣿㧕㧧ᐔᚑ 18 ᐕᐲ
2㧕 ᕺ⦟⡛৻㧘♿ࡁቯ଻⤿㧘᧻ፉ ⑲㧘㐳↰⌀ੑ㧦MR ⵝ⟎ߦࠃࠆ⏛ൻ⒖േലᨐᴺߣലᨐᲧṶ▚ࠍ૬↪
ߒߚ∛ᄌ⇣Ᏹߩᣧᦼᬌ಴ᴺ㧔⊒᣿㧕㧧ᐔᚑ 19 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᕺ⦟⡛৻㧦
1㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ∛ᘒ↢ℂቇળℂ੐(㨪⃻࿷)3㧕 ᣣᧄ∛ᘒ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⏛᳇౒㡆කቇળઍ⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᕺ⦟⡛৻㧦
1㧕 ╙ 34 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળ(2006 ᐕ 9 ᦬㧘ߟߊ߫, ᢎ⢒⻠Ṷ‫↢ޟ‬૕⚵❱ߩ✭๺ᤨ㑆㧙㜞ಽሶሽ࿷ਅߢߩ✭๺‫ޠ‬Ṷ⠪)
2㧕 ╙ 51 ࿁᧲ᶏቇᩞ଻ஜቇળ✚ળ(2008 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ಽሶ࡟ࡌ࡞ߢ⠨߃ࠆ∔ᖚߩ∛ᘒ↢ℂ㨪ಽሶකቇߩߺ߆ߚ࡮⠨߃ᣇ㨪‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᕺ⦟⡛৻㧦↢૕කᎿቇࠪࡦࡐࠫ࠙ࡓࡌࠬ࠻࡝ࠨ࡯࠴ࠕࡢ࡯࠼(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᕺ⦟⡛৻㧘♿ࡁቯ଻⤿㧘᧻ፉ ⑲㧘㐳↰⌀ੑ㧦⢄⤳߇ࠎ㧘⢄⎬ᄌ ⦡ᄌൻߢ੍ళ⊒⷗㧦⺒ᄁᣂ⡞(2007ᐕ 5 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ೨ภ߿೨‫ޘ‬ภߦ߅ߌࠆ⎇ⓥᬺ❣ߦᲧセߔࠆߣ㧘੹࿁ߩᬺ❣ߦ㑐ߒߡߪ㊰ൻ௑ะ߇ߺࠄࠇࠆ‫⃻ޟߒ߆ߒޕ‬㧙㧙⁁ߩ໧㗴ὐ‫⸥ߦޠ‬タߒߡ޿ࠆ෩ߒ޿⁁ᴫߩਛߢ㧘┹੎⊛ᄖㇱ⾗㊄ߩ₪ᓧ߿⊒᣿࡮․⸵಴㗿╬߽ⴕߞߡ߈
ߡ߅ࠅ㧘ߘࠇࠄߩὐߢ✚วߔࠆߣ߹ߕ߹ߕߩ⹏ଔߢ޽ࠈ߁߆‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 16 ᐕߩᄢቇᴺੱൻߩᐕߦ㧘ቇౝߩ੐ᖱߦࠃߞߡᒰ⹥ಽ㊁ߩഥᢎ᝼ࡐࠬ࠻ 1 ߇ᷫຬߐࠇߚ߹߹ 4ᐕ߇⚻ㆊߒߡ޿ࠆ‫ޕ‬ᢎ⢒࡮⎇ⓥߩ㊂ߣ⾰߇ߎࠇ߹ߢએ਄ߦⷐ᳞ߐࠇࠆ⃻࿷㧘ᢎቶຬᢙߩ࿶ୟ⊛ߥዋߥߐ㧔ᱜ㧦ᢎ᝼ 1㧘ഥᢎ 1㧕ߪᒰ⹥ಽ㊁ߩ੹ᓟߩ⊒ዷߦᄢ߈ߥࡉ࡟࡯ࠠߣߥࠆߢ޽ࠈ߁‫ߩߘޕ‬ታല⊛ߥኻᔕ╷߽෩ߒ޿ߩߢ㧘ቇౝᄖߢߩ౒ห⎇ⓥߣ޿߁߆ߚߜߢ᦭ᯏ⊛ߦᝄ⥰߁ߎߣߦࠃߞߡਸ਼ࠅಾߞߡ޿ߊࠃࠅઁ
ߪߥ޿ࠃ߁ߦᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸ਄⸥ߩ໧㗴ߪනߦᒰ⹥ಽ㊁ߩ৻ಽ㊁ߦ㒢ߞߚ․ᱶߥ⁁ᴫߢߪߥ޿‫⸃ޕ‬᳿╷ߪ߿ߪࠅੱ⊛⾗Ḯߩ⏕଻߇ᕆോ߆ߟࠞࡦࡈ࡞೷ߣߥࠈ߁߇㧘ߘࠇ߽ታ⃻ߢ߈ߥ޿ߩߢ޽ࠇ߫㧘੹ᓟߩዷᦸߪ⃻⁁એ਄ߦ߹ߔ߹ߔ෩
ߒ޿߽ߩߣߥࠆߢ޽ࠈ߁‫ޕ‬㧙㧙㧔3㧕⮎ℂ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⮎ℂቇ⊛ᚻᴺ㧘⚦⢩↢‛ቇ⊛ᚻᴺ߅ࠃ߮ಽሶ↢‛ቇ⊛ᚻᴺࠍ↪޿⎇ⓥࠍⴕ޿㧘ઍ⻢ᕈ∔ᖚ࡮ⴊᩖ∝࡮േ⣂⎬ൻ∝࡮ᶖൻེ♽∔ᖚߩ∛ᘒߩ⸃᣿ࠍㅢߒߡࡅ࠻ߦ᦭↪ߥᣂߚߥഃ⮎ࠍ⋡ᜰߒ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕⒳‫∛ߩޘ‬ᘒߦ߅ߌࠆૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰ߩᓎഀߩ⸃᣿
↢૕ߩࠬ࠻࡟ࠬᔕ╵ߦ߅޿ߡਛᔃ⊛ᓎഀࠍᜂ߁ߣ⠨߃ࠄࠇߡ޿ࠆࠬ࠻࡟ࠬⰮ⊕⾰ߦᵈ⋡ߒ,ਛߢ߽ಽሶ
㊂߇ 10-30kDa ߩૐಽሶ㊂ૐಽሶ㊂ߩᯏ⢻ࠍ⸃ᨆߒߡ޿ࠆ‫⾰⊕Ⱞࠬ࡟࠻ࠬޕ‬㧔low-molecular-weight heatshock protein㧕ߩࡈࠔࡒ࡝࡯ߩਛߢ㧘HSP20 ߣ B ࠢ࡝ࠬ࠲࡝ࡦ߇ᓥ᧪ߩ⚦⢩ౝࠪࡖࡍࡠࡦߣߒߡߩᯏ
⢻એᄖߦࠬ࠻࡟ࠬᔕ╵ߦ㓙ߒ㧘⚦⢩ᄖߦㆆ㔌ߐࠇⴊዊ᧼ᯏ⢻ࠍᛥ೙ߔࠆߎߣࠍ⊒⷗ߒ㧘ߘߩᵴᕈㇱ૏ࠍ⷗಴ߒߚ‫ᦨޕ‬ㄭ㧘HSP27 ߩ࡝ࡦ㉄ൻߩ⒟ᐲ߅ࠃ߮ HSP20 ߩ✚⊒⃻㊂߇ࡅ࠻⢄⚦⢩≸ߦ߅ߌࠆ TNM ࠬ࠹࡯ࠫߣㅒ⋧㑐ߔࠆߎߣࠍ⷗಴ߒ㧘⢄≸ߩ∛ᘒߦ߅޿ߡૐಽሶ㊂ HSP ߇≸⚦⢩ߩჇᱺ೙ᓮᯏ᭴ߦ㑐ਈߒߡ޿ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬,ⴊዊ᧼߆ࠄߩ㗰☸ಽᴲࠍ HSP27 ߩ࡝ࡦ㉄ൻ߇೙ᓮߒߡ޿ࠆߎߣࠍ᣿ࠄ߆ߣߒߡ޿
ࠆ‫⃻ޕ‬࿷㧘ૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰㧔HSP27࡮HSP20࡮B ࠢ࡝ࠬ࠲࡝ࡦ㧕ߩ⚦⢩ౝ㧔㛽⧘⚦⢩࡮␹⚻⚦⢩࡮ⴊዊ᧼࡮⢄≸⚦⢩࡮⤟≸⚦⢩㧕࡮⚦⢩ᄖߢߩᯏ⢻෸߮ᓎഀߩᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕㛽⧘⚦⢩࡮␹⚻⚦⢩࡮⢄⚦⢩࡮⤟⚦⢩ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃᣿
ೋઍၭ㙃⚦⢩߅ࠃ߮ࡕ࠺࡞ࠢࡠ࡯ࡦൻ⚦⢩ࠍ↪޿ߡ㧘⚦⢩Ⴧᱺ࿃ሶ࡮ࠨࠗ࠻ࠞࠗࡦ࡮ࡎ࡞ࡕࡦ╬⒳‫ߩޘ‬↢ℂᵴᕈ‛⾰ߩ⚦⢩ౝᖱႎવ㆐ᯏ᭴ߦߟ޿ߡᬌ⸛ࠍⴕߞߡ޿ࠆ‫⚦ޕ‬⢩ߩჇᱺ࡮ಽൻ߿ᱫߩࡔࠞ࠾࠭ࡓ࡮ߘ
ߩ೙ᓮ߅ߌࠆᓎഀࠍ⸃ᨆߒ㧘㛽☻㝃∝࡮ⴊᩖ∝࡮േ⣂⎬ൻ∝࡮ᕆᕈ౰∝୥⟲࡮⢄≸࡮⤟≸࡮ᄢ⣺≸ߩ∛ᘒߩ⸃᣿ࠍ⹜ߺߡ޿ࠆ‫ߦࠄߐޕ‬㧘ߎࠇࠄ∔ᖚߦ૶↪ߐࠇߡ޿ࠆ⒳‫ߩ‛⮎ߩޘ‬ᣂߚߥ૞↪ߩ⸃ᨆ߅ࠃ߮૞↪ᯏ᭴ߩᬌ⸛ࠍⴕߞߡ޿ࠆ‫ޕ‬
3㧕ઍ⻢∔ᖚ㧔♧ዩ∛࡮㛽☻㝃∝╬㧕߅ࠃ߮േ⣂⎬ൻ∝ߦ߅ߌࠆⴊዊ᧼ᯏ⢻ߩᄌൻߣ⺃⊒ߐࠇࠆ⒳‫∛ߩޘ‬
ᘒ↢ℂߩ⸃᣿
♧ዩ∛ߥߤߩઍ⻢∔ᖚߪ㧘ⴊᩖ∝㧔⯯ⴊ∔ᖚ㧕߿␹⚻࡮⤳ེ㓚ኂߥߤߩ 2 ᰴ⊛∔ᖚߩ⺃⊒₸߇㜞ߊ㧘ⴊዊ᧼ᯏ⢻ߩᄌൻߣⴊᩖ∝߿ฦ⤳ེ㓚ኂߣߩ㑐ଥࠍㅊ᳞ߒߡ޿ࠆ‫ᦨޕ‬ㄭ㧘㛽☻㝃∝ߩᴦ≮⮎ߣߒߡ૶↪ߐࠇ
ߡ޿ࠆ SERM ߩ৻ߟߢ޽ࠆ࡜ࡠࠠࠪࡈࠚࡦ߇ߘߩ೽૞↪ߣߒߡⴊዊ᧼ಝ㓸⢻ࠍ੣ㅴߐߖࠆߎߣࠍ᣿ࠄ߆
ߣߒߡ޿ࠆ‫⃻ޕ‬࿷㧘ઍ⻢∔ᖚ㧔♧ዩ∛࡮㛽☻㝃∝╬㧕߅ࠃ߮േ⣂⎬ൻ∝ߦ߅ߌࠆⴊዊ᧼ߩᯏ⢻߅ࠃ߮ⴊዊ
᧼⚦⢩ౝᖱႎવ㆐ᯏ᭴ߩ⸃ᨆࠍⴕߞߡ޿ࠆ‫ޕ‬
4㧕ࠕࡐ࠻࡯ࠪࠬ⊒⃻ᯏᐨߩ⸃᣿ߣߘߩ੍㒐ᴺߩ⏕┙⒳‫∔ߩޘ‬ᖚߦ㧘ࠕࡐ࠻࡯ࠪࠬߦ߅ߌࠆ⚦⢩ᱫ߇ᷓߊ㑐ਈߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߡ߈ߡ޿ࠆ‫࠽ࠬޕ‬ࡀ࠭ࡒ߿ࡑ࠙ࠬߦ߅ߌࠆ⣖⯯ⴊ࡮ౣẑᵹߦߣ߽ߥ߁ᶏ㚍␹⚻⚦⢩ᱫࡕ࠺࡞߿✂⤑␹⚻⚦⢩ᱫࡕ࠺࡞㧘޽ࠆ޿ߪᅢਛ⃿⚦⢩ᱫࡕ࠺࡞╬ࠍᜰᮡߦ㧘ߘߩ⊒⃻ᯏ᭴ߩ⸃᣿ߥࠄ߮ߦ੍㒐ᴺߩត᳞ࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ዊỈ ୃ
ᢎ᝼(૬છ)㧦 ਤ⠀㓷ਯ
⿷┙᡽ᴦ
ഥᢎ㧦

Osamu Kozawa
Masayuki Niwa
Seiji Adachi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 㜞੗ ାᴦ, ⿒᧻ ❥, ቟↰ ㍈੺, ዊỈ ୃ. ૐಽሶ㊂ࠬ࠻࡟ࠬ࠲ࡦࡄࠢ⾰ߣࡃ࠰ࡊ࡟ࠪࡦ㧦HSP27ߣⴊ▤ᐔṖ╭, ᣣᧄ⮎ℂቇ㔀⹹ 2006 ᐕ㧧128 Ꮞ㧦141̆145.
2㧕 ዊỈ ୃ. ᔃⴊ▤૞േ‛⾰ߣߒߡߩࡃ࠰ࡊ࡟ࠪࡦ㧦ߘߩ૞↪ᯏᐨ, 㤗㈮ 2008 ᐕ㧧57 Ꮞ㧦S77̆S85.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Hanai Y, Tokuda H, Takai S, Harada A, Ohta T, Kozawa O. Minodronate suppresses prostaglandin
F2D-induced vascular endothelial growth factor synthesis in osteoblasts. Horm Metab Res.

㧙㧙

2006;38:152-158.
2㧕 Hanai Y, Tokuda H, Ishisaki A, Matsushima-Nishiwaki R, Nakamura N, Yoshida M, Takai S, Ohta T,
Kozawa O. Involvement of p44/p42 MAP kinase in insulin-like growth factor-I-induced alkaline
phosphatase activity in osteoblast-like MC3T3-E1 cells. Mol Cell Endocrinol. 2006;251:42-48.
3㧕 Takai S, Tokuda H, Matsushima-Nishiwaki R, Hanai Y, Kato K, Kozawa O. Phosphatidylinositol
3-kinase/Akt plays a role in sphingosine 1-phosphate-stimulated HSP27 induction in osteoblasts. J
Cell Biochem. 2006;98:1249-1256.
4㧕 Takai S, Tokuda H, Yoshida M, Yasuda E, Matsushima-Nishiwaki R, Harada A, Kato K, Kozawa O.
Prostaglandin D2 induces the phosphorylation of HSP27 in osteoblasts: function of the MAP kinasesuperfamily. Prostaglandins Leukot Essent Fatty Acids. 2006;75:61-67.
5㧕 Nakajima K, Suga H, Matsuno H, Ishisaki A, Hirade K, Kozawa O. Differential roles of MAP kinases
in atorvastatin-induced VEGF release in cardiac myocytes. Life Sci. 2006;79:1214-1220.
6㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist, methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1058:33-42.
7㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Phosphatidylinositol 3-kinase/Akt plays a part intumor-necrosis factor-D-induced interleukin-6 synthesis in osteoblasts. Horm Metab Res.
2006;38;563-569.
8㧕 Tanabe K, Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Hirade K, Katagiri Y, Dohi S,
Kozawa O. Modulation by the steroid/thyroid hormone superfamily of TGF-E-stimulated VEGF releasefrom vascular smooth muscle cells. J Cell Biochem. 2006;99:187-195.
9㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration by a chemical hypoxia-mimicking agent, cobalt
chloride. Brain Res. 2006;1109:192-200.
10㧕 Hanai Y, Tokuda H, Ohta T, Matsushima-Nishiwaki R, Takai S, Kozawa O. Phosphatidylinositol
3-kinase/Akt auto-regulates PDGF-BB-stimulated interleukin-6 synthesis in osteoblasts. J Cell
Biochem. 2006;99:1564-1571.
11㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-D decreases HSP 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
12㧕 Hanai Y, Tokuda H, Yasuda E, Noda T, Ohta T, Takai S, Kozawa O. Up-regulation by zinc of
FGF-2-induced VEGF release through enhancing p44/p42 MAP kinase activation in osteoblasts. Life
Sci. 2006;80:230-234.
13㧕 Tokuda H, Takai S, Matsushima-Nishiwaki R,Akamatsu S, Hanai Y, Hosoi T, Harada A, Ohta T,
Kozawa O. (-)-Epigallocatechin gallate enhances prostaglandin F2D-induced VEGF synthesis via
up-regulating SAPK/JNK activation in osteoblasts. J Cell Biochem. 2007;100:1146-1153.
14㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Limitation by p70 S6 Kinase of PDGF-BB-induced IL-6
synthesis in osteoblast-like MC3T3-E1 cells. Metabolism. 2007;56:476-483.
15㧕 Takai S, Tokuda H, Hanai Y, Kozawa O. Activation of phosphatidylinositol 3-kinase/Akt
limitsFGF-2-induced VEGF release in osteoblasts. Mol Cell Endocrinol. 2007;267:46-54.
16㧕 Takai S, Tokuda H, Hanai Y, Harada A, Yasuda E, Matsushima-Nishiwaki R, Kato H, Ogura S, Ohta T,
Kozawa O. Negative regulation by p70 S6 kinase of FGF-2-stimulated VEGF release throughstress-activated/c-JunN-terminal kinase in osteoblasts. J Bone Miner Res. 2007;22:337-346.
17㧕 Takai S, Nagaki M, Imao M, Kimura K, Kozawa O, Moriwaki H. Intrinsic resistance to TNF-D-induced
hepatocyte apoptosis in ICR mice correlates with expression of a short form of c-FLIP. Lab Invest.
2007;87:572-581.
18㧕 Noda T, Kumada T, Takai S, Matsushima-Nishiwaki R, Yoshimi N, Yasuda E, Kato K, Toyoda H,
Kaneoka Y, Yamaguchi A, Kozawa O. Expression levels of heat shock protein 20 decrease in parallelwith tumor progression in patients with hepatocellular carcinoma. Oncol Rep. 2007;17:1309-1314.
19㧕 Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Hosoi T, Harada A, Ohta T, Kozawa O.
(-)-Epigallocatechin gallate suppresses endothelin-1-induced interleukin-6 synthesis in osteoblasts:
inhibition of p44/p42 MAP kinase activation. FEBS Lett. 2007;581:1311-1316.
20㧕 Ochiai S, Sekiguchi S, Hayashi A, Shimadzu M, Ishiko H, Matsushima-Nishiwaki R, Kozawa O,
Yasuda M, Duguchi T. Decreased affinity of mosaic-structure recombinant penicillin-bindingprotein 2
for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob. 2007;60:54-60.
21㧕 Takai S, Matsushima-Nishiwaki R, Tokuda H, Yasuda E, Toyoda H, Kaneoka Y, Yamaguchi A, Kumada
T, Kozawa O. Protein kinase C Ǭ regulates the phosphorylation of heat shock protein 27 in humanhepatocellular carcinoma. Life Sci. 2007;81:585-591.
22㧕 Tokuda H, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Doi T, Harada A, Takai S, Kozawa O.
Rho-kinase regulates endothelin-1-stimulated IL-6 synthesis via p38 MAP kinase in osteoblasts.
Biochem Biophys Res Commun. 2007;362:799-804.
23㧕 Yamauchi J, Takai S, Matsushima-Nishiwaki R, Hanai Y, Doi T, Kato H, Ogura S, Kato K, Tokuda H,
Kozawa O. (-)-Epigallocatechin gallate inhibits prostaglandin D2-stimulated HSP27 induction via
suppression of the p44/p42 MAP kinase pathway in osteoblasts. Prostaglandins Leukot Essent Fatty㧙㧙

IF 2.254

IF 2.971

IF 3.381

IF 2.000
IF 2.257

IF 2.218

IF 2.254

IF 3.381

IF 2.218

IF 3.381
IF 2.257

IF 2.257

IF 3.381
IF 2.647
IF 2.971

IF 6.004

IF 4.479

IF 1.597

IF 3.263

IF 4.038

IF 2.257

IF 2.749

Acids. 2007;77:173-179.
24㧕 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Akamatsu S, Ohta T, and Kozawa O.
Platelet-derived growth factor-BB amplifies PGF2-induced VEGF synthesis in osteoblasts: function ofphosphatidylinositol 3-kinase. Prostaglandins Leukot Essent Fatty Acids. 2007;77:187-193.
25㧕 Tokuda H, Takai S, Hanai Y, Harada A, Matsushima-Nishiwaki R, Kato H, Ogura S, Kozawa O.
Potentiation by platelet-derived growth factor-BB of FGF-2-stimulated VEGF release in osteoblasts. J
Bone Miner Metab. 2008;26:335-341.
26㧕 Tokuda H, Takai S, Hanai Y, Matsushima-Nishiwaki R, Yamauchi J, Harada A, Hosoi T, Ohta T,
Kozawa O. (-)-Epigallocatechin gallate inhibits basic fibroblast growth factor-induced interleukin-6
synthesis in osteoblasts. Horm Metab Res. 2008;40:674-678.
27㧕 Takai S, Hanai Y, Matushima-Nishiwaki R, Minamitani C, Otsuka T, Tokuda H, Kozawa O. p70 S6
kinase negatively regulates FGF-2-stimulated IL-6 synthesis in osteoblasts: function at a point
downstream from protein kinase C. J Endocrinol. 2008;197:131-137.
28㧕 Hayashi K, Takai S, Matsushima-Nishiwaki R, Hanai Y, Kato K, Tokuda H, Kozawa O.
(-)-Epigallocatechin gallate reduces transforming growth factor E-stimulated HSP27 induction
through the suppression of stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Life
Sci. 2008;82:1012-1017.
29㧕 Tanabe K, Takai S, Matsushima-Nishiwaki R, Kato K, Dohi S, Kozawa O. D2 Adrenoreceptor agonist
regulates protein kinase C-induced heat shock protein 27 phosphorylation in C6 glioma cells. J
Neurochem. 2008;106:519-528.
30㧕 Kato H, Takai S, Matushima-Nishiwaki R, Adachi S, Minamitani C, Otsuka T, Tokuda H, Akamatsu S,
Doi T, Ogura S, Kozawa O. HSP27 phosphorylation is correlated with ADP-induced platelet granulesecretion. Arch Biochem Biophys. 2008;475:80-86.
31㧕 Matsushima-Nishiwaki R, Takai S, Adachi S, Minamitani C, Yasuda E, Noda T, Kato K, Toyoda H,
Kaneoka Y, Yamaguchi A, Kumada T, Kozawa O. Phosphorylated heat shock protein 27 represses
growth of hepatocellular carcinoma via inhibition of extracellular-signal-regulated kinase. J Biol
Chem. 2008;283:18852-18860.
32㧕 Minamitani C, Otsuka T, Takai S, Matsushima-Nishiwaki R, Adachi S, Hanai Y, Mizutani J, Tokuda H,
Kozawa O. Involvement of Rho-kinase in prostaglandin F2-stimulated interleukin-6 synthesis via
p38 mitogen-activated protein kinase in osteoblasts. Mol Cell Endocrinol. 2008;291:27-32.
33㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
34㧕 Minamitani C, Takai S, Matsushima-Nishiwaki R, Hanai Y, Otsuka T, Kozawa O, Tokuda H. A case ofraloxifene-induced acceleration of platelet aggregation. Internal Med. 2008;47;1523-1528.
35㧕 Takai S, Matsushima-Nishiwaki R, Adachi S, Natsume H, Minamitani C, Mizutani J, Otsuka T, Tokuda
H, Kozawa O. (-)-Epigallocatechin gallate reduces platelet-derived growth factor-BB-stimulated
interleukin-6 synthesis in osteoblasts: suppression of SAPK/JNK. Mediators Inflamm.
2008;2008:291808.
36㧕 Tokuda H, Takai S, Matsushima-Nishiwaki R, Hanai Y, Adachi S, Minamitani C, Mizutani J, Otsuka T,
Kozawa O. Function of Rho-kinase in prostaglandin D2-induced interleukin-6 synthesis in osteoblasts.
Prostaglandins Leukot Essent Fatty Acids. 2008;79:41-46.

IF 2.000

IF 2.000

IF 1.425

IF 2.254

IF 2.636

IF 2.257

IF 4.451

IF 2.578

IF 5.581

IF 2.971

IF 5.406

IF 1.162

IF 2.000

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ, ࿯⢈ୃม㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽࿃ሶߩᓎഀߣ⥃ᐥ⊛ᗧ⟵㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,800
ජ౞(2,700㧦1,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆᓸዊⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣᴦ≮߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᗲ⍮⣢⤳⽷࿅⎇ⓥഥᚑ㧦♧ዩ∛ᕈ⣢∝ߩㅴዷߦኻߔ
ࠆⴊዊ᧼ᯏ⢻೙ᓮߩᓇ㗀ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧100 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆࠞ
࠹ࠠࡦߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦㛽ઍ⻢ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩಽሶၮ⋚ߩ⸃ᨆ㧦ࠬ࠻࡟ࠬⰮ⊕⾰ߩᯏ⢻⸃ᨆ㧧ᐔᚑ 19 ᐕ㧙
20 ᐕᐲ㧧3,500 ජ౞(2,200㧦1,300 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ૐಽሶ㊂ࠬ࠻࡟ࠬⰮ⊕⾰ࠍᮡ⊛ߣߒߚᣂߚߥ≸ᴦ≮ᴺߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(2,000㧦1,300 ජ౞)㧙㧙7㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦⧎੗ᶻᤩ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ᚑ㐳ߦ߅ߌࠆ Wnt/
Ǫ-catenin ࠪࠣ࠽࡞વ㆐⚻〝ߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕ㧧⎇ⓥ⾌ 500 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ㧧╙ 25 ࿁ⴊᶧකቇᶏᄖ⇐ቇഥᚑ㊄㧦⚦⢩㓚ኂᕈ T ⚦⢩ߩᯏ⢻ୃ㘼ߦࠃࠆᣂߚ
ߥ≸఺∉≮ᴺߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧2,000 ජ౞
9㧕⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦㜞੗ାᴦ, ᓼ↰ᴦᒾ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆᓸዊⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣᴦ≮߳ߩᔕ↪㧧ᐔᚑ 18 ᐕᐲ㧧120 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᗲ⍮⣢⤳⽷࿅⎇ⓥഥᚑ㧦♧ዩ∛ᕈ⣢∝ߩㅴዷߦኻߔ
ࠆⴊዊ᧼ᯏ⢻೙ᓮߩᓇ㗀ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧10 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦㜞੗ାᴦ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆࠞ
࠹ࠠࡦߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧50 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ᓼ↰ᴦᒾ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦♧ዩ∛ᖚ⠪ߦ߅ߌࠆⴊᩖᒻᚑ੣ㅴᯏᐨߩ⸃᣿ߣ◲ଢߥⴊዊ᧼ಝ㓸⢻ߩᬌᩏᴺߩ⏕┙㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
3,700 ජ౞(1,500㧦1,100㧦1,100 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦⿒᧻ ❥, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᔃⴊ▤♽ߦ߅ߌࠆㆊᄢଚⷅߦኻߔࠆࠬ࠻࡟ࠬᔕ╵ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,500㧦
1,000㧦1,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦↰ㄝਭ⟤ሶ, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ਛᨔ␹⚻♽ߦ߅ߌࠆ␹⚻଻⼔૞↪ߩಽሶၮ⋚ߩ⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,600 ජ౞(1,900㧦1,000㧦70
ජ౞)15㧕 ⎇ⓥઍ⴫⠪㧦᳓⼱ Ả, ⎇ⓥಽᜂ⠪㧦ዊỈ ୃ, ධ⼱ජᏔ, ᄐ⋡⧷㓶㧧ฬฎደᏒ┙ᄢቇ․೎⎇ⓥᅑബ⾌㧦✛⨥ߩਥᚑಽ㧔ࠞ࠹ࠠࡦ㧕ߩ㛽☻㝃੍㒐ലᨐߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧70 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ዊỈ ୃ, ⎇ⓥಽᜂ⠪㧦⿷┙᡽ᴦ㧧⽷࿅ᴺੱᚑ㐳⑼ቇදળഥᚑ㊄㧦㛽ߩᚑ㐳ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩᓎഀߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧50 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢽⾰࡜ࡈ࠻ࠍᮡ⊛ߣߒߚ EGCG
ߦࠃࠆᄢ⣺≸੍㒐ߩ⎇ⓥ㧧ᐔᚑ 20㧙21 ᐕᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ዊỈ ୃ, ዊୖ⌀ᴦ㧦ⴊዊ᧼ߦ߅ߌࠆࠕࡦ࠴࠻ࡠࡦࡆࡦΥߩ᛫ⴊᩖ૞↪ߩಽሶᯏᐨߩ⸃ᨆ㧧ᐔᚑ 18
㧙19 ᐕᐲ㧧1,000 ජ౞㧦ZLB ࡌ࡯࡝ࡦࠣ(ᩣ)
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ዊỈ ୃ㧦
1㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)ਤ⠀㓷ਯ㧦1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ዊỈ ୃ㧦
1㧕 ╙ 55 ࿁ᣣᧄ㤗㈮⑼ቇળ(ᐔᚑ 20 ᐕ 6 ᦬, ᮮᵿ, ᢎ⢒⻠Ṷ‫ޟ‬ᔃⴊ▤૞↪‛⾰ߣߒߡߩࡃ࠰ࡊ࡟ࠪࡦ㧦ߘߩ૞↪ᯏᐨ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ዊỈ ୃ, ⍹ፒ ᣿㧦ㆮવሶࡁ࠶ࠢࠕ࠙࠻ࡑ࠙ࠬࠍ↪޿ߚ㛽ઍ⻢ߦ߅ߌࠆ✢ṁ♽࿃ሶߩಽሶၮ⋚ߩ⸃ᨆ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ⿒᧻ ❥, ዊỈ ୃ, ࿯⢈ୃม㧦๟ⴚᦼᔃ╭⯯ⴊᓟߩᔃߩ࡝ࡕ࠺࡝ࡦࠣߦ߅ߌࠆ✢ṁ♽ห჻ߩᓎഀߣ
⥃ᐥ⊛ᗧ⟵㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔߎߩਃᐕ㑆ߩ᰷ᢥේ⪺⺰ᢥߣߒߡߩࠕ࠙࠻ࡊ࠶࠻ߪ 36 ႎߢ޽ߞߚ‫⺰ ޕ‬ᢥߩ⾰ߣߒߡߩ৻ߟߩᜰᮡߢ
޽ࠆࠗࡦࡄࠢ࠻ࡈࠔࠢ࠲࡯ߩᐔဋ୯ߪ 2.807 ߢ޽ࠆ‫ⷰߩߎޕ‬ὐ߆ࠄ߹ߛ߹ߛࠕ࠙࠻ࡊ࠶࠻ߩ̌⾰̍ࠍ਄ߍࠆߎߣ߇ᔅⷐߣᕁࠊࠇࠆ‫৻ޕ‬ᣇ, ଶߦ‫ޟ‬publish or perish‫ ࠆߥ߆޿ߦ߁ࠃࠆࠇࠊ޿ߣޠ‬data ߽ᦨ⚳⊛ߦࠠ࠴ࡦߣߒߚේ⪺⺰ᢥߣߒߡ಴ߔߎߣߪ㕖Ᏹߦᄢಾߥߎߣߢ޽ࠆߎߣߪ޿߁߹ߢ߽ߥ޿‫ߩߎޕ‬ၮᧄ⊛ᆫ൓ߢ޽ࠆࠕ࠙࠻ࡊ࠶࠻ߩ“㊂”ߩⷰὐ߆ࠄ߽ࠕ࠶ࡊߐߖߡ޿߈ߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷೨࿁ߩ╙ 6 ภߦ߽ᦠ޿ߚࠃ߁ߦ, ᦨ߽㊀ⷐߥὐߪ, ᣣ‫⎇ߩޘ‬ⓥࠍ৻✜ߦㅴ߼ߡߊࠇࠆఝ⑲ߥੱ᧚ߩ₪ᓧߢ޽ࠆ‫ࠅߪ߿ޕ‬, ⎇ⓥࠍㆀⴕߒߡ޿ߊ਄ߢ, ߎߩ৻ὐߦ ߆ߞߡ޿ࠆߣ޿ߞߡ߽ㆊ⸒ߢߪߥ޿‫ੱߩߎޕ‬ߚߜߩਛ߆ࠄ, ዁᧪ߩᜂ߁කቇ⎇ⓥ⠪߇৻ੱߢ߽⢒ᚑߢ߈ࠆࠃ߁ദജߒߡ޿߈ߚ޿‫ޕ‬੹ᓟߩዷᦸ⃻࿷ផߒㅴ߼ߡ޿ࠆ⎇ⓥᚑᨐ߆ࠄ, ዁᧪᦭ലߢ቟ోߥ⮎೷ࠍ㐿⊒ߔࠆߎߣ㧔ഃ⮎㧕ࠍ⋡ᜰߒ㧘޿ߟߩᣣ߆ᖚ⠪ߐࠎߦㆶరߒߚ޿ߣ⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔4㧕ነ↢⯻ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ኋਥነ↢⯻⋧੕૞↪ߦ㑐ߔࠆ⎇ⓥᗵᨴߩᯏળ߇޽ࠆߣነ↢⯻ߪኋਥߦᓇ㗀ࠍ෸߷ߒ, ኋਥߪነ↢⯻ߦᓇ㗀ࠍ෸߷ߔ‫ޕ‬ᓟ⠪ߪ, ᗵᨴ߇ᚑ┙ߔࠆ߆ุ߆ߩ᳿ቯⷐ࿃ߣߥࠆ‫ޕ‬೨⠪ߪ, ᗵᨴ∛ℂߦ⋥⚿ߔࠆ‫ޕ‬ᒰᢎቶߢߪ, ╭⡺ነ↢ᕈߩ✢⯻ߢ޽ࠆᣓᲫ
⯻ࠍ↪޿ߡነ↢⯻߇ኋਥߦ෸߷ߔᓇ㗀ࠍ, ಽሶ↢‛ቇ⊛, ⚦⢩↢‛ቇ⊛ߦ⸃ᨆߒߡ޿ࠆ‫ߚ߹ޕ‬, ᣓᲫ⯻߇ಽᴲߒ, ኋਥ߳ᓇ㗀ࠍਈ߃ࠆ↢ℂᵴᕈ‛⾰ߩㆮવሶᎿቇ⊛ߥวᚑࠍⴕߞߡ޿ࠆ‫ޕ‬એਅ, ⎇ⓥᚑᨐࠍౕ૕⊛ߦ⸥タߔࠆ‫ޕ‬ᣓᲫ⯻ߩᣂ↢ᐜ⯻ߪ, ╭⡺⚦⢩ౝߦଚ౉ߒ, ╭⡺⚦⢩ࠍᄌ⇣ߐߖࠆ‫╭ޕ‬⡺⚦⢩ߪ, ᄌ⇣ࠍଚ౉୘ᚲߦ㒢ዪߐߖࠆߚ߼ߦ⚦⢩⾰ߩㆤᢿࠍⴕ߁߇, ᣓᲫ⯻ߩਛߢ߽ T.pseudospiralis ߣ๭߫ࠇࠆ⒳ߩᗵᨴߢߪ, ߎߩㆤᢿ߇߅ߎࠄߕ, ଚ౉ߐࠇߚ╭⡺⚦⢩ో૕߇ᄌ⇣ߔࠆ‫╭ޕ‬⡺⚦⢩ߩᄌ⇣ߦ઻޿, ࠨ࠹࡜ࠗ࠻⚦⢩߇ಽⵚჇᱺߒ, ╭⡺⚦⢩ߦಽൻߒࠃ߁ߣߔࠆ߇, ᣓᲫ⯻ߪ╭⡺⚦ㇱ߳ߩಽൻࠍ⸵ߐߕ, ᣓᲫ⯻ߩᩕ㙃ߩߣឃᴭ‛ߩ਎⹤ࠍߔࠆ⚦⢩ߦᄌ⇣ߐߖࠆ‫߇ࠇߎޕ‬, ฎౖ⊛ߦⵍྙᒻᚑߣߒߡ⍮ࠄࠇߡ޿ߚ⃻⽎ߢ޽ࠆ߇, ߘߩ⹦⚦ߥ
∛ℂࠍᧄ⎇ⓥቶ߇᣿ࠄ߆ߦߒߚ‫ޕ‬ߐࠄߦ, ߎߩ╭⡺⚦⢩ߩᄌ⇣ߦ઻߁⊒⃻ㆮવሶߦߟ޿ߡᵈ⋡ߒ, ╭⡺⊒↢ߦ㑐ਈߔࠆ࿃ሶ MyoD,
myogenin, MRF4 ߩ᜼േࠍ᣿ࠄ߆ߦߒߚ‫ߚ߹ޕ‬, ྙሶᒻᚑߦ઻߁╭⡺⚦⢩ߩࠕࡐ࠻࡯ࠪࠬߦ㑐ਈߔࠆ࿃ሶ
ߩหቯࠍⴕߞߚ‫ޕ‬ᣓᲫ⯻ߩ cDNA ࡜ࠗࡉ࡜࡝࡯ࠍ૞⵾ߒ, ᦭↪ߥࡍࡊ࠲ࠗ࠼ߩㆮવሶࠍᰴ‫ࡦ࠾࡯ࡠࠢߦޘ‬ࠣߢ߈ߚ‫ߩߘޕ‬ਛߦߪ, ᣂߒ޿࠲ࠗࡊߩࡊࡠ࠹ࠕ࡯࠯㒖ኂ೷෸߮ࡊࡠ࠹ࠕ࡯࠯, ࡑࠢࡠࡈࠔ࡯ࠫㆆ⿛㒖ᱛ࿃ሶ߽޽ࠅ, ⃻࿷, 㑐ㅪߩ․⸵ขᓧ, ߹ߚߪ․⸵಴㗿ਛߢ޽ࠆ‫ޕ‬
2㧚ฬ★
㜞ᯅఝਃ
ᢎ᝼㧦
ಎᢎ᝼㧦 㐳㊁ഞ๓ᔒ⦟ഥᢎ㧦Yuzo Takahashi
Isao Nagano
ZhiLiang Wu

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 㜞ᯅఝਃ✬⪺㧚⥄Ꮖߣ⒳ᣖ଻ሽߩߚ߼ߩ઀⚵ߺ㧦ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧚
2㧕 㜞ᯅఝਃ, ਛ੗೑ᤘ✬㓸ઍ⴫㧚ᬌᩏ୯ߩߺ߆ߚ㧙ઃ ࡄ࠾࠶ࠢ୯࡮⼊ᚓ୯㧙ᡷ⸓ 3 㧦᧲੩㧦ਛᄖකቇ␠㧧
2006㧦788㧙789㧚
3㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ᫪↰໪ਯ, ဈ ᣽▸㧚ࡅ࠻߇↢߈ᱷࠆߚ߼ߩ૕ߩߒߊߺ, ฬฎደ㧦ਃᕺ␠㧦29㧙47, 67
㧙86, 2007 ᐕ㧚
4㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ᫪↰໪ਯ, ဈ ᣽▸㧚ࡅ࠻߇↢߈ᱷࠆߚ߼ߩ૕ߩߒߊߺ㧘2 , ฬฎደ㧦ਃᕺ␠㧦2008ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Suzuki Y, Niwa M, Shibata T, Takahashi Y, Chirasak K, Ariyawardana A, Ramesh JC, Evans P. Tan
O-S, Problem-based Learning in eLearning Breakthroughs. Singapore: Thomson; 2006:131-146.
2㧕 Nagano I, Takahashi Y. Parasitic Zoonoses in Asian-Pacific Regions 2006. Nagoya: Sankeisha; 2006.
✚⺑㧔๺ᢥ㧕
1㧕 ᫃↰๺↵, ⍹Ⴆ㆐ᄦ. ♧ዩ∛, ౝಽᴲ∔ᖚߦࠃࠆ⓭ὼᱫ, ᴺක∛ℂ 2006 ᐕ㧧12 Ꮞ㧦17㧙21㧚
2㧕 㜞ᯅఝਃ, ኹ᎑ศ଻㧚ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍ↪޿ߚකቇᢎ⢒ߩታ㓙ᣂߒ޿කቇᢎ⢒ߩᵹࠇ࡯, ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳, 2007㧦51㧙63㧚✚⺑㧔᰷ᢥ㧕
1㧕 Wu Z, Sofronic-Milosavljevic L, Nagano I, Takahashi Y. Trichinella spiralis: Nurse cell formation
with emphasis on analogy to muscle cell repair. Parasite and Vectors. 2008;27:1-8.
2㧕 Takahashi Y. Problem-Based Learning and Task-based Learning: A practical Synthesis. Kaoshiung
Medical Journal. 2008;24:S31-S34.
3㧕 Nagano I, Wu Z, Takahashi Y. Functional genes and proteins of Trichinella spp. Parasitol Res.
2008;104:197-207.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅఝਃ㧚ත೨කቇᢎ⢒ߩᣂߒ޿േะ㧝㧙໧㗴┙⣉ဳ࠹ࡘ࠻࡯࡝ࠕ࡞㧙, කቇᢎ⢒೎ౠ කቇᢎ⢒⊕ᦠ
2006 ᐕ  2006 ᐕ㧧56㧙59.
2㧕 㜞ᯅఝਃ㧚ᢎ⢒ᯏ㑐ౝߩᢎ⢒㐿⊒⚵❱, කቇᢎ⢒೎ౠ කቇᢎ⢒⊕ᦠ 2006 ᐕ  2006 ᐕ; 110㧙113㧚㧙㧙3㧕 㜞ᯅఝਃ㧚ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒ߦዉ౉ߔࠆߦᒰߚߞߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળ
ႎ 2007 ᐕ㧧1 Ꮞ㧦47㧙60㧚
4㧕 㜞ᯅఝਃࠄ㧚ᖚ⠪ߩක≮ᖱႎࠍᢎ᧚ߦ೑↪ߔࠆߦᒰߚߞߡߩࠟࠗ࠼࡜ࠗࡦᆔຬળ᩺, කቇᢎ⢒㔀⹹ 2007
ᐕ㧧38 Ꮞ㧦173㧙177㧚
5㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍක≮⧷ળ⹤ߦ೑↪ߔࠆߚ߼ߩᢎ᧚ߩ૞ᚑ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯
࡚ࠪࡦ කቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦37㧙40.
6㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍක≮ᢎ⢒ߩᢎ᧚૞ࠅߦߟ޿ߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇ
ᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦41㧙43.
7㧕 ᅏᐘሶ, 㜞ᯅఝਃ. ࠪࡒࡘ࡟࡯࡚ࠪࡦߢࠬ࠹࠶ࡊࠕ࠶ࡊߒߟߟቇ߱ක≮⧷ળ⹤ᢎ᧚ߩ૞ᚑ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦44㧙50.
8㧕 ㋈ᧁᐽਯ, ਤ⠀㓷ਯ, 㜞ᯅఝਃ. ࠹ࡘ࠻࡝ࠕ࡞ߣࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒ࠍ E-learning ߢⴕ߁ࠪࠬ࠹ࡓߩ
᭴▽ߦߟ޿ߡ, ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળႎ 2008 ᐕ㧧2 Ꮞ㧦51㧙56.
ේ⪺㧔᰷ᢥ㧕
1㧕 Wu Z, Nagano I, Boonmars T & Takahashi Y. Involvement of the c-Ski oncoprotein in cell cycle
arrest and transformation during nurse cell formation after Trichinella spiralis infection. Int J
Parasitol. 2006;36:1159-1166.
2㧕 Nagano I, Wu Z, Boonmars T. & Takahashi Y. Molecular cloning and characterization of an Rcd1-likeprotein in excretory-secretory products of Trichinella pseudospiralis. Parasitology. 2006;133:785-792.
3㧕 Pei F, Nagano I, Wu Z, Takahashi Y. Preparation of a recombinant cysteine proteinase of
Clonorchis sinensis and its applied study for immunodiagnosis of Clonorchiasis. Parsitic Zoonoses in
Asian-Pacific Regions. 2006;9:40-53.
4㧕 Wu Z, Nagano I, Boonmars T, Takahashi Y. Thermally induced and developmentally regulated
expression of a small heat shock protein in Trichinella spiralis. Parasitol Res. 2007;101:201-212.
5㧕 Wu Z, Snabel V, Pozio E, Hurnikova Z, Nareaho A, Nagano I, Takahashi Y. Genetic
relationships among Trichinella pseudospiralis isolates from Australian, Nearctic, and Palearctic
regions. Parasitol Res. 2007;101:1567-1573.
6㧕 Yoshikawa H, Wu Z, Howe J, Hashimoto T, Geok-Choo N, Tan KSW. Ultrastructural andPhylogenetic Studies on Blastocystis Isolates from Cockroaches. J Eukaryot Microbiol. 2007;54:33-37.
7㧕 Li LH, Zhou XN, Du ZW, Wang XZ, Wang LB, Jiang JY, Yoshikawa H, Steinmann P,
Utzinger J, Wu Z, Chen JX, Chen SH, Zhang L. Molecular epidemiology of human Blastocystis
in a village in Yunnan province, China. Parasitol Int. 2007;56:281-286.
8㧕 Li LH, Zhang XP, Lu S, Zhang L, Yoshikawa H, Wu Z, Steinmann P, Utzinger J, Tong XM,
Chen SH, Zhou XN. Cross-sectional surveys and subtype classification of human Blastocystis
isolates from four epidemiological settings in China. Parasitol Res. 2007;102:83-90.
9㧕 Nagano, I, Wu, Z, Takahashi, Y.: Species-specific antibody responses to the recombinant
53-kilodalton excretory and secretory proteins in mice infected with Trichinella spp. Clin Vaccine
Immunol. 2008;15:468-473.
10㧕 Wu Z, Nagano I, Takahashi Y. Candidate genes responsible for common and different pathologies ofinfected muscle tissues between Trichinella spiralis and T. pseudospiralis infection. Parasitol Int.
2008;57:368-378.

IF 3.392
IF 2.081

IF 1.512

IF 1.512
IF 2.288

IF 1.776

IF 1.512

IF 1.7764㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ ഞ, ⎇ⓥಽᜂ⠪㧦๓ ᔒ⦟, 㚸 㓶ᚽ, ⵸ ⑔ో, ࠹ࠨ࠽࡮ࠨࡑ࡯ࡦ, ࠴࠳࡜࡮ࡉ࡯ࡦࡑ࡯ࠬ㧦ᐔ๺ਛፉ⽷࿅ ࠕࠫࠕ࿾ၞ㊀ὐቇⴚ⎇ⓥഥᚑ㧦⢄ๆ⯻㧔࠲ࠗ⢄ๆ⯻㧕⚵឵߃Ⱞ⊕᛫ේࠍ↪޿ߚਛ࿖߅ࠃ߮࠲ࠗ࿖ౝߦ߅ߌࠆⴊᷡ⸻ᢿᴺߩ⏕┙㧧2006 ᐕᐲ㧧1988 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦๓ ᔒ⦟, ⎇ⓥಽᜂ⠪㧦㐳㊁ ഞ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣓᲫ⯻ᗵᨴߦࠃࠆኋਥ╭⡺⚦⢩ᄌ⇣ߩㆮવሶ⊒⃻േᘒߩ⸃ᨆߣߘߩಽሶᯏ᭴ߩ⸃᣿㧧ᐔᚑ 17㧙18 ᐕᐲ㧧
3500 ජ౞㧔2,100㧦1,400 ජ౞㧕3㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌(⎇ⓥ)㧧ᣓᲫ⯻↱᧪ォ౮㑐ㅪ࿃ሶ Rcd1 ߇╭⡺⚦⢩ಽൻ⺃ዉߦ෸߷ߔᓇ㗀ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ⎇ⓥಽᜂ⠪㧦㎨⿷㓶ม, ฎጊᶈሶ, ๓ᔒ⦟㧧ጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼, ᄙಽ㊁౒ห⎇ⓥ㧧ഃ⮎࡜ࠗࡉ࡜࡝࡯ߣߒߡߩነ↢✢⯻ࠍ↪޿ߚᣂⷙ↢ℂᵴᕈ‛⾰ߩត⚝㧧ᐔᚑ 19 ᐕᐲ㧧800 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦㐳㊁ഞ, ⎇ⓥಽᜂ⠪㧦๓ᔒ⦟㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣓᲫ⯻↱᧪ォ౮㑐ㅪ࿃
ሶ Rcd1 ߇╭⡺⚦⢩ಽൻ⺃ዉߦ෸߷ߔᓇ㗀ߩಽሶ↢‛ቇ⊛⸃ᨆ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,960 ජ౞(1,560㧦1, 500㧦900 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦๓ ᔒ⦟㧧ᐔ๺ਛፉ⽷࿅ᄖ࿖ੱ᜗⥌ഥᚑ㧦࠲ࠗ⢄ๆ⯻ᗵᨴߦࠃࠆ⢙▤≸⊒↢ߩಽሶᯏ㧙㧙᭴㧧ᐔᚑ 20 ᐕ㧧2000 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒ ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻㧧ᐔᚑ 18 ᐕᐲ㧧
36, 943 ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅2㧕 㐳㊁ഞ㧦ጘ㒂ᄢቇ㒝ዻ∛㒮ߦ߅ߌࠆవ┵ක≮ᛛⴚᖱႎߦ㑐ߔࠆࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻↪࠺ࠫ࠲࡞ࠦࡦ࠹ࡦ࠷ߩ㐿⊒㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,000 ජ౞(1,500㧦1,500 ජ౞)㧦᦭㒢ળ␠ࡔ࠺ࠖࠞ࡞ᗲ
3㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧25,520 ජ౞㧦࿾ၞൻቇᛛⴚାઔ੐ᬺ⾌⵬ഥ㊄࡮⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ࡮ጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
4㧕 㜞ᯅఝਃ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒ ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻㧧ᐔᚑ 20 ᐕᐲ㧧
25,555 ජ౞㧦⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㐳㊁ ഞ, 㜞ᯅఝਃ, ๓ ᔒ⦟㧦ᣓᲫ⯻ߩ⒳․⇣⊛᛫ේ㧧߅ࠃ߮⹥᛫ේࠍ೑↪ߒߚᣓᲫ⯻ᗵᨴߩᬌᩏ
ᴺ(․⸵)㧧ᐔᚑ 20 ᐕᐲ⛮⛯಴㗿ਛ
2㧕 㜞ᯅఝਃ㧦⊹⤏㑐▵᭴ㅧ૕㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)3㧕 㜞ᯅఝਃ㧦૕േౣ⃻ⵝ⟎㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)4㧕 㜞ᯅఝਃ㧦࿁╬㖸ჿ⹺⼂ࠪࠬ࠹ࡓ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)5㧕 㜞ᯅఝਃ㧦⸻ኤ⸠✵ࡕ࠾࠲࡝ࡦࠣⵝ⟎㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)6㧕 㜞ᯅఝਃ㧦ක≮↪⺆⠡⸶⴫␜ࠪࠬ࠹ࡓ㧧ᐔᚑ 20 ᐕᐲ(․⸵಴㗿ਛ)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㜞ᯅఝਃ㧦
1㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄⴡ↢േ‛ቇળᐙ੐(㨪⃻࿷)
5㧕 International Commission on Trichinellosis: active member(㨪⃻࿷)6㧕 ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒ቇળળ㐳(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)7㧕 ⥃ᐥࠦ࡯࠴ࡦࠣ⎇ⓥળ೽ળ㐳(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)8㧕 ᣣᧄක≮ᢎ᝼ࠪࠬ࠹ࡓቇળℂ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)
㐳㊁ഞ㧦
1㧕 ᣣᧄነ↢⯻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
㜞ᯅఝਃ㧦1㧕 The Ninth Asian-Pacific Congress for Parasitic Zoonoses(ᐔᚑ 18 ᐕ 8 ᦬, ጘ㒂)3㧕ቇⴚ㔀⹹
㜞ᯅఝਃ㧦
1㧕 Parasitology : Editorial Board(2007 ᐕ㨪⃻࿷)2㧕 Parasites & Vectors BioMed Central, Editatorial Board(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ, ᜗ᓙࠪࡦࡐࠫࠬ࠻, ᐳ㐳㜞ᯅఝਃ㧦
1㧕 6th Asia-Pacific Conference on Problem-Based Learning(ᐔᚑ 18 ᐕ 5 ᦬, ᧲੩, ‫ޟ‬Needs of a set of
guiding questions to facilitate student’s scientific mind‫ޠ‬Ṷ⠪)㧙㧙

2㧕 ╙ 38 ࿁ᣣᧄකቇᢎ⢒ቇળ(ᐔᚑ 18 ᐕ 7 ᦬, ᄹ⦟, ‫޿⦟ࠅࠃޟ‬කቇᢎ⢒ߦะߌߡߩᣂߚߥⷞὔreflectionߩ૏⟎ߠߌ‫ޠ‬ᐳ㐳)
3㧕 ࡕ࠺࡞㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬, ‫࡞࠺ࡕޟ‬㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒⎇ⓥળߩ⦁಴‫ޠ‬Ṷ⠪)
4㧕 ╙ 8 ࿁ᣣᧄ⋴⼔ක≮ቇળቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 10 ᦬, ጘ㒂, ‫ޟ‬ක≮ᓥ੐⠪ߩᾫ✵ᒻᚑߦߪ૗߇ᔅⷐ
߆㧫‫ޠ‬Ṷ⠪)5㧕 ࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒ߩታ㓙ోੱ⊛ක≮ࠍታ〣ߢ߈ࠆක≮ੱߩ⢒ᚑࠍ⋡ᜰߒߡ㧙 ᐔᚑ 18 ᐕᐲᢥ
ㇱ⑼ቇ⋭ක≮ੱ GP ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 11 ᦬, ᧲੩, ‫ࠍࡦ࡚ࠪ࡯࡟ࡘࡒࠪޟ‬කቇᢎ⢒ߦᓎ┙ߟᒻߦߔࠆߚ߼ߩᎿᄦ‫ޠ‬Ṷ⠪)
6㧕 KMU International conference and workshop on PBL 2008.(ᐔᚑ 20 ᐕ, ᜗ᓙ⻠Ṷ, Attractive
scenario writing for PBL Ṷ⠪)
7㧕 ╙ 28 ࿁ᣣᧄක≮ᖱႎቇㅪวᄢળ(᜗ᓙ⻠Ṷ ࠪࡒࡘ࡟࡯࡚ࠪࡦࠍකቇᢎ⢒ߦዉ౉ Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 㜞ᯅఝਃ㧦ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓኻᔕဳߩකቇታ⠌ᢎ᧚ߩ㐿⊒ߣ᥉෸㧦ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ታ❣ႎ๔ᦠ ၮ⋚⎇ⓥ(B)(2006 ᐕ)2㧕 㐳㊁ ഞ㧦⢄ๆ⯻㧔࠲ࠗ⢄ๆ⯻㧕⚵឵߃Ⱞ⊕᛫ේࠍ↪޿ߚਛ࿖߅ࠃ߮࠲ࠗ࿖ౝߦ߅ߌࠆⴊᷡ⸻ᢿᴺ
ߩ⏕┙㧦ᐔᚑ 18 ᐕᐲᐔ๺ਛፉ⽷࿅ࠕࠫࠕ࿾ၞ㊀ὐቇⴚ⎇ⓥഥᚑႎ๔ᦠ(2007 ᐕ 5 ᦬)
3㧕 ๓ ᔒ⦟, 㐳㊁ ഞ㧦ᣓᲫ⯻ᗵᨴߦࠃࠆኋਥ╭⡺⚦⢩ᄌ⇣ߩㆮવሶ⊒⃻േᘒߩ⸃ᨆߣߘߩಽሶᯏ᭴ߩ
⸃᣿㧦ᐔᚑ 17 ᐕᐲ㧙18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ႎ๔ᦠ(2007 ᐕ 5 ᦬)
11㧚ႎ㆏1㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛㇱ⚻ᷣᣂ⡞(2006 ᐕ 1 ᦬ 1 ᣣ)
2㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦⺒ᄁᣂ⡞(2006 ᐕ 5 ᦬ 2 ᣣ)
3㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ฬฎደ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 5 ᦬)
4㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦Ფᣣ᡼ㅍ NEWS(2006 ᐕ 5 ᦬)
5㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ᦺᣣ᡼ㅍ(2006 ᐕ 5 ᦬)
6㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛ੩࠹࡟ࡆࡊ࡜ࠬࡢࡦ(2006 ᐕ 5 ᦬)
7㧕 㜞ᯅఝਃ㧦࠮࡞ࡈࠨࡐ࡯࠻࡮ࠦ࡯࠴ࡦࠣ࡮ࠗࡦ࠲ࡆࡘ࡯ ╙ 2 ࿁㧦JAMIC JOURNAL vol.26
No.6(2006 ᐕ 6 ᦬)
8㧕 㜞ᯅఝਃ㧦ᘠࠇೋ߼ߐࠎ㧦ጘ㒂᡼ㅍ࠾ࡘ࡯ࠬ(2006 ᐕ 6 ᦬)
9㧕 㜞ᯅఝਃ㧦ో࿖ࡃࠗࠝࠢ࡜ࠬ࠲࡯ត⸰ԙጘ㒂࡮ᄢ၂ࡠࡏ࠹ࠖ࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧦Bionics(2006ᐕ 7 ᦬)
10㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦᧲ᶏ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 7 ᦬)
11㧕 㜞ᯅఝਃ㧦ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ࡈࠫ࠹࡟ࡆࠬ࡯ࡄ࡯࠾ࡘ࡯ࠬ(2006 ᐕ 8 ᦬ 1 ᣣ)
12㧕 㐳㊁ഞ, 㜞ᯅఝਃ㧦ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞ᷝട ⊹⤏ࠤࡠࠗ࠼ᛥ೙ ጘ㒂ᄢ߇⊒⷗㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 11 ᦬ 11 ᣣ)
13㧕 㜞ᯅఝਃ㧦ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇߪ, ⃻ઍකቇᢎ⢒ߦ⊒⷗ߐࠇߚᣂᄢ㒽ߢ޽ࠆ‫ޕ‬㧦JMA ࡑࡀࠫࡔࡦ࠻
࡟ࡆࡘ࡯vol.12 No.11(2006 ᐕ 11 ᦬)
14㧕 㜞ᯅఝਃ㧦ነⓂ කቇᢎ⢒ߩ⻉໧㗴⸃᳿ߦࠪࡒࡘ࡟࡯࡚ࠪࡦߩᵴ↪ࠍ‫࡞࠺ࡕޟ‬㧒ࠪࡒࡘ࡟࡯࡚ࠪࡦ
කቇᢎ⢒⎇ⓥળ‫ߦ⿷⊒ޠ‬㓙ߒߡ㧦ㅳೀකቇ⇇ᣂ⡞(2006 ᐕ 12 ᦬ 4 ᣣ)
15㧕 㐳㊁ഞ, 㜞ᯅఝਃ㧦CMC ߢ߇ࠎჇᱺᛥ೙㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 12 ᦬ 14 ᣣ)
16㧕 㜞ᯅఝਃ㧦ක≮ታ⠌↪ᖚ⠪ࡠࡏ࠶࠻㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 6 ᦬ 15 ᣣ)
17㧕 㜞ᯅఝਃ, 㐳㊁ഞ㧦CMC㧦ᣣೀᎿᬺᣂ⡞(2007 ᐕ 2 ᦬ 6 ᣣ)
18㧕 㜞ᯅఝਃ㧦ࠪࡒࡘ࡟࡯࡚ࠪࡦකቇᢎ⢒㧦ࠫࡖࡒ࠶ࠢࠫࡖ࡯࠽࡞(2007 ᐕ 3 ᦬)
19㧕 㐳㊁ഞ㧦὇⚛❫⛽ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞, ⊕ⴊ∛⚦⢩Ⴧᱺࠍᛥ೙㧦ਛᣣᣂ⡞(2008 ᐕ 3 ᦬ 12 ᣣ)
20㧕 㐳㊁ഞ㧦ነ↢⯻ߣੱ㑆ߩ౒↢ࠍតࠆ㧦ጘ㒂ᣂ⡞(2008 ᐕ 8 ᦬ 5 ᣣ)㧙㧙

21㧕 㐳㊁ഞ㧦CMC㧔ࠞ࡯ࡏࡦࡑࠗࠢࡠࠦࠗ࡞㧕, ⊕ⴊ∛ᴦ≮ߦലᨐ, ߇ࠎ⚦⢩ߩჇᱺᛥ೙㧦ᣣೀᎿᬺᣂ
⡞(2008 ᐕ 3 ᦬ 31 ᣣ)
22㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮㧦ฬฎደ࠹࡟ࡆႎ㆏(2008 ᐕ 2 ᦬ 15 ᣣ)
23㧕 㜞ᯅఝਃ㧦ᄢቇ⊒ࡌࡦ࠴ࡖ࡯ડᬺ ࡔ࠺ࠖࠞ࡞ᗲ㧦ਛᣣᣂ⡞(2008 ᐕ 4 ᦬ 12 ᣣ)
24㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮㧦਎⇇ࠍᄌ߃ࠆᣣᧄੱ 100 ฬ㧦࠹࡟ࡆ᧲੩(2008 ᐕ 10 ᦬ 17 ᣣ)
25㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮 ᖚ⠪ࡠࡏ࠶࠻ ᘠࠇೋ߼ߐࠎ㧦ਛᣣᣂ⡞(2008 ᐕ 12 ᦬ 4 ᣣ)
26㧕 㜞ᯅఝਃ㧦ࡃ࡯࠴ࡖ࡞∛㒮 ߅ߪࠃ߁ᣣᧄ㧦NHK ࠹࡟ࡆ(2008 ᐕ 11 ᦬ 14 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᣓᲫ⯻ߩᗵᨴ∛ℂߦߟ޿ߡಽሶ↢‛ቇ⊛ߦ⸃ᨆࠍㅴ߼ߡ޿ࠆ‫ߩߘޕ‬ᚑᨐߪ, ᐢߊᶏᄖߦ⍮ࠄࠇᣓᲫ⯻∝ߩಽ㊁ߢߪ᣿ࠄ߆ߦࡄࠗࠝ࠾ࠕ⊛ߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬ጘ㒂ᄢቇౝߦ޽ߞߡߪ, ነ↢⯻ᗵᨴ∝ߩࠦࡦࠨ࡞࠲ࡦ࠻ᬺോࠍᜂߞߡ޿ࠆ‫ޕ‬ዋߥ޿ੱᢙߥ߇ࠄ, ነ↢⯻ቇળ߿ᄢቇ߳ߩ⽸₂ᐲߪᄢ߈޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇㇱߢၮ␆කቇࠍᔒߔ⧯⠪ߪᷫዋߒߡ޿ࠆ‫ޕ‬ነ↢⯻ቇߩಽ㊁ߪ․ߦ⪺ߒ޿‫ᦨ߇ࠇߎޕ‬ᄢߩ໧㗴ߢ޽ࠅ, ኻᔕ╷ߪਲߒ޿‫ޕ‬੹ᓟߩዷᦸᣓᲫ⯻∝ߩᗵᨴ∛ℂ⎇ⓥߦ㑐ߒߡߪ, ᗵᨴ╭⡺ߩ⚵❱∛ℂ߆ࠄోりߩ෻ᔕ߳⸃ᨆߩ㊀ὐࠍ⒖ߒ, ߎߩಽ㊁ߢ߽਎⇇ߩ࡝࡯࠼ᓎࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔5㧕ㆮવ⊒↢ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ㆮવ⊒↢ಽ㊁ߩ⎇ⓥ⋡⊛ߪ↢๮ࠍㆮવߣ⊒↢ߩⷞὐ߆ࠄ⸃᣿ߒ㧘ߐࠄߦߘࠇࠍ∔ᖚߩ⸃᣿ߣ⸻ᢿᴦ≮ߦᔕ↪ߔࠆߎߣ㧘߅ࠃ߮ߎߩ⋡⊛ࠍㆀⴕߢ߈ࠆੱ᧚ࠍ⢒ᚑߔࠆߎߣߢ޽ࠆ‫ޕ‬⎇ⓥ㕙ߢߪ㧘ࠕ࡟࡞ࠡ࡯㧘వᄤᕈ఺∉ਇో∝㧘వᄤᕈઍ⻢⇣Ᏹ㧘≸㧘ࡅ࠻ߩ⊒↢㧘ಽൻ㧘␹⚻ߥߤߦߟ޿ߡ㧘↹ᦼ⊛㧘⁛ഃ⊛ߥ idea ߣ strategy ࠍ㚟૶ߒߡ㧘ಽሶㆮવቇ⊛߆ߟ᭴ㅧ↢‛ቇ⊛ߦ⸃ᨆߒߡ޿ࠆ‫ޕ‬ㄭᐕ㧘ㆮવᕈ∔ᖚߪ⸻ᢿ㧘ᴦ≮ߩߺߢߥߊ㧘ࠞ࠙ࡦ࠮࡝ࡦࠣ㧘ࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘ᔃℂ⊛ࠤࠕ㧘␠ળ⊛ࠨࡐ࡯࠻ࠍ฽߼ߚ✚ว⊛ࡈࠜࡠ࡯ࠕ࠶ࡊߩ㊀ⷐᕈ߇ต߫ࠇߡ޿ࠆ‫⎇ޕ‬ⓥᚑᨐߩᔕ↪ߣߒߡᧄቇߦ߅
޿ߡ߽㧘ㆮવ∛⸻≮߇ߥߐࠇ㧘ቯᦼ⊛ߥ∝଀ࠞࡦࡈࠔ࡟ࡦࠬࠍ㐿௅ߒ㧘ࠃࠅ⦟޿ㆮવ∛⸻≮ࠍ⋡ᜰߒߡᵴേߒߡ޿ࠆ‫ߩߘޕ‬ౝኈߪਥߦ㧘ᖚ⠪߅ࠃ߮ࠢ࡜ࠗࠛࡦ࠻ߦኻߔࠆᖱႎឭଏ㧘ࠞ࠙ࡦ࠮࡝ࡦࠣᣇ㊎ߩᬌ⸛㧘⥃ᐥㆮવߦ㑐ߔࠆᦨᣂ⍮⷗㧘⻉⺖㗴ߦߟ޿ߡߩᖱႎᗧ⷗੤឵㧘⥃ᐥฦ⑼ߩ⋧⺣߳ߩኻᔕߥߤߢ޽ࠆ‫ޕ‬߹ߚ㧘2003 ᐕߦߪᣣᧄੱ㘃ㆮવቇળᣂ೙ᐲߦࠃࠆ⎇ୃᜰቯࠍ₪ᓧߒߚ‫ޕ‬2004 ᐕᤐࠃࠅᣂߚߦㆮવ⊒↢ಽ㊁ߣߒߡ⁛┙ߒߚߩࠍᯏળߦ㧘ߐࠄߦ⎇㐭ߦദ߼ߡ޿ࠆ‫ߩ࠻ࡅޕ‬಴↢೨ᦼߩㆮવ࡮⊒↢෸߮㧘಴↢ᓟߩᚑ㐳࡮⊒㆐ߦ߅ߌࠆ↢ℂ⊛߆ߟ∛⊛⁁ᘒࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬ၮ␆⎇ⓥߦ߅޿ߡ㧘ᐞߟ߆ߩಽ㊁ߦ⛉ࠆߎߣߦࠃࠅ㧘ᅏᷓ޿⎇ⓥ߇ㅴ߼ࠄࠇߡ޿ࠆ‫࡯ࠡ࡞࡟ࠕޕ‬㧘఺∉ਇో㧘ઍ⻢⇣Ᏹߩฦಽ㊁ߢᐞߟ߆ߩ∔ᖚߩ∛࿃ㆮવሶ߇ᒰ⻠ᐳߢ਎⇇ߦవ㚟ߌࠢࡠ࡯࠾ࡦࠣߐࠇ㧘਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐ߇ᐞߟ߽ヘ಴ߐࠇ㧘ᣂ⡞⚕਄ߩ৻㕙ߢ߽ขࠅ਄ߍࠄࠇߡ޿ࠆ‫ޕ‬ฦ࠹࡯ࡑߦ౒ㅢߔࠆߎߣߪ㧘
ฦಽ㊁ߩ∔ᖚߩ∛࿃ߣ∛ᘒߩ⸃᣿ߢ޽ࠅ㧘ߘߩᚑᨐࠍ⸻ᢿ࡮ᴦ≮࡮੍⍮࡮੍㒐ߦㆡᔕߒߡ޿ߊߎߣߢ޽ࠆ‫ޕ‬ߐࠄߦߎࠇࠄࠍㅢߓߡ㧘ࡅ࠻ߩㆮવ࡮⊒↢㧘ᚑ㐳࡮⊒㆐ߩᣂߚߥ⸃᣿ߦߟߥߍߡ޿ࠆ‫ޕ‬ᣇᴺ⺰⊛ߦߪ㧘ᣣᏱ⥃ᐥߩਛ߆ࠄࡅࡦ࠻ߣ⊒ᗐ߇ᓧࠄࠇ㧘ㆮવሶቇ⊛ᚻᴺߦട߃㧘කቇ߳ߩ᭴ㅧ↢‛ቇߩዉ౉㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩ᭴ㅧ↢‛කቇ structure biological medicine ㄭ⮮ߦࠃࠆ㧕ࠍߒߡ޿ࠆ‫ࡓࡁࠥޕ‬ㆮવሶ⇣Ᏹ߆ࠄࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ㧘ㆮવሶ⊒⃻⇣Ᏹࠍ⚻ߡ࠲ࡦࡄࠢ┙૕᭴ㅧߩ⇣Ᏹߣᯏ⢻⇣Ᏹߣߩ㑐ㅪࠍ⸃ᨆߒ㧘⸻ᢿ࡮ᴦ≮߳ߩᔕ↪ࠍㅴ߼ߡ޿ࠆ‫ޕ‬਎⇇⊛߆ߟ↹ᦼ⊛ߥᚑᨐ߇ᦼᓙߐࠇߡ޿ࠆ‫ߩࠄࠇߎޕ‬ᚑᨐߪᐞߟ߆ߩᄢဳ┹ว⊛⎇ⓥ⾌₪ᓧߦ⃻ࠇߡ޿ࠆ‫ޕ‬એਅ⹦⚦ߪ㧘ዊఽ∛ᘒቇߣ౒หߢ޽ࠆ‫ޕ‬1㧕ࠕ࡟࡞ࠡ࡯
Ԙࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ߩᛥ೙♽ߩ∛࿃ㆮવሶࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒ㧔Lancet 1996 ᐕ㧘
BBRC1999 ᐕߦ⛯޿ߡ, JACI 2003 ᐕ㧕㧘IgE ↥↢ߩᛥ೙♽ IL-12IL-12 ࡟࠮ࡊ࠲࡯߹ߚߪ IL-18IL-18
࡟࠮ࡊ࠲࡯IFNJࠪࠣ࠽࡝ࡦࠣߩ㊀ⷐᕈࠍ␜ߒߚ‫ޕ‬ԙߎࠇࠄߩᚑᨐࠍ߽ߣߦߒߡ਎⇇ߦవ㚟ߌߡ㧘ᣂߚߦࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ࠍㆮવሶቇ⊛ߦಽ㘃ߒߚ‫ޕ‬Ԛߐࠄߦ㧘ߎࠇࠍ߽ߣߦࠕ࡟࡞ࠡ࡯㧔ࠕ࠻ࡇ࡯㧕ߩㆮવሶ⸻ᢿࠠ࠶࠻ࠍ㐿⊒ߒ㧘․⸵↳⺧ਛߢ޽ࠆ㧔2007㧘2008 ᐕ㧕‫ޕ‬ԛࡅ࠻ IL-18 ߩ࠲ࡦࡄࠢ┙૕᭴ㅧࠍ਎
⇇ߦవ㚟ߌߡ⸃᣿ߒ㧔Nature structure biology 2003㧕㧘ߘߩ⥃ᐥᔕ↪ߣߒߡߩૐಽሶഃ⮎ࠍㅴ߼ߡ޿ࠆ‫ޕ‬Ԝㆮવሶᖱႎߣ᛫ࠕ࡟࡞ࠡ࡯⮎ലᨐ߆ࠄ୘೎ൻක≮㧘ߔߥࠊߜ㧘ࠕ࡟࡞ࠡ࡯ߩࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮ߩ⏕┙
ࠍㅴ߼“᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂᴺߩߚ߼ߩᚻᒁ߈”ࠍ਎⇇ߢೋ߼ߡ૞ᚑߒߚ‫ޕ‬ԝㆮવሶ⊒⃻㧘RNA ࡊࡠ࠮࠶ࠪࡦࠣ․ߦ RNA editing ߣ alternative splicing ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ㑐ࠊߞߡ޿ࠆߎߣࠍ
਎⇇ߢೋ߼ߡ⸃᣿ߒߚ‫ޕ‬Ԟ㘩‛ࠕ࡟࡞ࠡ࡯ߩ᛫ේ․⇣ᕈߩ⊒⃻ᯏ᭴ߩ⸃᣿ߩߚ߼㧘T ⚦⢩ࠢࡠ࡯ࡦߩ᮸┙ߦ਎⇇ߢೋ߼ߡᚑഞߒ㧘ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆ HLAࡍࡊ࠴࠼T ⚦⢩࡟࠮ࡊ࠲࡯ߩ․⇣ᕈߣ⚿วᕈࠍ⚻ญ఺∉ኡኈࠍ⺃ዉߔࠆᴦ≮ᴺ⏕┙૕᭴ㅧ߆ࠄ⸃᣿ߒߡ޿ࠆ‫ޕ‬
㧔PNAS 2008 ઁ㧕ԟߎߩᚑᨐߦၮߠ޿ߡ㧘⚻┙ߩߚ߼“㘩ߴߡᴦߔ㘩ຠߩ㐿⊒”ࡊࡠࠫࠚࠢ࠻߇⃻࿷ㅴⴕߒߡ޿ࠆ‫ޕ‬ԠⅣႺߣㆮવሶߦࠃࠆࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩㆮ
ㆮવሶ↢ᘒකቇ genetic ecological medicine -ㄭ⮮ߦࠃࠆ㧕‫ޕ‬᷷ᐲᄌൻߦࠃࠅ㧘NF-kappaB ߩᯏ⢻߇ᄌൻߒ㧘ࠨࠗ࠻ࠞࠗࡦ↥↢ࡄ࠲࡯ࡦ߇ᄌൻߔࠆߎߣࠍ
᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬᭎ᣣ࡝࠭ࡓߩⷞὐ߆ࠄ㧘శߣ૕ౝᤨ⸘ㆮવሶߣߩ㑐ㅪࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԡ⥄ὼ఺∉♽ߣ∔ᖚߣߩ㑐ㅪࠍត᳞ߒᴦ≮㐿⊒ߦߟߥߍࠆߚ߼ߦ㧘Toll like receptor㧔TLR㧕߅ࠃ߮ߘߩࠪࠣ࠽࡞વ
㆐♽ߩ MyD88 ಽሶߥߤߩಽሶ߅ࠃ߮ߘࠇࠄߩ⚿ว᭽ᑼࠍ᣿ࠄ߆ߦߒ㧘หᤨߦߘࠇࠄߩㆮવሶቇ⊛࠲ࡦࡄࠢ᭴ㅧቇ⊛⇣Ᏹࠍ᣿ࠄ߆ߦߒߡ޿ࠆ‫ޕ‬Ԣࠬ࠻࡟ࠬߣࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧘࠙ࠗ࡞ࠬᗵᨴߦ
ࠃࠆࠕ࡟࡞ࠡ࡯⊒∝㧘ࠕ࡜ࠠ࠼ࡦ㉄ࠞࠬࠤ࡯࠼ߩ⹏ଔߣࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮㧘⾰ߩ㜞޿ QOL ⹏ଔ⴫ߩ૞
ᚑ㧘⤯Ꮺⴊࡊࡠࠫࠚࠢ࠻㧘FACS ࠍ↪޿ߚ⥄ὼ఺∉♽⺞▵ᕈ T ⚦⢩ߩ⸃ᨆߣ₪ᓧ఺∉♽ Th1࡮Th2 ࠕࡦࡃ࡜ࡦࠬߩ⸃᣿ߣᔕ↪ߥߤ‫ޕ‬ԣએ਄ߩࡊࡠࠫࠚࠢ࠻ߦ㑐ߒߡએਅߩᄢဳ┹ว⊛ᄖㇱ⾗㊄ࠍ₪ᓧߢ߈ߚ‫ޕ‬㧔ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ߥߤߪ೎㗄ෳᾖ㧕
1. 㧨ᢥㇱ⑼ቇ⋭㜞╬ᢎ⢒ዪ㧪ᢥㇱ⑼ቇ⋭㜞ᐲవㅴක≮㐿⊒⚻⾌‫∔࡯ࠡ࡞࡟ࠕ࡮∉఺ޟ‬ᖚ∛࿃࠲ࡦࡄࠢ
⾰┙૕᭴ㅧߦၮߠ޿ߚ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦࠃࠆᴦ≮ᴺߩ⏕┙‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⎇ⓥදജ⠪ ട⮮ༀ৻㇢㧘◉↰⚩ม㧘ኹᧄ⾆⧷㧘ਅỈિⴕ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘᪀↰৻ᄦ㧘㋈ᧁᱜᤘ㧘⊕Ꮉ᣽㧙㧙ብ 㧔ᐔᚑ 13㧙15 ᐕ㧕
2. 㧨ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧪఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ਥછ⎇ⓥ⠪ ㄭ⮮ ⋥ታ ⃰ຬ ᧻੗ ᳗ሶ߶߆㧔ᐔᚑ 16㧙21 ᐕ㧕
3. 㧨↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧪⇣ಽ㊁Ⲣว⎇ⓥ㐿⊒ဳ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㘩ຠߩၮ␆⎇ⓥߦၮߠߊ↹ᦼ⊛ഃᚑ‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⃰ຬ ㊄ሶ⧷㓶߶߆㧔ᐔᚑ 17 ᐕࠃࠅ 5 ᐕ㑆㧕2㧕వᄤᕈ఺∉ਇో∝ߣ DNA ୃᓳ
IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߩ∛࿃ߣߥࠆㆮવሶ⇣Ᏹࠍ਎⇇ߦవ㚟ߌ᣿ࠄ߆ߦߒߚ㧔J Clin Invest ෸߮
JACI 㧕‫ޕ‬Ᏹᨴ⦡૕ఝᕈߩㆮવᒻᑼࠍߣࠆ㜞 IgM ∝୥⟲ߩ∛࿃ߦߟ޿ߡ߽ AID ߩ dominant negative ലᨐߦࠃࠆߎߣࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒߚ (JACI 2003 ᐕ)‫ޕ‬Ყセ⊛㗫ᐲߩ㜞޿఺∉ਇో∝ߢ޽ࠆ IgA ᰳ៊∝ߦߟ޿ߡ⸃ᨆࠍⴕ޿ߘߩ B ⚦⢩ߩಽൻ㓚ኂㇱ૏ࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬㧘ᧄ㇌ 2 ଀⋡ߩ఺∉ࠣࡠࡉ
࡝ࡦ㊀㎮ㆮવሶߩᰳ៊ኅ♽ࠍႎ๔ߒߚ‫ޕ‬㜞⊒≸ߣ఺∉ਇోࠍ␜ߔ Bloom ∝୥⟲߿ Ataxia-telangiectasiaߩ∛࿃ㆮવሶ BLM ߣ ATM ߩᯏ⢻ߣ᭴ㅧߩ⸃ᨆࠍㅢߒߡ⚦⢩๟ᦼ㧘DNA ୃᓳ㧘ࠪࠣ࠽࡞વ㆐ߦߟ߈⸃
᣿ߒ⊒≸ᯏ᭴ߩ⸃᣿ࠍⴕߞߡ޿ࠆ㧔Blood ,CEI, PNAS ઁ㧕‫ߦࠄߐޕ‬ᄙᓀߥ⥄ὼ఺∉ਇో∝㧘⥄ᏆἻ∝ᕈ∔ᖚߩ∛࿃∛ᘒ⸃᣿ߣᴦ≮㐿⊒ߦ⌕ᚻߒߚ‫ޕ‬3㧕᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧘․ߦࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯(SCOT)ߣ  ࠤ࠻࠴ࠝ࡜
࡯࠯ᰳ៊∝ߩ㉂⚛⸻ᢿ߿ㆮવሶ⸻ᢿߦ߅޿ߡߪ㧘਎⇇ਛ߆ࠄߩଐ㗬ࠍ߁ߌߡ⸃ᨆࠍⴕߞߡ޿ࠆ‫ߢ߹ࠇߎޕ‬ᄙߊߩㆮવሶᄌ⇣ߣߘߩ․ᓽࠍ᣿ࠄ߆ߦߒߡ߈ߚ‫ޕ‬ᱷሽᵴᕈࠍ߽ߟシ∝ဳߩEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝㧘
SCOT ᰳ៊∝ߩౖဳ଀ߣߩ⥃ᐥ௝ߩ㆑޿ߦߟ޿ߡ߽᣿ࠄ߆ߦߒߡ޿ࠆ‫౒ߩߣࡊ࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ห⎇ⓥߢ㧘ࡅ࠻ߩ⚦⢩⾰࠴ࠝ࡜࡯࠯ߣࡒ࠻ࠦࡦ࠼࡝ࠕࠕ࠮࠻ࠕ࠮࠴࡞-CoA ࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧࠍ᳿ቯߒ㧘ߐࠄߦࠕࡒࡁ㉄ᄌൻ߇Ⱞ⊕ߦਈ߃ࠆᓇ㗀ߦߟ޿ߡߩ⸃ᨆࠍㅴ߼ߡ޿ࠆ㧚ፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄
 ㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ߈ߡ޿ࠆ‫ޕ‬
4㧕ㆮવᕈࡓࠦᄙ♧∝ㆮવᕈࡓࠦᄙ♧∝ߦߟ޿ߡᣧᦼ⸻ᢿ㧘ಽሶ∛ᘒ⸃ᨆ㧘ᴦ≮ᴺ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ࠦࡓߦ․ޕ‬ᄙ♧∝ΦA ဳߩ⎇ⓥߢߪ㧘࿖㓙ࡊࡠࠫࠚࠢ࠻ߩ✚᜝⊛┙႐ߢ∔ᖚ⸃ᨆ࡮ᴦ≮ᴺ㐿⊒ࠍⴕߞߡ߅ࠅ㧘Τဳߩ⥄ὼᱧ⺞ᩏ߿㉂⚛⵬ల≮ᴺ㧘ࡓࠦᄙ♧∝ో⥸ߩᣧᦼࡑࠬࠬࠢ࡝࡯࠾ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒߽૬ߖߡ㧘ࡌࡦ࠴ࡖ࡯ડᬺ
ߣߩ౒ห⎇ⓥ߽ㅴ߼ߡ޿ࠆ‫ޕ‬
5㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛వᄤᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߩ∛࿃ߣᴦ≮ߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ߅ࠅ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩᣂⷙ∛࿃ㆮવሶ PEX16,19,13,3,26 ߩหቯ㧘᷷ᐲᗵฃᕈ⃻⽎ߩ⊒⷗㧘ᣂߚߥE㉄ൻ㉂⚛ᰳ៊∝ߩ⊒⷗㧘೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩ㛽㜑⒖ᬀߩฦ‫ߡ޿ߟߦޘ‬਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐࠍ᜼ߍߡ޿ࠆ‫ޕ‬ㆮવሶ⸻ᢿߣߒ
ߡ PEX10 ㆮવሶߩ 2 Ⴎၮᰳᄬ㧘PEX16 ㆮવሶ⇣Ᏹ㧘PEX26 ㆮવሶ⇣Ᏹߥߤࠍ⸻ᢿߒߚ߶߆㧘㕖Ᏹߦ․߹ߚ㧘⇣ߥ଀ߣߒߡ㧘Zellweger ∝୥⟲ߩ⥃ᐥ௝ࠍ๒ߒ ALDP ㆮવሶࠍ฽߻ large deletion ଀ࠍ⸻ᢿߒߚ‫ޕ‬ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩ᷷ᐲᗵฃᕈߦߟ޿ߡߪ࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ߿シ∝ဳ᷷ᐲᗵฃᕈࡕ࠺࡞ࡑ࠙
ࠬߩ૞ᚑߥߤࠍⴕ޿㧘ᧄ∝ߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ␹
⚻⊒↢ㆊ⒟ߦ߅ߌࠆᓎഀߦߟ޿ߡ㧘఺∉⚵❱ൻቇ⊛ᚻᴺࠍ↪޿ߡ⸃ᨆਛߢ޽ࠆ‫ޕ‬
6㧕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ
ዊఽߩ∔ᖚ㑐ㅪⰮ⊕⾰ߩ┙૕᭴ㅧ⸃ᨆߦၮߠ޿ߚ∛ᘒ⸃ᨆ࡮ᴦ≮ᴺߩ㐿⊒ߥߤࠍⴕ߁”᭴ㅧකቇ”ߩ⏕┙ࠍ⋡ᜰߒ㧘ૐಽሶ࡝ࠟࡦ࠼ࠬࠢ࡝࡯࠾ࡦࠣ࡮Ⱞ⊕࡟ࡌ࡞ߢߩⰮ⊕Ꮏቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆᴦ≮ᴺߩ㐿⊒ߦ㊀ὐࠍ⟎޿ߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘⥄ὼ఺∉߆ࠄ₪ᓧ఺∉ߦ⥋ࠆ⚻〝ߦ㑐ਈߔࠆ㧘IL-18㧘IL-1㧘෸߮ Toll-like Receptor ⟲ߦᔅ㗇ߥಽሶߢ޽ࠆࠪࠣ࠽࡞વ㆐ࠕ࠳ࡊ࠲࡯Ⱞ⊕ࠍਛᔃߦߒߚ᭴ㅧቇ⊛⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߩᚑᨐߩ৻ߟߣߒߡ㧘ᄙᰴరᩭ⏛᳇౒㡆ᴺߦߡ᳿ቯߒߚࡅ࠻ IL-18 ┙૕᭴ㅧࠍ߽ߣߦ㧘ᄌ⇣૕⸃ᨆࠍⴕ޿㧘ࠗࡦ࠲࡯ࡠࠗࠠࡦߦ߅ߌࠆᣂߒ޿⚿ว᭽ᑼߩ⸃᣿ߦ⥋ߞߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ㄭ⮮⋥ታᢎ᝼(૬છ)㧦 ᪀↰৻ᄦ

Naomi Kondo
Kazuo Kuwata3㧚 ⎇ⓥᚑᨐߩ⊒⴫ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ㧙㧙4㧚 ⎇ⓥ⾌₪ᓧ⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
5㧚 ⊒᣿࡮․⸵಴㗿⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
6㧚 ቇળᵴേ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
7㧚 ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
8㧚 ቇⴚ⾨╬ߩฃ⾨⁁ᴫዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
9㧚 ␠ળᵴേ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
10㧚ႎ๔ᦠ
ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
11㧚ႎ㆏ዊఽ∛ᘒቇ㧘ੱ₞ᗵᨴ㒐ᓮ࠮ࡦ࠲࡯ෳᾖ
12㧚⥄Ꮖ⹏ଔ
⹏ଔ✚ว⊛ߦߪߘࠇߥࠅߩ⹏ଔߪߢ߈ࠆ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈⎇ⓥᚑᨐߣᬺ❣ߩᦝߥࠆ⛽ᜬ㧘ะ਄߇ᦸ߹ࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷ዊఽ∛ᘒቇߣ౒หߒߡ޿ࠆ‫ోޕ‬㗔ၞࠍࠞࡃ࡯ߔࠆዊఽ⑼ߩ⥃ᐥ߆ࠄࠊ߈಴ࠆ⇼໧ߣ࠹࡯ࡑߩోߡߦ⌕ᚻߔࠆߎߣߪ࿎㔍ߢ޽ࠆ߇㧘ࠕ࡟࡞ࠡ࡯࡮఺∉࡮ઍ⻢ߦട߃ߡⅣႺ߿ᗵᨴߣㆮવሶߩࠃ߁ߥᣂߚߥࡊࡠ
ࠫࠚࠢ࠻ࠍ┙ߜ਄ߍߡㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߩ࠹࡯ࡑߣᣇะᕈߩᦝߥࠆలታߣ᜛ᄢ‫ߦࠄߐޕ‬㧘ߎࠇࠄߩᚑᨐࠍක≮ߦ⋥ធ⊛ߦᔕ↪ߔࠆ㧔࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴㧕‫ޕ‬㧙㧙㧔6㧕ౝಽᴲઍ⻢∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᣣᧄੱߩ 2 ဳ♧ዩ∛ߪᲧセ⊛߿ߖဳߢࠗࡦࠬ࡝ࡦಽᴲਇోࠍ․ᓽߣߔࠆߩߢ㧘⤟ౝಽᴲᯏ⢻ߣ㑐ㅪߔࠆౝಽᴲࠪࠬ࠹ࡓࠍ✚ว⊛ߦℂ⸃ߒ㧘ᣣᧄੱߦ․᦭ߩ∔ᖚᗵฃᕈࠍ᳞߼ࠆ‫ޕ‬ᚢ⇛ߣߒߡ㧘∔ᖚ⊒∝ߩ⽿છㆮવሶࠍಽሶㆮવቇ⊛ߦหቯߔࠆߎߣߦࠃߞߡ㧘♧ዩ∛ߩ⊒∝ᯏ᭴ߩ⸃᣿ߣ⟕ᖚ૕⾰ߩㆮવሶ⸻ᢿᴺߩ㐿⊒ࠍ⋡ᜰߔ‫ߚ߹ޕ‬㧘♧ዩ∛⸻≮ߩ⋡⊛ߪว૬∝ߩ੍㒐ߦ޽ࠆߩߢ㧘⒳‫ߩޘ‬ઍ⻢⇣Ᏹ㧘േ⣂⎬ൻ㧘⚦ዊⴊ▤∛ᄌߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒߽หᤨߦផㅴߔࠆ‫ޕ‬৻ᣇ㧘2 ဳ♧ዩ∛ߪ↢ᵴ⠌ᘠ∛ߩઍ⴫∔ᖚߢ޽ࠆߩߢ㧘㘩⠌ᘠ㧘ᣣᏱߩり૕ᵴേ㧘ࠬ࠻࡟ࠬᔕ╵ߥߤߩ⺞ᩏ⎇ⓥࠍ࿾ၞਥ૕ߦታᣉߔࠆߎߣߦࠃߞߡ㧘୘‫ߩޘ‬૕⾰ࠍ⠨ᘦߒߚࠝ࡯࠳࡯ࡔࠗ࠼⊛ߥ↢ᵴᜰዉᴺߩ㐿⊒߽ⷞ㊁ߦ⟎ߊ‫ޕ‬2㧚ฬ★
ᢎ᝼㧦ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦
ಎᢎ᝼(૬છ)㧦
ಎᢎ᝼(૬છ)㧦
⻠Ꮷ㧦
⻠Ꮷ(૬છ)㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
ഥᢎ㧦
කຬ㧦
කຬ㧦

ᱞ↰ ⚐
ጊᧄ⋿↱⟤
ട⚊సᓼ
㋈ᧁ⧷ม
ၳᎹᐘ↵
⺪⸰ື਽
૒‫ᧁޘ‬ᤘᒾ
Ꮉ࿾ᘕ৻
Ⴎ⼱⌀↱⟤
ᑝ↰ථ↵
ફ⷗ትବ
ằ⼱㜞ᔒ

Jun Takeda
Mayumi Yamamoto
Yoshinori Kano
Eiji Suzuki
Yukio Horikawa
Tetsuya Suwa
Akihiko Sasaki
Shin-ichi Kawachi
Mayumi Enya
Takuo Hirota
Nobutoshi Fushimi
Takashi Shibuya

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ቬ ෹ෘ㧚೽⣢㧙ࠕ࡞࠼ࠬ࠹ࡠࡦ⇣Ᏹ∝ ේ⊒ᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝߅ࠃ߮㘃✼∔ᖚ 11EHSD2 ᰳ៊∝(AME∝୥⟲)㧙ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥ೎ౠ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 1 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006 ᐕ㧦
651㧙654㧚2㧕 ጊᧄ⋿↱⟤㧚╙Σ▵ ஜᐽ⸻ᢿ㧘╙Χ▵ ᗵᨴ∝㧘ઃ㍳ ක≮࡮⑔␩೙ᐲ㧦ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧧2006 ᐕ㧦8㧙11㧘89㧙92㧘111㧙113㧚
3㧕 ૒‫ᧁޘ‬ᤘᒾ㧘ၳᎹᐘ↵㧘ᱞ↰ ⚐㧚♧ઍ⻢㧙MODY(1-6 ဳ) ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥ೎ౠ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 3 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006 ᐕ㧦54㧙57㧚
4㧕 㘵Ⴆൎ⟤㧘ၳᎹᐘ↵㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ⊒∝ⷐ࿃ߣߒߡߩౝ⤳⢈ḩ࡮⢽⢌⚦⢩ᯏ⢻⇣Ᏹ㧙⢽⢌⚦⢩ߩಽൻ࡮Ⴧᱺߩ߆߆ࠊࠆ࿃ሶ ChREBP. ਛየ ৻๺✬㧚ᣣᧄ⥃ᐥჇೀ 64 Ꮞ㧘ᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2006
ᐕ㧦249㧙253㧚
5㧕 ㋈ᧁ⧷ม㧚ၮ␆✬㧦PWV ࠍ⍮ࠆ ⤳ེ࡮ᯏ⢻㓚ኂߣ PWV㧚ਅ⢇ᓴⅣߣ PWV㧘ࡂࡦ࠭ࠝࡦࡉ࠶ࠢ PWVࠍ⍮ࠆ PWV ߢ⸻ࠆ ᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦132㧙138㧚
6㧕 ၳᎹᐘ↵㧘Ⴎ⼱⌀↱⟤㧚∔ᖚᗵฃᕈㆮવሶ⸃᣿ߩ⃻⁁ ᴡ⋓ 㓉ㅧ✬. ᣣᧄ⥃ᐥᣂᤨઍߩ♧ዩ∛ቇ(1)㧧
2008 ᐕ㧦387㧙392㧚
7㧕 Ⴎ⼱⌀↱⟤, ၳᎹᐘ↵㧚♧ዩ∛ߣ NASH-C. ⢽⢌⢄㧘♧ዩ∛㧘⢈ḩ౒ㅢㆮવ⚛࿃ߦߟ޿ߡ ⷏ේ೑ᴦ✬.
NASH ⸻≮ ਛᄖකቇ␠㧧2008 ᐕ㧦98㧙103㧚
8㧕 ၳᎹᐘ↵, Ⴎ⼱⌀↱⟤. TCF7L2 ㆮવሶ ᴡ⋓ 㓉ㅧ✬. ᣣᧄ⥃ᐥ㧦2008 ᐕ㧦678㧙683.
9㧕 ㋈ᧁ⧷ม㧚C㧚♧ዩ∛ߩ∉ቇ࡮∛ᘒ࡮⸻ᢿቇߩㅴᱠ 㨂㧚♧ዩ∛ᬌᩏቇߩㅴᱠ ♧ዩ∛㑐ㅪ⻉ᬌᩏ᧩᷹ቯ
ᴺ㧘 ⥃ᐥ⊛ᗧ⟵㧘 ⹏ଔᴺ᧩↹௝ᬌᩏ MRA㧘 ᣣᧄ⥃ᐥ ╙ 66 Ꮞ Ⴧೀภ 4 ᣂᤨઍߩ♧ዩ∛ቇ 2 Ꮞᄢ㒋㧦ᣣᧄ⥃ᐥ␠㧧2008 ᐕ㧦546㧙550㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚㜞ⴊ♧ߣⴊ▤⎬ൻ㧘Medical View Point 2006 ᐕ㧧27 Ꮞ㧦2㧚2㧕 ᱞ↰ ⚐㧚♧ዩ∛ߣࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍ߼ߋࠆ࠻ࡇ࠶ࠢࠬ㧘Medical View Point 2006 ᐕ㧧27 Ꮞ㧦1㧚
3㧕 ၳᎹᐘ↵㧚♧ዩ∛ߣࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍ߼ߋࠆ࠻ࡇ࠶ࠢࠬ㧙ࠗࡦࠬ࡝ࡦᛶ᛫ᕈߣㆮવ⚛࿃㧘Medical View
Point 2006 ᐕ㧧27 Ꮞ㧦4㧚4㧕 ᱞ↰ ⚐㧚♧ዩ∛㧙⤳ེ㓚ኂߩ੍㒐ࠍਛᔃߦ㧘MEDICAMENT NEWS 2006 ᐕ㧧1858 Ꮞ㧦14㧙16㧚㧙㧙

5㧕 Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧚⤟ፉ⊒⃻ㆮવሶߩࡊࡠࡈࠔࠗ࡝ࡦࠣ㧘ࠥࡁࡓකቇ 2006 ᐕ㧧5 Ꮞ㧦521㧙525㧚
6㧕 ጊᧄ⋿↱⟤㧚ൕഭ⠪ߩ♧ዩ∛ߩ∛ᘒߣ੍㒐㧘ᕺ㇊කᏧળߛࠃࠅ 2006 ᐕ㧧50 Ꮞ㧦35㧙41㧚
7㧕 ᱞ↰ ⚐㧚⚻ญᴦ≮⮎ߦࠃࠆⴊ♧▤ℂߩᦨ೨✢㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦335㧙340㧚
8㧕 ૒ ਭ 㑆 ඳ ਽ 㧘 ᑝ ↰ ථ ↵ 㧘 ᧛ ᧻  ቇ 㧘 ቬ  ෹ ෘ 㧚 ේ ⊒ ᕈ ࠕ ࡞ ࠼ ࠬ ࠹ ࡠ ࡦ ∝ ߩ 㘃 ✼ ∔ ᖚ 㧙 Apparent
Mineralocorticoid Excess ∝୥⟲㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦50㧙55㧚
9㧕 ᱞ↰ ⚐㧚♧ዩ∛ߩ⮎‛ᴦ≮ߩࠦ࠷㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦69㧙72㧚
10㧕 ጊᧄ⋿↱⟤㧚ጘ㒂⋵ߩ߅ߌࠆ♧ዩ∛ኻ╷ߩขࠅ⚵ߺߦߟ޿ߡ㧙♧ዩ∛ߩࡑࡀ࡯ࠫࡔࡦ࠻ࠍਛᔃߦ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦63㧙68㧚
11㧕 Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧘ቬ ෹ෘ㧘ᱞ↰ ⚐㧚⧯ᐕ⊒∝ߩ♧ዩ∛ߦ߅ߌࠆㆮવሶࠬࠢ࡝࡯࠾ࡦࠣ㧘ጘ㒂⋵කᏧળකቇ 㔀⹹ 2006 ᐕ㧧20 Ꮞ㧦29㧙31㧚
12㧕 ጊᧄ⋿↱⟤㧘ᱞ↰ ⚐㧘♿ࡁቯ଻⤿㧚ోᯏ⒳ߩ⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲ࠍጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹਄ߢ
ㆇ↪ߐߖࠆ⹜ߺ㧘Q&A ߢࠊ߆ࠆ‫ޟ‬⢈ḩߣ♧ዩ∛‫ ޠ‬2006 ᐕ㧧5 Ꮞ㧦47㧙51㧚
13㧕 ጟ቟િੑ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂ૕೙ᡷༀࠍ⋡⊛ߣߒߚ㒮ౝᮡḰᦠߩ૞ᚑߣߘߩ
⹏ଔ㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦464㧙468㧚
14㧕 ᱞ↰ ⚐㧘ᧃᑝ ᱜ㧘ᨋ⊓ᔒ㓶㧚♧ዩ∛ᖚ⠪ߩ⢽⾰▤ℂߣേ⣂⎬ൻ Medical View Point 2006 ᐕ㧧27
Ꮞ㧦5㧙6㧚
15㧕 ᱞ↰ ⚐㧚ᣣᧄ♧ዩ∛දળߣߪߤࠎߥ࿅૕㧫㧙‫⊓ޟ‬㍳ක‫ߚߒ੺ࠍޠ‬ᣂߒ޿‫⸻∛ޟ‬ᖚㅪ៤‫ߜߚ߆ߩޠ‬㧘ጘ㒂⋵කᏧળႎ 2006 ᐕ㧧660 Ꮞ㧦18㧙19㧚
16㧕 ૒ਭ㑆ඳ਽㧘ᱞ↰ ⚐㧚SHP ߣ♧⢽⾰ઍ⻢㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧23 Ꮞ㧦52㧙56㧚
17㧕 ᱞ↰ ⚐㧚⧯޿ᅚᕈߩ∳ߖᔒะࠍᘷ޿ߡ㧘ጘ㒂⋵කᏧળႎ 2006 ᐕ㧧661 Ꮞ㧦25㧙26㧚
18㧕 Ꮉ࿾ᘕ৻㧘ᱞ↰ ⚐㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߩਥⷐ∛ᘒߣߘߩ▤ℂ㧙ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߦ߅
ߌࠆⴊᩖᒻᚑ௑ะ㧘ᣣᧄ⥃ᐥ(Ⴧೀ) 2006 ᐕ㧧64 Ꮞ㧦445㧙448㧚
19㧕 ቬ ෹ෘ㧘ጊ↰ᣤሶ㧘ᑝ↰ථ↵㧘᧛᧻ ቇ㧘⺪⸰ື਽㧚ࡒࡀ࡜ࡠࠦ࡞࠴ࠦࠗ࠼ߩಽሶㆮવቇ㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧23 Ꮞ㧦643㧙647㧚
20㧕 ጊᧄ⋿↱⟤㧚ᗵᨴ∝ߣᄢቇ଻ஜ▤ℂ㧘ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠᐔᚑ 17 ᐕᐲ 2006
ᐕ㧧31㧙34㧚
21㧕 ᱞ↰ ⚐㧘ቬ ෹ෘ㧘ᄢᵢዏม㧘ᨋ ᘕ㧘ਃᶆ ᷕ㧚New Evidence for EVENT REDUCTION in
Hypertensive Patients ᦨᣂߩ ASCOT ⹜㛎߆ࠄ㒠࿶ᴦ≮ߦ߅ߌࠆࡌ࡯ࠬ⮎ߣߒߡߩࠕࡓࡠࠫࡇࡦߩ᦭↪
ᕈࠍᬌ⸽ߔࠆ Medical Tribune 2006 ᐕ㧧1㧙4㧚
22㧕 ᑝ↰ථ↵㧘᧛᧻ ቇ㧘૒ਭ㑆ඳ਽㧘⺪⸰ື਽㧘ቬ ෹ෘ㧘ᱞ↰ ⚐㧚னᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝㧦ᒝࡒࡁ C ߿↞⨲ࠍ฽߻ṽᣇ⮎ߪ૶ࠊࠇߡ޿ߥ޿߆㧫㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦893㧙894㧚
23㧕 ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᧄᄙᕶሶ㧘↰ਛᓕ㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇߦ߅ߌࠆ༛ᾍ
ኻ╷ߩ᦭ലᕈߩᬌ⸛㧙࠾ࠦ࠴ࡦࡄ࠶࠴ߩቇ↢ήఘឭଏࠍ⹜ߺߡ㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦160㧚
24㧕 ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩญ⣧ஜ⸻⚿ᨐߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦211㧚
25㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ㗡∩ߩታᘒ⺞ᩏ㧙▤ℂᜰዉ૕೙ߦ㑐ߔࠆᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦238㧚
26㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᬀᧁ໪ᢥ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚UPI ߣ GHQ60
ߩหᤨ⺞ᩏ⚿ᨐࠃࠅ㧘 ቇ↢ஜᐽ⺞ᩏߦ߅ߌࠆ UPI ᦭↪ᕈߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦269㧚
27㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ࡑࠢࡠࠕࡦࠡࠝࡄࠪ࡯ߩᬌᩏ࡮⸻ᢿᴺߩㅴᱠ ⏛᳇౒㡆ᴺߦࠃࠆᣂߒ޿⸻ᢿᴺ㧘 ᣣᧄ⥃
ᐥ 2006 ᐕ㧧64 Ꮞ㧦2062㧙2068㧚
28㧕 ㋈ᧁ⧷ม㧚Technics Guide ⏛᳇౒㡆ࠍ↪޿ߚࡈ࠶࠻ࡊࡠ࠻ࠦ࡞ߦࠃࠆ♧ዩ∛⿷∛ᄌߩᣧᦼ⊒⷗㧘 Diabetes
Journal 2006 ᐕ㧧35 Ꮞ㧦31㧙35㧚
29㧕 ૒ ਭ㑆ඳ਽ 㧘ᑝ ↰ථ↵㧘 ᧛᧻  ቇ㧘ቬ  ෹ෘ 㧚ౝಽᴲᕈ㜞 ⴊ࿶∝ ⸻ᢿ ߣᴦ≮ߩㅴᱠ  Apparent
Mineralocorticoid Excess ∝୥⟲㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦662㧙667㧚
30㧕 ቬ ෹ෘ㧚ࠕ࡞࠼ࠬ࠹ࡠࡦࠞࠬࠤ࡯࠼ߣㆮવሶᄙဳ㧘කቇߩ޽ࠁߺ 2007 ᐕ㧧221㧦709㧙715㧚
31㧕 ቬ ෹ෘ㧚Cushing ∝୥⟲㧘Year Note ೎ౠ 2007 ᐕ㧧589㧙593㧚
32㧕 㘵Ⴆൎ⟤, ၳᎹᐘ↵. ࠞ࡞ࡄࠗࡦ 10, ࠞ࡜࡯  ♧ዩ∛ቇ̆ၮ␆ߣ⥃ᐥ̆ 2007 ᐕ㧧319㧙322.
33㧕 Ⴎ⼱⌀↱⟤, ၳᎹᐘ↵, ᱞ↰ ⚐. SHP ߣ♧⢽⾰ߦ㑐ߔࠆઍ⻢⇣Ᏹ, ᦨᣂකቇ 2007 ᐕ㧧62 Ꮞ㧦63㧙68㧚
34㧕 ㋈ᧁ⧷ม㧚ᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘 Diabetes In The News(DITN) 2007 ᐕ㧧353 Ꮞ㧦
8㧚35㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ᖚ⠪ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Angiology Frontier 2007 ᐕ㧧
6㧚
36㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻. ක≮ࠍᄌ߃ࠆ IT ൻߩࡔ࡝࠶࠻㧘ක≮ኾ㐷⡯ߩࡑࡀࠫࡔࡦ࠻ᢎ⢒ߦ߅
ߌࠆ IT ᵴ↪ߩน⢻ᕈ ᣂක≮ 2007 ᐕ㧦54㧙57㧚
37㧕 ቬ ෹ෘ. JAC 2007 ᐕࠍᝄࠅ㄰ߞߡ࡯ᦨㄭߩࠕ࡞࠼ࠬ࠹ࡠࡦ⎇ⓥߩേะࠍតࠆ࡯Medical tribune, 2008
ᐕ㧦82㧙83㧚38㧕 ጊᧄ⋿↱⟤㧘Ⴎ⼱⌀↱⟤㧘ၳᎹᐘ↵㧘ᱞ↰ ⚐㧚ጘ㒂Ꮢߦ߅ߌࠆ♧ዩ∛⸻≮ߩታᘒ⺞ᩏ ጘ㒂⋵කᏧળකቇ㔀⹹ 2008 ᐕ㧧21 Ꮞ㧦89㧙94㧚
39㧕 ၳᎹᐘ↵. ♧ዩ∛ߩᣂߒ޿ㆮવ⚛࿃ Diabetes Frontier 2008 ᐕ㧧19 Ꮞ㧦441㧙452㧚 
40㧕 㐳ἑᳯ೑㧘 ᓮ↰᧛⋧ᮨ㧘 ↰ਛ↢㓷㧘 ᱞ↰ ⚐㧘 ጊᧄ⋿↱⟤. ᄢቇ↢ࠍኻ⽎ߦታᣉߒߚ㗡∩ታᘒ⺞ᩏ ቇᩞ଻ஜ⎇ⓥ 2008 ᐕ㧧50 Ꮞ㧦264㧚
41㧕 ጊᧄ⋿↱⟤㧘Ꮉ಴㕏ᒾ㧘ᚭ⼱ℂ⧷ሶ㧘ᱞ↰ ⚐㧘᪢ᧄᢘᄦ㧘♿ࡁቯ଻⤿ጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓߦ߅㧙㧙ߌࠆ㧘♧ዩ∛⸻ㅪ៤ࠨࡐ࡯࠻ࠪࠬ࠹ࡓߩ⹜૞ ⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ㧦556㧙561㧚42㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ߣᧃ᪳ᓴⅣ㓚ኂ㧘৻ችකႎ 2008 ᐕ㧧172 Ꮞ㧦12㧙17㧚✚⺑㧔᰷ᢥ㧕
1㧕 Horikawa Y. Calpain-10(NIDDM1) as a susceptibility gene for common type 2 diabetes. Endocr. J.
2007;53:567-576.
2㧕 Iizuka K, Horikawa Y. ChREBP: A glucose-activated transcription factor involved in the developmentof metabolic syndrome Endocr. J .2008;55:617-624.
ේ⪺㧔๺ᢥ㧕
1㧕 ↰ਛ↢㓷㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ᵴߣࡔࡦ࠲࡞ࡈ࡞ࠬࠨࡐ࡯࠻㧙2005 ᐕጘ㒂ᄢቇቯᦼஜᐽ⸻ᢿᤨ UPI ⺞ᩏࠃࠅ⠨ኤ㧘߉߰♖␹଻ஜ⑔␩ 2006 ᐕ㧧42 Ꮞ㧦47㧙52㧚
2㧕 Ꮉ࿾ᘕ৻㧘ᱞ↰ ⚐㧚᛫ࠕ࡟࡞ࠡ࡯೷ߩ૬↪ߢ⣕ᗵᩏߦᚑഞߒߚහᤨဳోりࠗࡦࠬ࡝ࡦࠕ࡟࡞ࠡ࡯ߩ 1 ଀㧘♧ዩ∛ 2006 ᐕ㧧9 Ꮞ㧦441㧙444㧚
3㧕 ጊᧄ⋿↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2006 ᐕ㧧24 Ꮞ㧦32㧙37㧚
4㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2006 ᐕ㧧44 Ꮞ㧦109㧙114㧚
5㧕 ጊᧄ⋿↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2007 ᐕ㧧24 Ꮞ㧦32㧙37㧚
6㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧚ጘ㒂ᄢቇ↢ᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧24 Ꮞ㧦109㧙114㧚
7㧕 ጊᧄ⋿↱⟤㧘ᱞ↰ ⚐㧘♿ࡁቯ଻⤿㧚SMBG ࠺࡯࠲ߩ㔚ሶࠞ࡞࠹਄ߢߩㆇ↪ߪ㧫⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲
ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺߦߟ޿ߡᢎ߃ߡߊߛߐ޿㧘⢈ḩߣ♧ዩ∛ 2007 ᐕ㧧6 Ꮞ㧦475㧙477㧚
8㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᒄ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
9㧕 ቬ ෹ෘ㧘ጊ↰ትሶ㧘ᑝ↰ථ↵㧘Ꮉ࿾ᘕ৻㧘૒‫ᧁޘ‬ᤘᒾ㧘⺪⸰ື਽㧘ᱞ↰ ⚐㧚㘩Ⴎᗵฃᕈㆮવሶ㧘ⴊ࿶
2007 ᐕ㧧14 Ꮞ㧦958㧙962㧚ౝ೨㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
10㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰ ⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇߩቇ↢࡮⡯ຬోຬߦᣉⴕߒߚᢝ࿾ౝ೨㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
11㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰ ⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇ⡯ຬߩ༛ᾍ⠪ࠍኻ⽎ߦታᣉߒߚ༛ᾍߩታᘒ⺞ᩏ㧙ᢝ࿾ౝో㕙⑌ᾍᣉⴕ 2 ᐕࠍ⚻ㆊߒߡ㧘ᣂක≮ 2007 ᐕ㧧1 Ꮞ㧦18㧙23㧚
12㧕 ⥓੗ࠆࠅሶ, ↰ਛ↢㓷, ૒ᯅᢥੳ, ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑, ᱞ↰ ⚐, ጊᧄ⋿↱⟤. ஜᐽ⸻ᢿߩ⾰ߩะ਄ࠍ⋡ᜰߒߡ࡯ቇ↢ߩฃ⸻ḩ⿷ᐲߩⷰὐ߆ࠄ࡯, Campus Health 2007 ᐕ㧧1 Ꮞ㧦125㧚
13㧕 ૒ᯅᢥੳ㧘↰ਛ↢㓷㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤. ቇ↢㧘⡯ຬోຬߦᣉ
ⴕߒߚቇౝ⑌ᾍߩࠕࡦࠤ࡯࠻⺞ᩏ̆ᢝ࿾ౝ⑌ᾍታᣉ 2 ᐕࠍ⚻ㆊߒߡ࡯, Campus Health 2007 ᐕ㧧44
Ꮞ㧦149㧚
14㧕 ↰ਛ↢㓷, ᫃Ꮉᐘ਎, ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ, ᱞ↰ ⚐, ጊᧄ⋿↱⟤. ቇ↢↢ᵴߢ᳞߼ࠄࠇࠆ଻ஜ▤ℂ࠮ࡦ࠲࡯ ࡯ࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻ߩᓎഀߦ㑐ߔࠆᬌ⸛̆, Campus Health 2007
ᐕ㧧44 Ꮞ㧦196㧚
15㧕 ᫃Ꮉᐘ਎, ↰ਛ↢㓷, Ꮉፉᕺሶ, Ꮉㄝᢘሶ, ૒ᯅᢥੳ, ᓮ↰᧛⋧ᮨ, 㐳ἑᳯ೑, ᱞ↰ ⚐, ጊᧄ⋿↱⟤.
UPI ᓧὐߣ↢ᵴ⠌ᘠ⺞ᩏߩ㑐ㅪߦߟ޿ߡ, Campus Health 2007 ᐕ.㧧44 Ꮞ㧦198㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yoshimura T, Suzuki E , Egawa K, Nishio Y, Maegawa H, Morikawa S, Inubushi T, Hisatomi A,
Fujimoto K, Kashiwagi K. Low blood flow estimates in lower-leg arteries predict cardiovascular event
in Japanese patients with type 2 diabetes with normal ankle-brachial indexes. Diabetes Care.
2006;29:1884-1890.
2㧕 Isomura Y, Mune T, Morita H, Suwa T, Takeda N, Yamamoto Y, Takeda J. Physiologic role of11Ǫ-hydroxysteroid dehydrogenase type 2 in kidney. Metabolism. 2006;55:1352-1357.
3㧕 Yokoi N, Kanamori M, Horikawa Y, Takeda J, Sanke T, Furuta H, Nanjo K, Mori H, Kasuga M, Hara K,
Kadowaki T, Tanizawa Y, Oka Y, Iwami Y, Ohgawara H, Yamada Y, Seino Y, Yano H, Cox NJ, Seino S.
Association studies of variants in the genes involved in pancreatic Ǫ-cell function in type 2 diabetes inJapanese. Diabetes. 2006;55:2379-2386.
4㧕 Gu N, Adachi T, Matsunaga T, Takeda J, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. Mutant HNF-1
ǩand mutant HNF-1 Ǫidentified in MODY3 and MODY5 downregulate DPP-IV gene expression in
Caco-2 cells. Biochem Biophys Res Commun. 2006;346:1016-1023.
5㧕 Gu N, Adachi T, Takeda J, Aoki N, Tsujimoto G, Ishihara A, Yasuda K, Tsuda K. Surrase-isomaltase
gene expression is inhibited by mutant hepatocyte nuclear factor (HNF)-1 ǩand mutant HNF-1 ǪinCaco-2 cells. J Nutr Sci Vitaminol. 2006;52:105-112.
6㧕 Moro H, Sato H, Ida I, Oshima A, Sakurai N, Shihara N, Horikawa Y, Mikuni M. Effect SKF-38393, adopamine D1 receptor agonist on expression of amphetamine-induced behavioral sensitization andexpression of immediate early gene are in prefrontal cortex of rats. Pharmacol Biochem Behav.
2007;87:56-64.

㧙㧙

IF 7.071
IF 2.143

IF 8.848

IF 2.904

IF 0.784

IF 2.092

7㧕 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawahito Y, Yoshida N, Suetsugu A,
Kato T, Okuda J, Ida K, Yoshokawa T. Nomalcoholic fatty liver disease is a novel predictor of
cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584.
IF 3.318
8㧕 Yamada Y, Sekihara H, Omura M, Yanase T, Takayanagi R, Mune T, Yasuda K, Ishizuka T, Ueshiba H,
Miyachi Y, Iwasaki T, Nakajima A, Nawata H. Changes in serum sex hormone profiles after
short-term low-dose administration of dehydroepiandrosterone (DHEA)to young and elderlypersons.
Endocr J. 2007;54:153-162.
IF 1.1409㧕 Ishizuka T, Miura A, Kajita K, Matsumoto M, Sugiyama C, Matsubara K, Ikeda T, Mori I, Morita H,
Uno Y, Mune T, Kanoh Y, Ishizawa M. Effect of dehydroepiandrosterone on insulin sensitivity in
Otsuka Long-Evans Tokushima-fatty rats. Acta Diabetol. 2007;44:219-226.
IF 1.676
10㧕 Oda N, Imamura S, Fujita T, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y,
Itoh M. The ratio of leptin / adiponectin can be used as an index of insulin resistance. Metabolism.
2008;57:268-273.
IF 2.647
11㧕 Miyake K, Horikawa Y, Hara K, Yasuda K, Osawa H, Furuta H, Hirota Y, Yamagata K, Hinokio Y, Oka
Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Yamamoto K, Tokunaga K,
Takeda J, Makino H, Nanjo K, Kadowaki K, Kasuga M. Association of TCF7L2 polymorphisms withsusceptibility to type 2 diabetes in 4,087 Japanese subjects. J Hum Genet. 2008;53:174-180.
IF 2.275
12㧕 Zenibayashi M, Miyake K, Horikawa Y, Hirota Y, Teranishi T, Kouyama K, Sakaguchi K, Takeda J,
Kasuga M. Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in theJapanese population. Endocr J. 2008;55:699-707.
IF 1.572
13㧕 Horikawa Y, Miyake K, Yasuda K, Enya M, Hirota Y, Yamagata K, Hinokio Y, Oka Y, Iwasaki N,
Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Yamamoto K, Tokunaga K, Takeda J,
Kasuga M. Replication of genome-wide association studies of type 2 diabetes susceptibility in Japan. J
Clin Endocrinol Metab. 2008;93:3136-3141.
IF 5.493
14㧕 Sato H, Horikawa Y, Iizuka K, Sakurai N, Tanaka T, Shihara N, Ohshima A, Takeda J, Mikuni M.
Large-scale analysis of glucocorticoid target genes in rat hypothalamus. J Neurochem.
2008;106:805-814.
IF 4.451
15㧕 Enya M, Horikawa Y, Kuroda E, Yonemaru K, Tonooka N, Tomura H, Oda N, Shihara N, Iizuka K,
Saibara T, Takeda J. Mutations in the small heterodimer partner gene increase morbidity risk inJapanese type 2 diabetes patients. Hum Mutat. 2008;29:E271-E277.
IF 6.273
16㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.
IF 1.823
17㧕 Iizuka K, Horikawa Y. Regulation of lipogenesis via BHLHB2/DEC1 and ChREBP feedback looping
Biochem Biophys Res Commun. 2008;374:95-100.
IF 2.749
18㧕 Okauchi Y, Iwahashi H, Okita K, Yuan M, Matsuda M, Tanaka T, Miyagawa J, Funahashi T, Horikawa
Y, Shimomura I, Yamagata K. PGC-1D Gly482Ser polymorphism is associated with the plasma
adiponectin level in type 2 diabetic men. Endocr J. 2008;55:991-997.
IF 1.572
19㧕 Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, Mori H, Jonsson A, Sato Y,
Yamagata K, Hinokio Y, Wang HY, Tanahashi T, Nakamura N, Oka Y, Iwasaki N, Iwamoto Y, Yamada Y,
Seino Y, Maegawa H, Kashiwagi A, Takeda J, Maed E, Shin HD , Cho YM, Park KS, Lee HK, Ng MCY,
Ma RCW, So WY, Chan JCN, Lyssenko V, Tuomi T, Nilsson P, Groop L, Kamatani N, Sekine A,
Nakamura Y, Yamamoto K, Yoshida T, Tokunaga K, Itakura M, Makino H, Nanjo K, Kadowaki T,
Kasuga M.A multistage genome-wide association study identifies SNPs in KCNQ1 associated withsusceptibility to type 2 diabetes mellitusNat Genet. 2008;40:1092-1097.
IF 25.556
20㧕 Tokunaga A, Horikawa Y, Fukuda-Akita E, Okita K, Iwahashi H, Shimomura I, Takeda J, Yamagata K.
A common polymorphism in the P2 promoter of hepatocyte nuclear factor-4ǩgene is associated withan index of the early-phase insulin secretion in Japanese subjects with type 2 diabetes. Endocr J.
2008;55:999-1004.
IF 1.572
21㧕 Sasaki A, Horikawa Y, Suwa T, Enya M, Kawachi S, Takeda J. Case report of familial Carney complex
due to novel frameshift mutation c.597del C (p.Phe200LeufsX6) in PRKAR1A. Mol Genet Metab.
2008;95:182-187.
IF 2.550
22㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara K, Morita H Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARJ and AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.
IF 1.8234㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧⑼ቇᛛⴚᝄ⥝੐ᬺ࿅࡮ᚢ⇛⊛ഃㅧ⎇ⓥ (CREST)㧦ォ౮⺞▵♽ߩಽሶ⸃೬ߦ
ࠃࠆ♧ዩ∛⚛࿃ߩត⚝㧧ᐔᚑ 14㧙19 ᐕᐲ㧧455,970 ජ౞(52,000㧦106,200㧦107,500㧦107,270㧦
83,000 ජ౞)㧙㧙2㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ᢥㇱ⑼ቇ⋭⑼⎇⾌․ቯ㗔ၞ㧦⤟ፉ․⇣⊛ㆮવሶߩ⊒⃻⺞▵ゲߦὶὐࠍ⛉ߞߚ♧ዩ∛ㆮવሶߩត⚝㧧ᐔᚑ 17㧙20 ᐕᐲ㧧21,000 ජ౞(5,900㧦5,400㧦5,700㧦4,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ർ಴ᐘᄦ㧘⎇ⓥಽᜂ⠪㧦ᱞ↰ ⚐㧧⚻ᷣ↥ᬺ⋭࿾ၞᣂ↢ࠦࡦ࠰࡯ࠪࠕࡓ੐ᬺ㧦㜞ല₸ࡁ࠶ࠢ࠳࠙ࡦᯏ⢻ࠍ᦭ߔࠆ siRNA ⵾ㅧᴺߩ㐿⊒ߣᵴ↪㧧ᐔᚑ 17㧙18 ᐕᐲ㧧8,000 ජ౞(4,000㧦4,000ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ෘ↢ഭ௛⋭ࡅ࠻ࠥࡁࡓ࡮ౣ↢ක≮⎇ⓥ੐ᬺ㧦ࠞ࡞ࡄࠗࡦ 10 㑐ㅪಽሶࠍ↪޿
ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 16㧙18 ᐕᐲ㧧107,379 ජ౞(41,550㧦37,868㧦
27,961 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧⚻ᷣ↥ᬺ⋭ࠥࡁࡓഃ⮎ടㅦൻᡰេࡃࠗࠝၮ⋚ᛛⴚ㐿⊒⾌㧦ൻว‛╬ࠍᵴ↪
ߒߚ↢‛ࠪࠬ࠹ࡓ೙ᓮၮ⋚ᛛⴚ㐿⊒㧧ᐔᚑ 18㧙20 ᐕᐲ㧧193,000 ජ౞(85,000㧦68,000㧦40, 000 ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ᣂⷙ⤟ፉಽᴲ࠲ࡦࡄࠢߣ♧ዩ∛ᄢⴊ▤∝ߩ࡝ࡦࠢ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦Ⴎ⼱⌀↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ࠗࡦࠬ࡝ࡦಽᴲᛥ೙ㆮવሶ߆ࠄߺߚᣂⷙ 2 ဳ♧ዩ∛ᗵฃᕈㆮવሶߩ₪ᓧ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ోᣣᧄࠦ࡯ࡅ࡯දળ⎇ⓥഥᚑ㊄㧦ᣂⷙࠦ࡯ࡅ࡯᛽಴ᚑಽߦࠃࠆࠗࡦࠬ࡝ࡦ
ಽᴲᵴᕈൻᯏ᭴ߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧1,300 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ၳᎹᐘ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦⢄ࠗࡦࠬ࡝ࡦࠢ࡝ࠕ࡜ࡦࠬᵴᕈൻߣ޿߁ᣂⷙ 2ဳ♧ዩ∛ᴦ≮᭎ᔨߩ⏕┙㧧ᐔᚑ 19 ᐕᐲ㧧600 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ഃ⮎ၮ⋚ផㅴ⎇ⓥ੐ᬺ㧦૕⢽⢌ᷫዋ࿃ሶࠍ↪
޿ߚ 2 ဳ♧ዩ∛ߩᴦ≮㧧ᐔᚑ 19㧙20 ᐕᐲ㧧97,167 ජ౞(50,326㧦46,841 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦Ꮉ࿾ᘕ৻㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ォ౮࿃ሶ HNF-1ǩߣ HNF-1Ǫߩᮡ⊛ㆮવሶߩ✂⟜⊛⸃ᨆߦࠃࠆᯏ⢻Ꮕ⇣ߩ⸃᣿㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ቬ ෹ෘ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧500 ජ౞
13㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ᓴⅣེ∔ᖚ╬↢ᵴ⠌ᘠ∛ኻ╷✚ว⎇ⓥ੐ᬺ㧦ᓴⅣེ࡝ࠬࠢߣ⠴♧⢻㓚ኂߩലᨐ⊛ߥஜ⸻ࡑ࡯ࠞ࡯ߩត⚝㧧ᐔᚑ 20 ᐕᐲ㧧18,945 ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰ ⚐㧧ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦‫⤟ޟ‬ፉᯏ⢻ߦ㑐ㅪߔࠆࡑࠗࠢࡠ
ಽሶߩหቯߣᯏ⢻⸃ᨆ㧧ᐔᚑ 20 ᐕᐲ㧧1,900 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᱞ↰ ⚐㧦ࠗࡦࠬ࡝ࡦ૶↪ਛߩ 2 ဳ♧ዩ∛ᖚ⠪ࠍኻ⽎ߣߒߚᔃⴊ▤♽ࠗࡌࡦ࠻⊒↢࡝ࠬࠢߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 19㧙22 ᐕᐲ㧧1,500 ජ౞㧦ࠨࡁࡈࠖ࡮ࠕࡌࡦ࠹ࠖࠬᩣᑼળ␠
2㧕 ᱞ↰ ⚐㧦࡟ࡒࠤ࡯࠼ὐṢ㕒ᵈ↪ 100 ૶↪ᚑ❣⺞ᩏ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧315 ජ౞㧦
3㧕 ᱞ↰ ⚐㧦‫ࠬࠪ࡯࠲ࠬޟ‬㍤‫᦭ޠ‬ኂ੐⽎⹦⚦⺞ᩏ㧧ᐔᚑ 19 ᐕᐲ㧧21 ජ౞㧦
4㧕 ᱞ↰ ⚐㧦ࡒࠞ࡞࠺ࠖࠬ㍤ ․ቯ૶↪ᚑ❣⺞ᩏ㨪㐳ᦼ૶↪ᤨߩ⣖࡮ᔃⴊ▤ࠗࡌࡦ࠻ߦ㑐ߔࠆ⺞ᩏ㧧
ᐔᚑ 18㧙21 ᐕᐲ㧧252 ජ౞
5㧕 ᱞ↰ ⚐㧦࠰ࡃࡑ࡯࠻․ቯ૶↪ᚑ❣⺞ᩏ̆㐳ᦼ૶↪ߦ㑐ߔࠆ⺞ᩏ̆(ࡊࡠ࠻ࠦ࡯࡞ No.A6291023㧧ᐔᚑ 20㧙25 ᐕᐲ㧧189 ජ౞
6㧕 ࡅࡘ࡯ࡑ࠻ࡠ࡯ࡊ․ቯ૶↪ᚑ❣⺞ᩏ̆ᚑੱᚑ㐳ࡎ࡞ࡕࡦಽᴲਇో∝(㊀∝ߦ㒢ࠆ)㧧ᐔᚑ 20㧙21 ᐕᐲ㧧126 ජ౞7㧕 ࠕࠢ࠹ࡓ࡜․ቯ૶↪ᚑ❣⺞ᩏ(ో଀⺞ᩏ)㑐▵࡝࠙ࡑ࠴̆ᄙ㑐▵ߦᵴേᕈࠍ᦭ߔࠆ⧯ᐕᕈ⓭⊒ᕈ㑐▵Ἳ̆㧧ᐔᚑ 20㧙25 ᐕᐲ㧧94,500 ජ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠8㧕 ࠕࠢ࠹ࡓ࡜․ቯ૶↪ᚑ❣⺞ᩏ(㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊ⺞ᩏ)㑐▵࡝࠙ࡑ࠴㧧ᐔᚑ 20㧙25 ᐕᐲ㧧31,500 ජ౞㧦ਛᄖ⵾⮎ᩣᑼળ␠
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ᱞ↰ ⚐㧦
1㧕 ᣣᧄౝ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ♧ዩ∛ቇળ⋙੐㧘⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ♧ዩ∛ว૬∝ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ♧ዩ∛ᅧᆼቇળℂ੐㧘⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄ⠧ᐕ∛ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ♧ዩ∛⌒ቇળℂ੐(㨪⃻࿷)9㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)ቬ ෹ෘ㧦
1㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᔃⴊ▤ౝಽᴲઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)ၳᎹᐘ↵㧦1㧕 ᣣᧄ∛ᘒቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᴤൻቇળ᧲ᶏᡰㇱᏱછᓎຬ(㨪⃻࿷)㋈ᧁ⧷ม㧦1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ᱞ↰ ⚐㧦
1㧕 ᣣᧄੱ㘃ㆮવቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄౝ⑼ቇળ㧦⧷ᢥ⹹✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᱞ↰ ⚐㧦
1㧕 ╙ 40 ࿁♧ዩ∛ቇߩㅴᱠ(2006 ᐕ 2 ᦬㧘㊄ᴛ㧘․೎⻠Ṷ‫⚻ޟ‬ญᴦ≮⮎ߦࠃࠆⴊ♧▤ℂߩᦨ೨✢‫ޠ‬Ṷ⠪)2㧕 2006 ᐕࡊ࡜ࠗࡑ࡝ࠤࠕቇળ(2006 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߣᔃⴊ▤∛࡝ࠬࠢ‫ޠ‬Ṷ⠪)
3㧕 ╙ 27 ࿁ᣣᧄ⢈ḩቇળ(2006 ᐕ 10 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ࡦࡕࠦޟ‬ઍ⻢∛ߩᣣᧄੱ૕⾰‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ♧ዩ∛ቇቇળㄭ⇰࿾ᣇળ(2006 ᐕ 11 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬ᣣᧄੱ 2 ဳ♧ዩ∛ߣᔃⴊ▤ࠗࡌࡦ࠻࡝ࠬࠢ‫ޠ‬Ṷ⠪)5㧕 ක⑼ቇᔕ↪⎇ⓥ⽷࿅╙ 50 ࿁ቇⴚ⻠Ṷળ(2006 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߣᔃⴊ▤ࠗࡌࡦ࠻‫ޠ‬Ṷ⠪)
6㧕 ╙ 6 ࿁ಽሶ੍㒐ⅣႺකቇ⎇ⓥળ(2006 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ߩᣣᧄੱߩಽሶ∉ቇ‫ޠ‬Ṷ⠪)㧙㧙

7㧕 ╙ 3 ࿁౏㐿ࠪࡦࡐࠫ࠙ࡓ‫࠼ࠗࡔ࡯࡜࡯࠹ޟ‬ක≮ࠍ⋡ᜰߒߚࠥࡁࡓᖱႎᵴ↪ၮ⋚ᛛⴚ‫(ޠ‬2007 ᐕ 8 ᦬㧘᧲੩㧘‫ޟ‬ォ౮ࡀ࠶࠻ࡢ࡯ࠢߩಽሶ⸃೬ߦࠃࠆ♧ዩ∛⚛࿃ߩหቯ‫ޠ‬Ṷ⠪)8㧕 ╙ 42 ࿁♧ዩ∛ቇߩㅴᱠ(2008 ᐕ 2 ᦬㧘㜞᧻㧘․೎⻠Ṷ‫ޟ‬ォ౮࿃ሶ⇣Ᏹߦࠃࠆࠗࡦࠬ࡝ࡦวᚑಽᴲ㓚ኂ‫ޠ‬ᐳ㐳 
9㧕 ╙ 23 ࿁♧ዩ∛ว૬∝ቇળ(2008 ᐕ 10 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬2 ဳ♧ዩ∛ᖚ⠪ߩ࠻࡯࠲࡞࡝ࠬࠢࡑࡀ
࡯ࠫࡔࡦ࠻‫ޠ‬ᐳ㐳 ቬ ෹ෘ㧦
1㧕 International Symposium The Kidney and Hypertension(2006 ᐕ 10 ᦬㧘઄บ㧘․೎⻠Ṷ‫ޟ‬Common
genetic variation in the mineralocorticoid pathway‫ޠ‬Ṷ⠪)
2㧕 ISH Symposium for Aldosterone Hypertension(2006 ᐕ 10 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬Polymorphisms in
the aldosterone cascade‫ޠ‬Ṷ⠪)
3㧕 ╙ 29 ࿁ㄭ⇰ౝಽᴲߣ㜞ⴊ࿶⎇ⓥળ(2006 ᐕ 11 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬Re-definition of 11ǪHSDs‫ޠ‬Ṷ⠪)ၳᎹ ᐘ↵㧦1㧕 ╙ 7 ࿁㒋␹ࡔ࠲ࡏ࡝࠭ࡓ⎇ⓥળ(2006 ᐕ 6 ᦬㧘ዦፒ㧘᜗ᓙ⻠Ṷ‫ޟ‬2 ဳ♧ዩ∛ߣㆮવ⚛࿃‫ޠ‬Ṷ⠪)2㧕 ᳯ⯃ᄢቇ⻠Ṷળ(2006 ᐕ 6 ᦬㧘ਛ࿖ᳯ⯃⋭㎾ᳯᏒ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߩㆮવቇ⎇ⓥߩᣂߒ޿ዷ㐿‫ޠ‬Ṷ⠪)3㧕 ᳯ⯃ᄢቇ⻠Ṷળ(2006 ᐕ 6 ᦬㧘ਛ࿖ᳯ⯃⋭㎾ᳯᏒ㧘᜗ᓙ⻠Ṷ‫ޟ‬ᣣᧄߩ♧ዩ∛ᴦ≮ߩ⃻⁁‫ޠ‬Ṷ⠪)
4㧕 ࠥࡁࡓഃ⮎ࡈࠜ࡯࡜ࡓ╙ 9 ࿁ࠪࡦࡐࠫ࠙ࡓ(2006 ᐕ 11 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫⋧⾰ࠢࡄࡦ࠲ޟ‬੕૞↪ὐ
ߦࠃࠆ 2 ဳ♧ዩ∛ㆮવሶࡄ࠭࡞ߩ⸃᣿‫ޠ‬Ṷ⠪)
5㧕 ╙ 12 ࿁ࠪࡦࡐࠫ࠙ࡓ♧ዩ∛(2008 ᐕ 4 ᦬㧘᧲੩㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛⤟ፉಽᴲ࠲ࡦࡄࠢ(ࠝࠬ࠹ࠝࡀࠢ࠴ࡦ)ߣ♧ዩ∛ᄢⴊ▤∝ߩ࡝ࡦࠢ‫ޠ‬Ṷ⠪)
6㧕 ╙ 43 ࿁ㆮવකቇ⎇ⓥળ(2008 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫♧ޟ‬ዩ∛ᗵฃᕈㆮવሶหቯߩ⃻⁁ߣᧂ᧪௝‫ޠ‬Ṷ⠪)㋈ᧁ ⧷ม㧦1㧕 ╙ 3 ࿁੩ㇺᧃ᪳ᓴⅣ㓚ኂᬌ⸛ળ(2006 ᐕ 2 ᦬㧘੩ㇺ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߣേ⣂⎬ൻ‫ޠ‬Ṷ⠪)2㧕 Management of PAD ਅ⢇ⴊ▤∛ᄌߦ㑐ߔࠆ∛⸻ㅪ៤(2006 ᐕ 6 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫ࠖ࠺࡞ࡀࡄޟ‬ࠬࠞ࠶࡚ࠪࡦ ♧ዩ∛ᖚ⠪ߦ߅ߌࠆ⏛᳇౒㡆ࠍ↪޿ߚਅ⢇ⴊᵹ⸃ᨆ‫ޠ‬Ṷ⠪)ጊᧄ⋿↱⟤㧦
1㧕 ࠤ࡯ࠬᣉⴕ᝼ᬺ㜞ᐲක≮ࠦࡦ࠰࡯ࠪࠕࡓ(2006 ᐕ 2 ᦬㧘ᄢ㒋㧘᜗ᓙ⻠Ṷ‫ࡓ࡯࠴ޟ‬ක≮ߣක≮ࡕ࠺࡞㧙♧ዩ∛⸻≮ࡕ࠺࡞‫ޠ‬Ṷ⠪)
2㧕 ╙ 70 ࿁⸥ᔨᣣᧄᓴⅣེቇળ✚ળ (2006 ᐕ 3 ᦬㧘ฬฎደ㧘᜗ᓙ⻠Ṷ‫♧ޟ‬ዩ∛ߣേ⣂⎬ൻ∝㧙੍㒐ߩ㊀ⷐᕈ㧙‫ޠ‬Ṷ⠪)
3㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(2007 ᐕ 7 ᦬, ㊄ᴛ, ‫ࠬࡄࡦࡖࠠޟ‬ౝ⑌ᾍ 2 ᐕࠍ⚻ㆊߒߡ࡯⃻⁁ߣ⺖㗴̆‫⻠ޠ‬Ṷࠪࡦࡐࠫࠬ࠻)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ᱞ↰ ⚐㧦
1㧕 ᣣᧄ⥃ᐥౝ⑼කળጘ㒂⋵೽ળ㐳(㨪⃻࿷)2㧕 ᢥㇱ⑼ቇ⋭ࠥࡁࡓࡀ࠶࠻ࡢ࡯ࠢផㅴᆔຬળᆔຬ(㨪⃻࿷)3㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ)
4㧕 ᣣᧄ♧ዩ∛දળጘ㒂⋵ᡰㇱ㐳(㨪⃻࿷)5㧕 ᢥㇱ⑼ቇ⋭⑼ቇᛛⴚ࡮ቇⴚክ⼏ળኾ㐷ᆔຬ(㨪⃻࿷)6㧕 ጘ㒂⋵♧ዩ∛ኻ╷ផㅴ⹏⼏ળ೽ળ㐳(㨪⃻࿷)7㧕 ᣣᧄ♧ዩ∛දળ≮㙃ᜰዉᆔຬળᆔຬ㐳(㨪⃻࿷)㧙㧙ၳᎹ ᐘ↵㧦1㧕 ጘ㒂࿾ၞක≮ㅪ៤⎇ⓥળᐙ੐(㨪⃻࿷)2㧕 ጘ㒂࿾ၞකᏧળㅪ៤ࡄࠬㆇ༡ᆔຬળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળ♧ዩ∛࿾ၞㅪ៤ࡄࠬࡢ࡯ࠠࡦࠣࠣ࡞࡯ࡊᆔຬ㐳(㨪⃻࿷)5㧕 ᣣᧄ♧ዩ∛දળጘ㒂⋵ᡰㇱઍ⼏ຬ(㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᕺ㇊࿾ၞ♧ዩ∛ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵ᚑੱ∛ᬌ⸻▤ℂᜰዉද⼏ળᓴⅣེ∔ᖚ╬ᆔຬળຬ(㨪⃻࿷)3㧕 ጘ㒂↢ᵴ⠌ᘠ∛ㆇേ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)4㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬)
5㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬᐳ㐳(㨪⃻࿷)6㧕 ጘ㒂Ꮢஜᐽ↥ᬺᝄ⥝ಽ⑼ળᆔຬ(ᐔᚑ 19 ᐕ 8 ᦬㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ෸߮࿾ၞ଻ஜ⸘↹ㇱળᆔຬ(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ၳᎹᐘ↵㧦ࠞ࡞ࡄࠗࡦ 10 㑐ㅪಽሶࠍ↪޿ߚ 2 ဳ♧ዩ∛ㆮવሶ⸻ᢿᴺߣᣂⷙᴦ≮ᴺߩ㐿⊒㧦ᐔᚑ 16
ᐕᐲ㧙18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝ႎ๔ᦠ(2006 ᐕ 1 ᦬)
2㧕 ቬ ෹ෘ㧘⺪⸰ື਽㧘᧛᧻ ቇ㧘ᱞ↰ ⚐㧚Disabled-2 ߩ೽⣢⊹⾰ߦ߅ߌࠆᯏ⢻ߣ೽⣢⣼⣲ߢߩ⊒⃻㧘೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 17 ᐕᐲ⎇ⓥႎ๔ᦠ㧦109㧙112(2006 ᐕ 3 ᦬)
3㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧚ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻≮ࡕ࠺࡞㧙♧ዩ∛㧙ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ 㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࡓ㧘ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ታ❣ႎ๔ᦠ㧦141㧙176(2006 ᐕ 1 ᦬)
4㧕 ᱞ↰ ⚐㧦૕⢽⢌ᷫዋ࿃ሶࠍ↪޿ߚ 2 ဳ♧ዩ∛ߩᴦ≮㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌ ഃ⮎ၮ⋚ផㅴ⎇ⓥ੐ᬺႎ๔ᦠ(2008 ᐕ 4 ᦬)
5㧕 ᱞ↰ ⚐㧦⤟ፉ․⇣⊛ㆮવሶߩ⊒⃻⺞▵ゲߦὶὐࠍ⛉ߞߚ♧ዩ∛ㆮવሶߩត⚝㧦ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞႎ๔ᦠ(2008 ᐕ 4 ᦬)
6㧕 ቬ ෹ෘ㧦CYP11B1 common variants ߣ⴫⃻ဳߩ㑐ㅪ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ೽⣢ࡎ࡞ࡕࡦ↥↢⇣Ᏹߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ(2008 ᐕ 3 ᦬)
7㧕 ၳᎹᐘ↵㧦ൻว‛╬ࠍᵴ↪ߒߚ↢‛ࠪࠬ࠹ࡓ೙ᓮၮ⋚ᛛⴚ㐿⊒㧦⚻ᷣ↥ᬺ⋭ࠥࡁࡓഃ⮎ടㅦൻᡰេ
ࡃࠗࠝၮ⋚ᛛⴚ㐿⊒⾌ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ
11㧚ႎ㆏
1㧕 ቬ ෹ෘ㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫⚛ޠ‬࿃߰߹߃ࠃࠅ⦟޿↢ᵴࠍ㧦ጘ㒂ᣂ⡞(2006 ᐕ 10 ᦬)2㧕 ㋈ᧁ⧷ม㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫↢ޠ‬ᵴ⠌ᘠ∛ߩ੍㒐ᴺࠍ⺞ᩏ㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬)
3㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆ቇ↢ᡰេ GP ߦㆬቯ̆↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 9 ᦬)
4㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆ቇ↢ᡰេ GP ߦណᛯ̆ᄢቇߪ↢ᶦஜᐽߩࠬ࠲࡯࠻࿾ὐ㧦ᦺᣣᣂ⡞(2007 ᐕ
10 ᦬)
5㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ̆↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ࡯↢ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽ
ᡰេߩలታ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬)
6㧕 ᱞ↰ ⚐㧦♧ዩ∛ක≮ㅪ៤ࠍ࡝࡯࠼ߔࠆ‫ޟ‬ጘ㒂ࠪࠬ࠹ࡓ‫ߊ⸃ߺ⺒ࠍޠ‬㧦DITN(2008 ᐕ 2 ᦬)
7㧕 ၳᎹᐘ↵㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ޿߹‫↢ޠ‬ᵴ⠌ᘠ∛ᴦ≮⮎ࠍ⎇ⓥ㧦ጘ㒂ᣂ⡞(2008 ᐕ 2 ᦬)
8㧕 ᱞ↰ ⚐㧦りㄭߥ∛᳇‫♧ޟ‬ዩ∛‫ߦ✜৻ࠍޠ‬⠨߃ࠆ㧦ਛᣣᣂ⡞(2008 ᐕ 11 ᦬)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥߦ㑐ߒߡߪ㧘ᄙᣉ⸳౒ห⎇ⓥߦࠃࠅᣂߒ޿♧ዩ∛ㆮવሶ KCNQ1㧔Nature Genetics 2008 ᐕ㧕ߥߤ޿ߊߟ߆ߩ⽿છㆮવሶࠍหቯߔࠆߎߣߦᚑഞߒߚ߇㧘೨ 3 ᐕߦᲧߒߡ਎⇇ࠍ࡝࡯࠼ߔࠆ⎇ⓥ⺰ᢥ߇ᷫߞߚߎߣߪ෻⋭ὐߢ޽ࠆ㧔᰷ᢥේ⪺ 22 ✬㧕‫৻ޕ‬ᣇ㧘2008 ᐕ 3 ᦬ߦᄢဳ⎇ⓥߢ޽ࠆ CREST㧔ઍ⴫㧦ᱞ↰⚐㧕߇⚳ੌߒߚ߇㧘ߘߩᓟࠍ⵬ቢߔࠆ߆ߚߜߢ NEDO ⎇ⓥ㧔ઍ⴫㧦ၳᎹᐘ↵㧕ߣ 2 ߟߩෘ↢⑼⎇㧔ઍ⴫㧦ᱞ↰⚐㧕ߩᄢဳ⾗㊄ࠍ₪ᓧߢ߈ߚߎߣߪ㜞⹏ଔߦ୯ߔࠆ‫ޕ‬㧙㧙♧ዩ∛ߦ㑐ߔࠆ␠ળᵴേߣߒߡߪ㧘‫ޟ‬ጘ㒂ࡕ࠺࡞‫ߡߒߣޠ‬ጘ㒂⋵♧ዩ∛ኻ╷ផㅴද⼏ળߩਥዉ⊛ᓎഀࠍᨐߚߒߡ޿ࠆ‫ⴕޕ‬᡽ߣߩද⺞ߢߩᏒ᳃⻠ᐳ㧘໪⊒ࠠࡖࡦࡍ࡯ࡦߣߒߡߩ਎⇇♧ዩ∛࠺࡯ᵴേ㧔ጘ㒂ၔ࡜ࠗ࠻ࠕ࠶ࡊߥߤ㧕㧘ක≮ࠬ࠲࠶ࡈ⎇ୃ㧘⊓㍳ක࡮≮㙃ᜰዉක೙ᐲߩዉ౉ߥߤ߇ታᣉߐࠇߚ‫ޕ‬3 ᐕ㑆ߢ㧘ጘ㒂ߩ♧ዩ∛࿾ၞක≮ߦ㑐ߔࠆ⚂ 40 ࿁ߩ⻠Ṷଐ㗬߇ో࿖߆ࠄ޽ߞߚߎߣߪ⹏ଔߦ୯ߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷㒝ዻ∛㒮ߩ⸻≮⑼ㆇ༡ߦᢎቶੱຬ߇ഀ߆ࠇ㧘චಽߥ⎇ⓥ⠪ߣ⎇ⓥᤨ㑆߇⏕଻ߢ߈ߥ߆ߞߚߎߣ߇໧㗴ὐߢ޽ߞߚ‫ޕ‬ኻ╷ߣߒߡߪ㧘2009 ᐕ 4 ᦬ࠃࠅ⟲㚍ᄢቇߩ⎇ⓥ࠴࡯ࡓࠍᑄߒߡጘ㒂࠴࡯ࡓߦ⛔วߒ㧘ߐࠄߦᄢቇ㒮↢ߩ 1 ฬჇຬࠍ੍ቯߔࠆ‫ޕ‬ታ㛎⵬ഥຬߩᦝߥࠆ⏕଻ߩߚ߼ߦ㧘ᄖㇱ⾗㊄ࠍߐࠄߦ₪ᓧߔࠆࠃ߁
ദജߔࠆ‫ޕ‬੹ᓟߩዷᦸవ㚟⊛ߢ޽ࠆ‫⤟ޟ‬ፉ࠻࡜ࡦࠬࠢ࡝ࡊ࠻࡯ࡓ‫ߦޠ‬㑐ߔࠆࠥࡁࡓ⎇ⓥࠍផㅴߐߖࠆ‫ࡦ࡝ࠬࡦࠗޕ‬วᚑߣಽᴲߦ㑐ߔࠆᣂⷙߩ↢ℂᵴᕈ‛⾰ߩᯏ⢻⸃᣿ࠍㅢߓߡ♧ዩ∛ߩ⸻ᢿߣᴦ≮߳ߩዷ㐿ࠍ࿑ࠆ‫ౕޕ‬૕⊛ߦߪ㧘⤟ౝಽᴲߩ․ᕈߦ㑐ㅪߔࠆน⢻ᕈ߇޽ࠆᶧᕈ࿃ሶࠍหቯߒߡ޿ࠆߩߢ㧘ⴊਛ᷹ቯ⸻ᢿߣᴦ≮ᔕ↪ࠍ⋡ᜰߔ‫ޕ‬หᤨߦ㧘∔ᖚᗵฃᕈߩ୥⵬ㆮવሶᄙဳࠍ↪޿ߚ㑐ㅪ⸃ᨆߦࠃࠆ㧘⟕ᖚ૕⾰ߩ DNA ⸻ᢿᴺߩ㐿⊒ࠍⷞ㊁ߦ⟎ߊ‫ޕ‬ᶏᄖ৻ᵹ⹹ߢߩᚑᨐ⊒⴫ߣ․⸵ขᓧࠍᒰ㕙ߩ೔㆐⋡ᮡߣߔࠆ‫ޕ‬࿾ၞ♧ዩ∛ቇߣߒߡߪ㧘ⴕ᡽㧘කᏧળ㧘㑐ㅪ࿅૕ߣߩㅪ៤ߩ߽ߣߦ㧘∉ቇ⊛ߥ∛ᘒ⺞ᩏ⎇ⓥ㧘ᣧᦼ⊒⷗ߣ⊒∝੍㒐ߩ૕೙᭴▽㧘࿾ၞߢᵴ↪ߐࠇࠆ⮎‛≮ᴺߩ㐿⊒ߥߤࠍផㅴߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬㧙㧙㧔7㧕ዊఽ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᒰᢎቶߦ߅ߌࠆၮ␆⎇ⓥ࡮⥃ᐥ⎇ⓥߪ޿ߕࠇ߽⥃ᐥߦ┙⣉ߒ㧘ᭂ߼ߡၮ␆⊛ߥㅊ᳞߇ߥߐࠇ㧘ߘߩᚑᨐߪᔅߕ߿⥃ᐥߦㆶరߐࠇࠆ߽ߩߢ޽ࠆ‫ߩߘߚ߹ޕࠆ޽߽ߢ࠴࡯ࠨ࡝࡞࠽࡚ࠪ࡯࡟ࠬࡦ࡜࠻ޕ‬ౝኈߣᚻᴺߪ
Ᏹߦㆊ෰߆ࠄ⃻࿷ߩᱧผߦ┙⣉ߒߡ㧘዁᧪ࠍ⷗ᝪ߃ߚᭂ߼ߡ࡙࠾࡯ࠢߥ࠹࡯ࡑߢ޽ࠅ㧘߆ߟᚻᴺߢ޽ࠆ‫ޕ‬಴↢೨ዊఽᦼߩㆮવ࡮⊒↢෸߮㧘ዊఽߩᚑ㐳࡮⊒㆐ߣో⥃ᐥಽ㊁ߦࠊߚࠆ∛⊛⁁ᘒߩߔߴߡࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬ၮ␆⎇ⓥߦ߅޿ߡߪ㧘ᐞߟ߆ߩಽ㊁ߦ⛉ࠆߎߣߦࠃࠅ㧘ᅏᷓ޿⎇ⓥ߇ㅴ߼ࠄࠇߡ޿ࠆ‫࡯ࠡ࡞࡟ࠕޕ‬㧘఺∉ਇో㧘ઍ⻢⇣Ᏹߩฦಽ㊁ߢᐞߟ߆ߩ∔ᖚߩ∛࿃ㆮવሶ߇ᒰᢎቶߢ਎⇇ߦవ㚟ߌࠢࡠ࡯࠾ࡦࠣߐࠇ㧘਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐ߇ᐞߟ߽ヘ಴ߐࠇ㧘ᣂ⡞⚕਄ߩ৻㕙ߢ߽ขࠅ਄ߍࠄࠇߡ޿ࠆ‫ޕ‬ฦ࠹࡯ࡑߦ౒ㅢߔࠆߎߣ
ߪ㧘ฦಽ㊁ߩ∔ᖚߩ∛࿃ߣ∛ᘒߩ⸃᣿ߢ޽ࠅ㧘ߘߩᚑᨐࠍ⸻ᢿ࡮ᴦ≮࡮੍⍮࡮੍㒐ߦㆡᔕߒߡ޿ߊߎߣߢ
޽ࠆ‫ࠍࠄࠇߎߦࠄߐޕ‬ㅢߓߡ㧘ࡅ࠻ߩㆮવ࡮⊒↢㧘ᚑ㐳࡮⊒㆐ߩᣂߚߥ⸃᣿ߦߟߥߍߡ޿ࠆ‫ޕ‬ᣇᴺ⺰⊛ߦߪ㧘ᣣᏱ⥃ᐥߩਛ߆ࠄࡅࡦ࠻ߣ⊒ᗐ߇ᓧࠄࠇ㧘ㆮવሶቇ⊛ᚻᴺߦട߃㧘කቇ߳ߩ᭴ㅧ↢‛ቇߩዉ౉㧔21਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩ᭴ㅧ↢‛කቇ structure biological medicine гㄭ⮮ߦࠃࠆ㧕ࠍߒߡ޿ࠆ‫ࠥޕ‬ࡁࡓㆮવሶ⇣Ᏹ߆ࠄࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ㧘ㆮવሶ⊒⃻⇣Ᏹࠍ⚻ߡ࠲ࡦࡄࠢ┙૕᭴ㅧߩ⇣Ᏹߣᯏ⢻⇣Ᏹߣߩ㑐ㅪࠍ⸃ᨆߒ㧘⸻ᢿ㧘ᴦ≮߳ߩᔕ↪ࠍㅴ߼ߡ޿ࠆ‫ޕ‬਎⇇⊛߆ߟ↹ᦼ⊛ߥᚑᨐ߇ᓧࠄࠇ⊒⴫ߐࠇߡ޿ࠆ‫ޕ‬ߎࠇࠄߩᚑᨐߪᐞߟ߆ߩᄢဳ┹ว⊛⎇ⓥ⾌₪ᓧ㧘ᐕ㑆⺰ᢥ✚ᢙ⚂ 100 ✬㧘ߘߩ߁ߜ࿖㓙⹹ឝタߩ⧷ᢥ⺰ᢥᐕ㑆⚂ 30 ✬ߦ⃻ࠇߡ޿ࠆ‫ޕ‬1㧕ࠕ࡟࡞ࠡ࡯
Ԙࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ߩᛥ೙♽ߩ∛࿃ㆮવሶࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒ㧔Lancet 1996 ᐕ㧘
BBRC1999 ᐕߦ⛯޿ߡ, JACI 2003 ᐕ㧕㧘
IgE ↥↢ߩᛥ೙♽ IL-12̆IL-12 ࡟࠮ࡊ࠲࡯߹ߚߪ IL-18̆IL-18
࡟࠮ࡊ࠲࡯̆IFNǫࠪࠣ࠽࡝ࡦࠣߩ㊀ⷐᕈࠍ␜ߒߚ‫ޕ‬ԙߎࠇࠄߩᚑᨐࠍ߽ߣߦߒߡ਎⇇ߦవ㚟ߌߡ㧘ᣂߚߦࠕ࠻ࡇ࡯㧔ࠕ࡟࡞ࠡ࡯㧕ࠍㆮવሶቇ⊛ߦಽ㘃ߒߚ‫ޕ‬Ԛߐࠄߦ㧘ߎࠇࠍ߽ߣߦࠕ࡟࡞ࠡ࡯㧔ࠕ࠻ࡇ࡯㧕ߩ‫ޕ‬ԛࡅ࠻ IL-18 ߩ࠲ࡦࡄࠢ┙૕᭴ㅧࠍㆮવሶ⸻ᢿࠠ࠶࠻ࠍ㐿⊒ߒ㧘․⸵↳⺧ਛߢ޽ࠆ㧔2007㧘2008 ᐕ㧕਎⇇ߦవ㚟ߌߡ⸃᣿ߒ㧔Nature structure biology 2003㧕㧘ߘߩ⥃ᐥᔕ↪ߣߒߡߩૐಽሶഃ⮎ࠍㅴ߼ߡࠕ࡟࡞ࠡ࡯ߩࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮޿ࠆ‫ޕ‬Ԝㆮવሶᖱႎߣ᛫ࠕ࡟࡞ࠡ࡯⮎ലᨐ߆ࠄ୘೎ൻක≮㧘ߔߥࠊߜ㧘ࠕߩ⏕┙ࠍㅴ߼̌᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂᴺߩߚ߼ߩᚻᒁ߈̍ࠍ਎⇇ߢೋ߼ߡ૞ᚑߒߚ‫ޕ‬ԝㆮવሶ⊒⃻㧘RNA ࡊࡠ࠮࠶ࠪࡦࠣ․ߦ RNA editing ߣ alternative splicing ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ㑐ࠊߞߡ޿ࠆߎߣࠍ਎⇇ߢೋ߼ߡ⸃᣿ߒߚ‫ޕ‬Ԟ㘩‛ࠕ࡟࡞ࠡ࡯ߩ᛫ේ․⇣ᕈߩ⊒⃻ᯏ᭴ߩ⸃᣿ߩߚ߼㧘T ⚦⢩ࠢࡠ࡯ࡦߩ᮸┙ߦ਎⇇ߢೋ߼ߡᚑഞߒ㧘ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆ HLĂࡍࡊ࠴࠼̆T ⚦⢩࡟࠮ࡊ࠲࡯ߩ․⇣⚻ญ఺∉ኡኈࠍ⺃ዉᕈߣ⚿วᕈࠍ┙૕᭴ㅧ߆ࠄ⸃᣿ߒߡ޿ࠆ‫ޕ‬
㧔PNAS 2008 ઁ㧕ԟߎߩᚑᨐߦၮߠ޿ߡ㧘⚻
ߔࠆᴦ≮ᴺ⏕┙ߩߚ߼̌㘩ߴߡᴦߔ㘩ຠߩ㐿⊒̍ࡊࡠࠫࠚࠢ࠻߇⃻࿷ㅴⴕߒߡ޿ࠆ‫ޕ‬ԠⅣႺߣㆮવሶߦࠃㆮ વሶ↢ᘒකቇ geneticࠆࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧔21 ਎♿ဳࡐࠬ࠻ࠥࡁࡓߣߒߡߩㆮ
ecological medicine -ㄭ⮮ߦࠃࠆ㧕‫ޕ‬᷷ᐲᄌൻߦࠃࠅ㧘NF-kappaB ߩᯏ⢻߇ᄌൻߒ㧘ࠨࠗ࠻ࠞࠗࡦ↥↢ࡄ࠲࡯ࡦ߇ᄌൻߔࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬᭎ᣣ࡝࠭ࡓߩⷞὐ߆ࠄ㧘శߣ૕ౝᤨ⸘ㆮવሶߣߩ㑐ㅪࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬ԡ⥄ὼ఺∉♽ߣ∔ᖚߣߩ㑐ㅪࠍត᳞ߒᴦ≮㐿⊒ߦߟߥߍࠆߚ߼ߦ㧘Toll like receptor㧔TLR㧕
߅ࠃ߮ߘߩࠪࠣ࠽࡞વ㆐♽ߩ MyD88 ಽሶߥߤߩಽሶ߅ࠃ߮ߘࠇࠄߩ⚿ว᭽ᑼࠍ᣿ࠄ߆ߦߒ㧘หᤨߦߘࠇ
ࠄߩㆮવሶቇ⊛࠲ࡦࡄࠢ᭴ㅧቇ⊛⇣Ᏹࠍ᣿ࠄ߆ߦߒߡ޿ࠆ‫ޕ‬Ԣࠬ࠻࡟ࠬߣࠕ࡟࡞ࠡ࡯⊒∝ߩಽሶㆮવቇ⊛⸃᣿㧘࠙ࠗ࡞ࠬᗵᨴߦࠃࠆࠕ࡟࡞ࠡ࡯⊒∝㧘ࠕ࡜ࠠ࠼ࡦ㉄ࠞࠬࠤ࡯࠼ߩ⹏ଔߣࠝ࡯࠳࡯ࡔࠗ࠼ᴦ≮㧘⾰ߩ㜞޿ QOL ⹏ଔ⴫ߩ૞ᚑ㧘⤯Ꮺⴊࡊࡠࠫࠚࠢ࠻㧘FACS ࠍ↪޿ߚ⥄ὼ఺∉♽⺞▵ᕈ T ⚦⢩ߩ⸃ᨆߣ₪ᓧ఺∉♽ Th1࡮Th2 ࠕࡦࡃ࡜ࡦࠬߩ⸃᣿ߣᔕ↪ߥߤ‫ޕ‬ԣએ਄ߩࡊࡠࠫࠚࠢ࠻ߦ㑐ߒߡએਅߩᄢဳ┹ว⊛ᄖㇱ⾗㊄ࠍ₪ᓧߢ߈ߚ‫ޕ‬㧔ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ߥߤߪ೎㗄ෳᾖ㧕
1. 㧨ᢥㇱ⑼ቇ⋭㜞╬ᢎ⢒ዪ㧪ᢥㇱ⑼ቇ⋭㜞ᐲవㅴක≮㐿⊒⚻⾌‫∔࡯ࠡ࡞࡟ࠕ࡮∉఺ޟ‬ᖚ∛࿃࠲ࡦࡄࠢ
⾰┙૕᭴ㅧߦၮߠ޿ߚ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦࠃࠆᴦ≮ᴺߩ⏕┙‫⎇ޠ‬ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⎇ⓥදജ⠪ ട⮮ༀ৻㇢㧘◉↰⚩ม㧘ኹᧄ⾆⧷㧘ਅỈિⴕ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘᪀↰৻ᄦ㧘㋈ᧁᱜᤘ㧘⊕Ꮉ᣽ብ㧔ᐔᚑ 13̅15 ᐕ㧕
2. 㧨ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧪఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ਥછ⎇ⓥ⠪ ㄭ⮮ ⋥ታ ⃰ຬ ᧻੗ ᳗ሶ߶߆㧔ᐔᚑ 16̅21 ᐕ㧕
3. 㧨↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧪⇣ಽ㊁Ⲣว⎇ⓥ㐿⊒ဳ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ኻ╷㧔ᐔᚑ 17 ᐕࠃࠅ 5 ᐕ㑆㧕㘩ຠߩၮ␆⎇ⓥߦၮߠߊ↹ᦼ⊛ഃᚑ‫ޠ‬⎇ⓥઍ⴫⠪ ㄭ⮮⋥ታ ⃰ຬ ㊄ሶ⧷㓶߶߆㧙㧙2㧕వᄤᕈ఺∉ਇో∝ߣ DNA ୃᓳ
IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߩ∛࿃ߣߥࠆㆮવሶ⇣Ᏹࠍ਎⇇ߦవ㚟ߌ᣿ࠄ߆ߦߒߚ㧔J Clin Invest ෸߮
JACI㧕‫ޕ‬Ᏹᨴ⦡૕ఝᕈߩㆮવᒻᑼࠍߣࠆ㜞 IgM ∝୥⟲ߩ∛࿃ߦߟ޿ߡ߽ AID ߩ dominant negative ലᨐߦࠃࠆߎߣࠍ਎⇇ߢೋ߼ߡ᣿ࠄ߆ߦߒߚ㧔JACI 2003 ᐕ㧕‫ޕ‬Ყセ⊛㗫ᐲߩ㜞޿఺∉ਇో∝ߢ޽ࠆ IgA ᰳ៊∝ߦߟ޿ߡ⸃ᨆࠍⴕ޿ߘߩ B ⚦⢩ߩಽൻ㓚ኂㇱ૏ࠍ᣿ࠄ߆ߦߒߚ‫ߦࠄߐޕ‬㧘ᧄ㇌ 2 ଀⋡ߩ఺∉ࠣࡠࡉ࡝ࡦ㊀㎮ㆮવሶߩᰳ៊ኅ♽ࠍႎ๔ߒߚ‫ޕ‬㜞⊒≸ߣ఺∉ਇోࠍ␜ߔ Bloom ∝୥⟲߿ Ataxia-telangiectasia ߩ∛࿃ㆮવሶ BLM ߣ ATM ߩᯏ⢻ߣ᭴ㅧߩ⸃ᨆࠍㅢߒߡ⚦⢩๟ᦼ㧘DNA ୃᓳ㧘ࠪࠣ࠽࡞વ㆐ߦߟ߈⸃᣿
ߒ⊒≸ᯏ᭴ߩ⸃᣿ࠍⴕߞߡ޿ࠆ㧔Blood, CEI, PNAS ઁ㧕‫ߦࠄߐޕ‬ᄙᓀߥ⥄ὼ఺∉ਇో∝㧘⥄ᏆἻ∝ᕈ∔ᖚߩ∛࿃∛ᘒ⸃᣿ߣᴦ≮㐿⊒ߦ⌕ᚻߒߚ‫ޕ‬3㧕᦭ᯏ㉄ઍ⻢⇣Ᏹ∝ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧘․ߦࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧔SCOT㧕ߣEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝ߩ㉂⚛⸻ᢿ߿ㆮવሶ⸻ᢿߦ߅޿ߡߪ㧘਎⇇ਛ߆ࠄߩଐ㗬ࠍ߁ߌߡ⸃ᨆࠍⴕߞߡ޿ࠆ‫߹ࠇߎޕ‬ߢᄙߊߩㆮવሶᄌ⇣ߣߘߩ․ᓽࠍ᣿ࠄ߆ߦߒߡ߈ߚ‫ޕ‬ᱷሽᵴᕈࠍ߽ߟシ∝ဳߩEࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝㧘
SCOT ᰳ៊∝ߩౖဳ଀ߣߩ⥃ᐥ௝ߩ㆑޿ߦߟ޿ߡ߽᣿ࠄ߆ߦߒߡ޿ࠆ‫౒ߩߣࡊ࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ห⎇ⓥߢ㧘ࡅ࠻ߩ⚦⢩⾰࠴ࠝ࡜࡯࠯ߣࡒ࠻ࠦࡦ࠼࡝ࠕࠕ࠮࠻ࠕ࠮࠴࡞-CoA ࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧࠍ᳿ቯߒ㧘ߐࠄߦࠕࡒࡁ㉄ᄌൻ߇Ⱞ⊕ߦਈ߃ࠆᓇ㗀ߦߟ޿ߡߩ⸃ᨆࠍㅴ߼ߡ޿ࠆ㧚ፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄
E㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ߈ߡ޿ࠆ‫ޕ‬
4㧕ㆮવᕈࡓࠦᄙ♧∝ㆮવᕈࡓࠦᄙ♧∝ߦߟ޿ߡᣧᦼ⸻ᢿ㧘ಽሶ∛ᘒ⸃ᨆ㧘ᴦ≮ᴺ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ࠦࡓߦ․ޕ‬ᄙ♧∝ΦA ဳߩ⎇ⓥߢߪ㧘࿖㓙ࡊࡠࠫࠚࠢ࠻ߩ✚᜝⊛┙႐ߢ∔ᖚ⸃ᨆ࡮ᴦ≮ᴺ㐿⊒ࠍⴕߞߡ߅ࠅ㧘Τဳߩ⥄ὼᱧ⺞ᩏ߿㉂⚛⵬ల≮ᴺ㧘ࡓࠦᄙ♧∝ో⥸ߩᣧᦼࡑࠬࠬࠢ࡝࡯࠾ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒߽૬ߖߡ㧘ࡌࡦ࠴ࡖ࡯ડᬺ
ߣߩ౒ห⎇ⓥ߽ㅴ߼ߡ޿ࠆ‫ޕ‬
5㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛వᄤᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߩ∛࿃ߣᴦ≮ߦߟ޿ߡ⎇ⓥࠍㅴ߼ߡ߅ࠅ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩᣂⷙ∛࿃ㆮવሶ PEX16,19,13,3,26 ߩหቯ㧘᷷ᐲᗵฃᕈ⃻⽎ߩ⊒⷗㧘ᣂߚߥE㉄ൻ㉂⚛ᰳ៊∝ߩ⊒⷗㧘೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩ㛽㜑⒖ᬀߩฦ‫ߡ޿ߟߦޘ‬਎⇇ࠍ࡝࡯࠼ߔࠆᚑᨐࠍ᜼ߍߡ޿ࠆ‫ޕ‬ㆮવሶ⸻ᢿߣߒ
ߡ PEX10 ㆮવሶߩ 2 Ⴎၮᰳᄬ㧘PEX16 ㆮવሶ⇣Ᏹ㧘PEX26 ㆮવሶ⇣Ᏹߥߤࠍ⸻ᢿߒߚ߶߆㧘㕖Ᏹߦ․⇣ߥ଀ߣߒߡ㧘Zellweger ∝୥⟲ߩ⥃ᐥ௝ࠍ๒ߒ ALDP ㆮવሶࠍ฽߻ large deletion ଀ࠍ⸻ᢿߒߚ‫ޕ‬߹ߚ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߩ᷷ᐲᗵฃᕈߦߟ޿ߡߪ࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ߿シ∝ဳ᷷ᐲᗵฃᕈࡕ࠺࡞ࡑ࠙
ࠬߩ૞ᚑߥߤࠍⴕ޿㧘ᧄ∝ߩ∛ᘒ⸃᣿ߣᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫৻ޕ‬ᣇߢ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ␹
⚻⊒↢ㆊ⒟ߦ߅ߌࠆᓎഀߦߟ޿ߡ㧘఺∉⚵❱ൻቇ⊛ᚻᴺࠍ↪޿ߡ⸃ᨆਛߢ޽ࠆ‫ޕ‬
6㧕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ
ዊఽߩ∔ᖚ㑐ㅪⰮ⊕⾰ߩ┙૕᭴ㅧ⸃ᨆߦၮߠ޿ߚ∛ᘒ⸃ᨆ࡮ᴦ≮ᴺߩ㐿⊒ߥߤࠍⴕ߁̍᭴ㅧකቇ̍ߩ⏕┙ࠍ⋡ᜰߒ㧘ૐಽሶ࡝ࠟࡦ࠼ࠬࠢ࡝࡯࠾ࡦࠣ࡮Ⱞ⊕࡟ࡌ࡞ߢߩⰮ⊕Ꮏቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆᴦ≮ᴺߩ㐿⊒
ߦ㊀ὐࠍ⟎޿ߡ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘⥄ὼ఺∉߆ࠄ₪ᓧ఺∉ߦ⥋ࠆ⚻〝ߦ㑐ਈߔࠆ㧘IL-18㧘IL-1㧘
෸߮ Toll-like Receptor ⟲ߦᔅ㗇ߥಽሶߢ޽ࠆࠪࠣ࠽࡞વ㆐ࠕ࠳ࡊ࠲࡯Ⱞ⊕ࠍਛᔃߦߒߚ᭴ㅧቇ⊛⎇ⓥࠍ
ㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߩᚑᨐߩ৻ߟߣߒߡ㧘ᄙᰴరᩭ⏛᳇౒㡆ᴺߦߡ᳿ቯߒߚࡅ࠻ IL-18 ┙૕᭴ㅧࠍ߽ߣߦ㧘ᄌ⇣૕⸃ᨆࠍⴕ޿㧘ࠗࡦ࠲࡯ࡠࠗࠠࡦߦ߅ߌࠆᣂߒ޿⚿ว᭽ᑼߩ⸃᣿ߦ⥋ߞߚ‫ޕ‬7㧕⃻࿷౒หߢⴕࠊࠇߡ޿ࠆࡊࡠࠫࠚࠢ࠻
IL-18 ߣߘߩ⚿วಽሶߩ࠲ࡦࡄࠢ┙૕᭴ㅧߣᯏ⢻㧦㧔ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧕੩ㇺᄢቇ ⊕Ꮉ᣽ብ㧘
Ataxia-telangiectasia ߣ Bloom ∝୥⟲ߩ∛ᘒ⸃ᨆ㧦㧔ㄭ⮮⋥ታ㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Instituteof Medical Research Professor M. Lavin㧘ዊఽ᳇▤ᡰ༎ᕷߩ QOL ⹏ଔ㧔ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧕ᐔጊ⠹৻㇢㧘᛫ࠕ࡟࡞ࠡ࡯⮎ߣㆮવሶߦ㑐ߔࠆ⎇ⓥ㧦㧔ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧕ᄢ㢈⮎ຠᎿᬺ㧘ࡓࠦᄙ♧∝ߩ㉂⚛⵬ల≮ᴺߩၮ␆⊛⎇ⓥ߅ࠃ߮⥃ᐥᔕ↪㧦㧔ㄭ⮮⋥ታ㧘᛬ዬᕡᴦ㧕USA St.Louis University ഥᢎ᝼ ᚭ᧻ବᴦ㧘᡼኿✢㜞ᗵฃᕈ∔ᖚߩಽሶ∛ᘒߦ㑐ߔࠆ⎇ⓥ㧦
㧔ᷓየᢅᐘ㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Institute ofMedical Research Professor M. Lavin㧘࠴ࠝ࡜࡯࠯Ⱞ⊕ߩ 3 ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㧦
㧔ᷓየᢅᐘ㧕ࡈࠖࡦ࡜ࡦ࠼ Oulu University Professor R.Wierenga㧘CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯Ⱞ⊕ߩ 3 ᰴ᭴ㅧߣᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࡈࠖࡦ࡜ࡦ࠼ Oulu University Dr.P.Kursula㧘వᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࠝ࡜ࡦ࠳ Amsterdam Medical Center Professor RJA Wanders㧘వᄤᕈࠤ࠻ࡦ
㧔ᷓየᢅᐘ㧕USA Oregon Heath and University Professor M. Gibson㧘వ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦
ᄤᕈࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߦ㑐ߔࠆ⎇ⓥ㧦㧔ᷓየᢅᐘ㧕ࠞ࠽࠳ Ste-Justine Hospital, Montreal, Professor
GA. Mitchell㧘Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝ߦ߅ߌࠆ␹⚻ᄌᕈᯏ᭴ࠍ⸃᣿ߔࠆߚ߼ߩၮ␆⊛⎇ⓥ㧦㧔᛬ዬᑪᴦ㧘ㄭ⮮⋥ታ㧕USA St.Jude Childrens Research Hospital Associate member Peter J. McKinnon㧘Ᏹᨴ㧙㧙⦡૕ഠᕈ㜞 IgE ∝୥⟲ߩේ࿃ㆮવሶߩᬌ⸛㧦
㧔㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧕᧲੩ක⑼ᱤ⑼ᄢቇᄢቇ㒮 ఺∉ࠕ࡟࡞ࠡ࡯ ፃጯసⴕ㧘ATM ߣ BLM ߩળว㧦
㧔㊄ሶ⧷㓶㧕ࠝ࡯ࠬ࠻࡜࡝ࠕ Queensland Institute of Medical
Research Professor M. Lavin‫ޕ‬8㧕ᣂߚߥࡊࡠࠫࠚࠢ࠻
㔍ᴦᕈ␹⚻∔ᖚ㧔⣄㜑ᕈ╭⪜❗∝ߥߤ㧕ߩ⸻ᢿߣᴦ≮㐿⊒㧔ౣ↢ක≮ߥߤ㧕,⧯ᐕᕈ㑐▵࡝࠙ࡑ࠴ߣ⥄Ꮖ఺∉∔ᖚߩᴦ≮㐿⊒㧘ㆮવᕈ㜞⊒≸∔ᖚ㧔P53 ᰳ៊㧘ATM ᰳ៊㧘BLM ᰳ៊ߥߤ㧕ߦኻߔࠆㆮવሶ㑐ㅪᴦ≮㐿⊒ߥߤߦ⌕ᚻߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ㄭ⮮⋥ታ
ᢎ᝼(૬છ)㧦 ᷓየᢅᐘᢎ᝼(૬છ)㧦 ㊄ሶ⧷㓶
ട⮮ༀ৻㇢
⻠Ꮷ㧦
ኹᧄ⾆⧷
⻠Ꮷ㧦
᧻੗᳗ሶ
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦 ᛬ዬᑪᴦ⥃ᐥ⻠Ꮷ㧦 ⥵ᚭ㆏ᓼ⥃ᐥ⻠Ꮷ㧦 ᄢ⷏⑲ౖ
Ꮉᧄ⟤ᄹሶ
කຬ㧦
ዊ㑐㆏ᄦ
කຬ㧦
㕍ᧁ㓶੺
කຬ㧦
᫪↰⑲ⴕ
කຬ㧦
ਭ଻↰৻↢
කຬ㧦
ᓼ⷗ືม
කຬ㧦
╣੗⧷㓶
කຬ㧦
ᢎ᝼(૬છ)㧦 ਅỈિⴕ

Naomi Kondo
Toshiyuki Fukao
Hideo Kaneko
Zenichiro Kato
Takahide Teramoto
Eiko Matsui
Kenji Orii
Michinori Funato
Hidenori Ohnishi
Minako Kawamoto
Michio Ozeki
Yusuke Aoki
Hideyuki Morita
Kazuo Kubota
Tetsuji Tokumi
Hideo Sasai
Nobuyuki Shimozawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚㘩‛ࠕ࡟࡞ࠡ࡯ߩ⊒∝ᯏᐨߣᴦ≮࡮੍㒐㧦દ⮮ ᱞ㧘Ꮉᧄિ৻㧘᧖ጊ⚐৻㧘⷏ፉၮᒄ㧘☨⼱᳃㓶✬㧚㘩ຠᬌᩏߣ࡝ࠬࠢ࿁ㆱߩߚ߼ߩ㒐ᓮᛛⴚ㧘᧲੩㧦ࠪ࡯ࠛࡓࠪ࡯಴ 㧧2006 ᐕ㧦137㧙147㧚
2㧕 ㄭ⮮⋥ታ㧚ਇ᣿ᾲ㧦ਃᴡᤐ᮸㧘᧻የቱᱞ㧘᫪Ꮉᤘᑝ✬㧚㐓೎⸻ᢿߩᚻᒁ߈࡯‫ޟ‬ዊఽᢇᕆߩᚻᒁ߈‫࡯ࡠࡈޠ‬࠴ࡖ࡯࠻ࠃࠅ࡯㧘᧲੩㧦⥃ᐥක⮎⎇ⓥදળ㧧2006 ᐕ㧦50㧚
3㧕 ㄭ⮮⋥ታ㧚఺∉∔ᖚ㧦᫪Ꮉᤘᑝ㧘ౝጊ ⡛㧘ේ ኼ㇢✬㧚ᮡḰዊఽ⑼ቇ ╙ 6 㧧᧲੩㧦කቇᦠ㒮㧧2006
ᐕ㧦288㧙311㧚
4㧕 ㄭ⮮⋥ታ㧚╙ 1 ┨ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩቯ⟵࡮∔ᖚ᭎ᔨ㧘∛ᘒ↢ℂ࡮∛࿃ 3,∛࿃㧦ጊᧄ᣹ჽ㧘ᴡ㊁㓁৻✬㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⸻≮ࠟࠗ࠼࡜ࠗࡦ 2006㧘᧲੩㧦ද๺ડ↹㧧2006 ᐕ㧦4㧙6㧚
5㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚ㧦ᷡ㊁૫♿㧘ዊᨋ㇌ᒾ㧘ේ↰⎇੺㧘᩶੗⋿㉿ሶ✬㧚NEW ዊఽ⑼ቇ ᡷ⸓╙ 2㧘᧲੩㧦ධశၴ㧧2006 ᐕ㧦286㧙304㧚
6㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧚╙ 6 ┨ࠕ࡟࡞ࠡ࡯∔ᖚ㧦ጊᧄ㊀ᄦ✬㧚ࡃࠗࠝ⸃ᨆ࡮⸻ᢿᛛⴚߩ࠹࡯࡜࡯
ࡔࠗ࠼ක≮߳ߩᔕ↪㧘᧲੩㧦ࠪ㧙ࠛࡓࠪ࡯಴ 㧧2006 ᐕ㧦138㧙144㧚
7㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧦੖ච፲㓉✬㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ╙ 3 㧘᧲੩㧦᧲੩කቇ␠㧧2006
ᐕ㧦258㧙259㧚
8㧕 ㄭ⮮⋥ታ㧚వᄤᕈ఺∉ਇో∝୥⟲㧦ᣣᧄ⊹⤏⑼ቇળ✬㧚ᐔᚑ 18 ᐕᐲ೨ታ❣⎇ୃળㆬᛯࠦ࡯ࠬ㧘᧲੩㧦ᣣᧄ⊹⤏⑼ቇળ㧧2006 ᐕ㧦1㧙27.
9㧕 ᷓየᢅᐘ㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧦ᄢ㑐ᱞᒾ㧘ฎᎹ ẋ㧘ᮮ↰ବ৻㇢✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎ ╙ 14 㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙169.
10㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚I-B ༎ᕷߩ∛ᘒߣ⊒∝ᯏᐨ㧚6㧚㑐ㅪߔࠆㆮવሶࠍ߼ߋߞߡ㧦ᄢ↰ ஜ㧘৻ࡁἑᱜ๺
✬㓸㧚๭ๆེ common disease ߩ⸻≮ ᳇▤ᡰ༎ᕷߩߔߴߡ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦62㧙66㧚
11㧕 ㄭ⮮⋥ታ㧚⥃ᐥ✬Υ㧚∔ᖚߣᩕ㙃 5㧚ࠕ࡟࡞ࠡ࡯∔ᖚ㧦ጟ↰ ᱜ㧘㚍႐ᔘ㓶㧘ጊၔ㓶৻㇢✬㓸㧚ᣂ⥃ᐥᩕ㙃ቇ㧘᧲੩㧦කቇᦠ㒮 2007 ᐕ㧦362㧙368㧚
12㧕 ㄭ⮮⋥ታ㧚╙ 1 ┨ 㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒߣ∝⁁㧦ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ✬㧚ࠕ࡟࡞ࠡ࡯∔ᖚ⸻ᢿ࡮ᴦ
≮ࠟࠗ࠼࡜ࠗࡦ㧘᧲੩㧦ද๺ડ↹㧧2007 ᐕ㧦317㧙322㧚
13㧕 ㄭ⮮⋥ታ㧚Φࠦࡦ࠻ࡠ࡯࡞ߐࠇߚๆ౉ࠬ࠹ࡠࠗ࠼ߩᷫ㊂ߣ㔌⣕ߩታ㓙 ⸛⺰㧦ਛፉ㊀ᓼ㧘ዊᨋ▵㓶㧘ችᧄᤘᱜ ✬㓸㧚᳇▤ᡰ༎ᕷߩࠃࠅࠃ޿ᴦ≮ߩߚ߼ߦ࡯Pharmaco Kinetics, Pharmaco Dynamics ߆ࠄ⷗ߚ༎ᕷ
ᴦ≮ߩౣ⠨㧘᧲੩㧦ਃႎ␠ශ೚ᩣᑼળ␠㧧2007 ᐕ㧦98㧙99.
14㧕 ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1㧙1855.
15㧕 ㄭ⮮⋥ታ㧚ዊఽ∔ᖚߩᴦ≮✚⺰㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008㧙㧙ᐕ㧦85㧙86.
16㧕 ㄭ⮮⋥ታ㧚ਇ᣿ᾲ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦267㧙273.
17㧕 ㄭ⮮⋥ታ㧚఺∉ᯏ᭴—↢૕㒐ᓮᯏ᭴㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦833㧙837.
18㧕 ㄭ⮮⋥ታ㧚఺∉ਇో∝ߩಽ㘃ߣ⸻ᢿ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦837㧙850.
19㧕 ㄭ⮮⋥ታ㧚Wiskott-Aldrich ∝୥⟲(WAS)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦862㧙863.
20㧕 ㄭ⮮⋥ታ㧚Ძ⚦ⴊ▤᜛ᒛᕈዊ⣖ᄬ⺞∝㧘Louis-Bar ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦863㧙864.
21㧕 ㄭ⮮⋥ታ㧚Nijmegen breakage ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦864.
22㧕 ㄭ⮮⋥ታ㧚Artemis ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
864.
23㧕 ㄭ⮮⋥ታ㧚Bloom ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
864.
24㧕 ㄭ⮮⋥ታ㧚DiGeorge ∝୥⟲㧘╙ 3࡮╙ 4 㟴ᑿ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦864.
25㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘∛࿃㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦925㧙928.
26㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
948㧙952.
27㧕 ᷓየᢅᐘ㧚ᭂ㐳㎮ࠕࠪ࡞ - CoA ⣕᳓⚛㉂⚛(VLCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚᧲੩㧦කቇᦠ
㒮㧧2008 ᐕ㧦475.
28㧕 ᷓየᢅᐘ㧚㐳㎮ 3 -ࡅ࠼ࡠࠠࠪࠕࠪ࡞ CoA ⣕᳓⚛㉂⚛(LCHAD)ᰳ៊∝ߣਃ㗡㉂⚛(MTP)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦476.
29㧕 ᷓየᢅᐘ㧚⍴㎮ 3 -ࡅ࠼ࡠࠠࠪࠕࠪ࡞ CoA ⣕᳓⚛㉂⚛(SCHAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊ
ఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦477.
30㧕 ᷓየᢅᐘ㧚2,4 -ࠫࠛࡁࠗ࡞- CoA ㆶర㉂⚛ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦478.
31㧕 ᷓየᢅᐘ㧚ਛ㎮ࠕࠪ࡞- CoA ⣕᳓⚛㉂⚛(MCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦477.
32㧕 ᷓየᢅᐘ㧚⍴㎮ࠕࠪ࡞- CoA ⣕᳓⚛㉂⚛(SCAD)ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦478.
33㧕 ㊄ሶ⧷㓶㧚Chediak—Higashi ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦865㧙866.
34㧕 ㊄ሶ⧷㓶㧚Griscelli ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
866.
35㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮࡝ࡦࡄჇᱺᕈ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦866㧙867.
36㧕 ㊄ሶ⧷㓶㧚ߘߩઁߩ఺∉⺞▵ਇోߩ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ
㒮㧧2008 ᐕ㧦867.
37㧕 ㊄ሶ⧷㓶㧚⛯⊒ᕈ఺∉ਇో∝ ✚⺰㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦879㧙883.
38㧕 ㊄ሶ⧷㓶㧚Behcet ∛㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦910
㧙912.
39㧕 ㊄ሶ⧷㓶㧚Sjogren ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
912㧙913.
40㧕 ㊄ሶ⧷㓶㧚⢷⤑Ἳ࡮⤥⢷㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1018
㧙1020.
41㧕 ኹᧄ⾆⧷㧚ࠢ࡝࠾ࠞ࡞ࡄࠬ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
290㧙29242㧕 ᧻੗᳗ሶ㧚ᕆᕈ㥦ຜ㗡Ἳ(ᗵ౨∝୥⟲)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦993.
43㧕 ᧻੗᳗ሶ㧚ᕆᕈຜ㗡ᚳ᩶Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
993㧙994.
44㧕 ᧻੗᳗ሶ㧚ᚳ᩶๟࿐⤥≌㧘ຜᓟ⤥≌㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦994.
45㧕 ᧻੗᳗ሶ㧚ᚳ᩶⢈ᄢ(ญ⬄ᚳ᩶㧘ࠕ࠺ࡁࠗ࠼)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦994㧙995.
46㧕 ᧻੗᳗ሶ㧚․⊒ᕈ㑆⾰ᕈ⢖Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
1012㧙1014.
47㧕 ᧻੗᳗ሶ㧚⢖ࡋࡕࠫ࠺ࡠ࡯ࠪࠬ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008㧙㧙ᐕ㧦1014㧙1015.
48㧕 ᧻੗᳗ሶ㧚⢖⢩Ⱞ⊕∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1015
㧙1016.
49㧕 ᧻੗᳗ሶ㧚ㆊᢅᕈ⢖⤳Ἳ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦1016
㧙1017.
50㧕 ᧻੗᳗ሶ㧚⢖ൻ⤥∝(⢖⤥≌)㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ ✚✬㓸㧚ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
1017㧙1018.
51㧕 ㄭ⮮⋥ታ ઁ㧚Ϊ㧚Ⴧᖡᤨߩᴦ≮ᴺ ⸛⺰㧦ችᧄᤘᱜ㧘ዊᨋ▵㓶㧘ਛፉ㊀ᓼ ✬㓸㧚༎ᕷߩჇᖡൻߣߘߩኻ
ᔕ㧘࡜ࠗࡈࠨࠗࠛࡦࠬ㧧2008 ᐕ㧦106㧙119.
52㧕 ૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008ᐕ㧚
53㧕 ㄭ⮮⋥ታ㧚⊒ᾲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦70㧙73.
54㧕 ㄭ⮮⋥ታ㧚⊒∐㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦93㧙94.
55㧕 ㄭ⮮⋥ታ㧚ຕ㧘∷㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦108㧙109.
56㧕 ㄭ⮮⋥ታ㧚఺∉ਇో∝ߩಽ㘃㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦335㧙337.
57㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⸻≮ߩၮ␆⍮⼂㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦361㧙363.
58㧕 ㄭ⮮⋥ታ㧚ዊఽ᳇▤ᡰ༎ᕷ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦364㧙367.
59㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯ᕈ㥦Ἳ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦368.
60㧕 ᷓየᢅᐘ㧚DNA㧘ㆮવሶ㧘ࠥࡁࡓ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦181㧙184.
61㧕 ᷓየᢅᐘ㧚ㆮવᕈ∔ᖚߩಽ㘃ߣ㗫ᐲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦185㧙187.
62㧕 ᷓየᢅᐘ㧚න৻ㆮવሶ∛㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦188㧙190.
63㧕 ᷓየᢅᐘ㧚ዩ⚛ࠨࠗࠢ࡞⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦221㧙222.
64㧕 ᷓየᢅᐘ㧚♧ઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦223㧙226.
65㧕 ᷓየᢅᐘ㧚ࡆ࡝࡞ࡆࡦઍ⻢⇣Ᏹ∝ߣࡐ࡞ࡈࠖ࡝ࡦઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦237㧙239.
66㧕 ᷓየᢅᐘ㧚Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦355㧙356.
67㧕 ᷓየᢅᐘ㧚ߘߩઁߩ఺∉⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦359㧙360.
68㧕 ㊄ሶ⧷㓶㧚఺∉ᯏ᭴㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦332㧙334.
69㧕 ㊄ሶ⧷㓶㧚ⶄว఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦338㧙339.
70㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮ήࠟࡦࡑࠣࡠࡉ࡝ࡦⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦343㧙344.
71㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦345㧙346.
72㧕 ㊄ሶ⧷㓶㧚IgA ᰳਲ∝㧘ㆬᛯ⊛ IgG ࠨࡉࠢ࡜ࠬᰳਲ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦347㧙348.
73㧕 ᧻੗᳗ሶ㧚ߓࠎ߹∐㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦369㧙370.
74㧕 ᧻੗᳗ሶ㧚ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦371㧙373.
75㧕 ᧻੗᳗ሶ㧚࠙ࠗ࡞ࠬᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦398㧙400.
76㧕 ᧻੗᳗ሶ㧚⚦⩶ᗵᨴ∝㧘ࡑࠗࠦࡊ࡜࠭ࡑ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦401㧙404.
77㧕 ᧻੗᳗ሶ㧚⌀⩶㧘ࠬࡇࡠࡋ㧙࠲㧘ࠢ࡜ࡒࠫࠕ㧘࡝ࠤ࠶࠴ࠕᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧦2008 ᐕ㧦405㧙406.
78㧕 ᧻੗᳗ሶ㧚ャ౉ᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧧ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦409㧙410.

㧙㧙79㧕 ᧻੗᳗ሶ㧚ㇱ૏೎ᗵᨴ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦411㧙413.
80㧕 ᧻੗᳗ሶ㧚ᢌⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม ✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ㧙␠㧧2008 ᐕ㧦414㧙415.
81㧕 ⥵ᚭ㆏ᓼ㧘ᄢႦ▵ሶ㧘ℙየᵏౖ㧚ャⴊߩታ㓙㧦MFICU Უ૕࡮⢝ఽࡑ࠾ࡘࠕ࡞㧘ࡔ࠺ࠖࠞ಴  ᄢ㒋㧧2008
ᐕ㧦368㧙374.
82㧕 ㄭ⮮⋥ታ㧚఺∉࡮ࠕ࡟࡞ࠡ㧙∔ᖚ㧦ጟ↰ ᱜ ⋙ୃ㧚᩟ਅ ᷕ㧘ጊ᧲ൕᒎ㧘↰ਛ⧐᣿㧘ᣧᎹ㤗ℂሶ ✬㓸㧚⥃ᐥᩕ㙃ቇᴦ≮ߩታ〣 ∛ᘒ೎✬㧘᧲੩㧦㊄ේ಴ 㧧2008 ᐕ㧦423㧙440.
83㧕 ㄭ⮮⋥ታ㧚᳇▤ᡰ༎ᕷ㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦122㧙126.
84㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦127㧙130.
85㧕 ㄭ⮮⋥ታ㧚⭄㤗∐㧦᧻የ ℂ ⋙ୃ㧚㋈ᧁᐽਯ ✬㓸㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 15 ዊఽ∔ᖚ㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2008 ᐕ㧦131㧙132.
86㧕 ⥵ᚭ㆏ᓼ㧚╙ 5 ┨ ⇣Ᏹಽᇂߩ▤ℂߣಣ⟎㧦MFICU(๟↥ᦼක≮)ㅪ⛊ද⼏ળ ✬㓸㧚MFICU Უ૕࡮⢝ఽ
ICU ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦ࡔ࠺ࠖࠞ಴ 㧧2008 ᐕ㧦368㧙374㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Kato Z, Kaneko H, Fukao T, Matsui E, Aoki M. Molecular mechanisms of hygiene hypothesis.
In: Holgate S, Marone G, Ring J, eds. Cellular and Molecular Targets in Allergy and Clinical
Immunology. Gottingen: Hogrefe & Huber Publishers; 2007:36-37.
2㧕 Matsuura N, Tada H, Nakamura Y, Uehara R, Kondo N, Yokota Y, Kaneko H, Fukushi M.Effects of
Dioxins in Breast Milk on Thyroid Function in Infants Born in Japan. Maatoshi Morita M et..
Persistent Organic Pollutants(POPS) Research in Asia, Tsukuba, 2008:368-374.
✚⺑㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ട⮮ༀ৻㇢㧘ᰞ੗㉿⟤㧘ᣂ੗㓉ᐢ㧘ዊỈ ੫㧘ᧁ᧛ ⽕㧚ࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ߪน⢻߆㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯
ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦44㧙54.
2㧕 ㄭ⮮⋥ታ㧚᣿⏕ߦቯ⟵ߐࠇߚ఺∉ਇో∝-Wiskott-Aldrich ∝୥⟲㧘Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝ߥߤ-㧘ዊఽ⑼⸻
≮ 2006 ᐕ㧧69 Ꮞ(Ⴧೀภ)㧦257㧙259.
3㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ዊఽࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆ QOL ⺞ᩏߩታ㓙㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13
Ꮞ㧦32㧙43.
4㧕 ㄭ⮮⋥ታ㧚1.ዊఽࠕ࡟࡞ࠡ࡯ߣ఺∉ㆮવቇ—ࠕ࡟࡞ࠡ࡯ߩ∛࿃࡮㑐ㅪㆮવሶߣㆮવሶቇ⊛ಽ㘃ߩ⹜ߺ࡯㧘
ዊఽ⑼⥃ᐥ 2006 ᐕ㧧59(Ⴧೀภ)㧦1209㧙1213.
5㧕 ะጊᓼሶ㧘⷏㑆ਃ㚌㧘᦭↰᣽ᒾ㧘દ⮮▵ሶ㧘ቝℂ㗇ෘ㓶㧘ᶏ⠧Ỉరብ㧘ㄭ⮮⋥ታ㧘ᩊ↰Ⅎ⟤ሶ㧘ฎᐣᏎผ㧘⋿ᑿశᢥ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᣣᧄዊఽ⑼ቇળ⹹ 2006 ᐕ㧧110 Ꮞ㧦904㧙911.
6㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⊒∝ߪ੍⍮ߢ߈ࠆ㧫㧘Q&A ߢࠊ߆ࠆࠕ࡟࡞ࠡ࡯∔ᖚ 2006 ᐕ㧧2 Ꮞ㧦318㧙320.
7㧕 ㄭ⮮⋥ታ㧚ዊఽ᳇▤ᡰ༎ᕷᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦ 2005 ࠍߤ߁⺒߻߆ ╙ 6 ┨ዊఽ᳇▤ᡰ༎ᕷߩෂ㒾࿃ሶߣߘߩ੍㒐㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦233㧙237.
8㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ 2005 ⸃⺑ ╙ 3 ┨㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘ᣣᧄዊఽࠕ࡟࡞
ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦238㧙239.
9㧕 ㄭ⮮⋥ታ㧘⑔↰৻ੳ㧚Ataxia-telangiectasia㧚ౝಽᴲ∝୥⟲(╙ 2 )Υ㧘ᣣᧄ⥃ῼ 2006 ᐕ㧧3 Ꮞ㧦114
㧙118.
10㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚੃ᐜఽᦼߦ߅ߌࠆㆮવ࡮ⅣႺⷐ࿃ߣࠕ࡟࡞ࠡ࡯∔ᖚ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006
ᐕ㧧46 Ꮞ㧦273㧙279㧚
11㧕 ㄭ⮮⋥ታ㧚ๆ౉ࠬ࠹ࡠࠗ࠼⮎ߩ⌒߳ߩᓇ㗀—ࡉ࠺࠰࠾࠼ๆ౉⵾೷ࠍਛᔃߦ㧘Pharma Medica 2006 ᐕ㧧
24 Ꮞ㧦49㧙53.
12㧕 ◉↰⚩ม㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚Υ.㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦22㧙28.
13㧕 ㄭ⮮⋥ታ㧚ᦨㄭߩࠕ࡟࡞ࠡ࡯⸻ኤࠟࠗ࠼࡜ࠗࡦ㧘ࠕ࡟࡞ࠡ࡯ࠕ 2006 ᐕ㧧35 Ꮞ㧦62㧙64㧚
14㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ዊఽ༎ᕷߩ৻ᰴ੍㒐㧘ੑᰴ੍㒐㧘ਃᰴ੍㒐ߩ⃻⁁ߣ໧㗴ὐ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯
⑼ 2006 ᐕ㧧46 Ꮞ㧦501㧙508.
15㧕 ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚ᵈ⋡ߔߴ߈ࠕ࡟࡞ࠥࡦߣߘߩ∛ᘒ ࠗ࠿㧘ࡀࠦ㘺⢒ߣࠕ࡟࡞ࠡ࡯ߩ⊒∝㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦604㧙612.
16㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤, ᧻੗᳗ሶ㧚ㆮવߣࠕ࡟࡞ࠡ࡯㧘߆ࠄߛߩ⑼ቇ 2006 ᐕ㧧252 Ꮞ㧦24㧙28.
17㧕 દ⮮▵ሶ㧘ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ࠟࠗ࠼࡜ࠗࡦ 2005 ⸃⺑ ╙ 5 ┨ 㘩‛ࠕ࡟࡞ࠡ࡯ߩ⸻ᢿ㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2006 ᐕ㧧20 Ꮞ㧦526㧙530.
18㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛㧚ࠊ߇࿖ߢ∛࿃߇⸃᣿ߐࠇߚవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006
ᐕ㧧69 Ꮞ㧦1646㧙1652.
19㧕 ㋈ᧁᐽਯ㧚㛽∝⁁ߢ⷗ߟ߆ࠆవᄤઍ⻢⇣Ᏹ∝㧚ᣣᏱ⸻≮ߢߩవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69
Ꮞ㧦1590㧙1594.
20㧕 ᛬ዬᕡᴦ㧘ᷓየᢅᐘ㧚ߌ޿ࠇࠎ㧘ᗧ⼂㓚ኂࠍ⿠ߎߔ∔ᖚߩᴦ≮࡮▤ℂߩࡐࠗࡦ࠻㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧦452㧙454.

㧙㧙21㧕 ᷓየᢅᐘ㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ataxia telangiectasia㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ(⥃ᤨჇೀภ)㧦232
㧙233.
22㧕 ኹᧄ⾆⧷㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚RS ࠙ࠗ࡞ࠬᗵ
ᨴߣ༎ᕷ⊒∝—ᗵᨴߦࠃࠆ༎ᕷߩ⊒∝㧘Ⴧᖡߩᯏᐨ—, ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦1031㧙1037.
23㧕 ੹੗৾㊀㧘⑔ን⌀ᥓሶ㧘᭑ᧄ߭ߣߺ㧘ᐔᨋ⹞ሶ㧘ጤ⿧ᶈሶ㧘ᧁ᧛ ⽕㧘ዊỈ ੫㧘ᰞ੗㉿⟤㧘ᷓየᢅᐘ㧘⑔ንᖈ㧘᛬ዬᔘᄦ㧚∛ఽ଻⢒࿦ߢߩ଻⢒ਛߩ∝⁁ߩᄌൻߦߟ޿ߡߩᬌ⸛㧘଻⢒ߣ଻ஜ 2006 ᐕ㧧12 Ꮞ㧦
31㧙33.
24㧕 ⑔ን ᖈ㧘ฬ↰ආ೑㧘㕍ᧁ㓶੺㧘㋈ᧁ໪ሶ㧘ᣂ੗㓉ᐢ㧘ᷓየᢅᐘ㧘ㄭ᧻↱⟤ሶ㧘ጤ⿧ᶈሶ㧚㤗㤛ḡߩࠗࡦࡈ࡞ࠛࡦࠩߩว૬∝⁁ߦኻߔࠆലᨐߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2006 ᐕ㧧20 Ꮞ㧦44㧙53.
25㧕 ጟᧄ⟤ቁ㧘ᴡ㊁㓁৻㧘ㄭ⮮⋥ታ㧚ᐳ⺣ળ‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩ⊒∝੍⍮ߣ੍㒐ߪน⢻߆㧫‫ޠ‬
㧘Q&A ߢࠊ߆ࠆ
ࠕ࡟࡞ࠡ࡯∔ᖚ 2006 ᐕ㧧2 Ꮞ㧦337㧙350.
26㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧚᳇▤ᡰ༎ᕷߩ⊒∝੍㒐㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦23㧙27㧚
27㧕 ㄭ⮮⋥ታ㧚ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ㧘ዊఽౝ⑼ ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ╙ 3  2007 ᐕ㧧38 Ꮞ(Ⴧೀภ)㧦258
㧙259.
28㧕 ㄭ⮮⋥ታ㧚༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼(୘೎ൻ)ක≮ߩ⃻⁁ߣ዁᧪߳ߩࠕࡊࡠ㧙࠴㧘International Review of
Asthma 2007 ᐕ㧧9 Ꮞ㧦8㧙29.
29㧕 ㄭ⮮⋥ታ㧚ࠕ࡟࡞ࠡ࡯⊒∝ߦ߅ߌࠆㆮવሶߣⅣႺ㧘ࠕ࡟࡞ࠡ࡯ 2007 ᐕ㧧56 Ꮞ㧦94㧙100㧚
30㧕 ㄭ⮮⋥ታ㧚Q&A ⧎☳∝ߦ߅ߌࠆዪᚲ∝⁁ߣోり⊛ߥ∝⁁ߪ㧘ߤߩࠃ߁ߦኻᔕߒߚࠄࠃ޿ߢߔ߆㧚Allergy
From the Nose to the Lung 2007 ᐕ㧧5 Ꮞ㧦17㧚
31㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘ᣂ੗㓉ᐢ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᪀ේᗲ⟤㧚ⅣႺ߇↢૕ߦ෸߷ߔᓇ㗀㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦92㧙95㧚
32㧕 ⿷┙㓶৻㧘੗਄ᄈ⨃㧘ᯅᧄశม㧘ㄭ⮮⋥ታ㧘⋿ᑿశᢥ㧘᫪Ꮉᤘᑝ㧘⷏㑆ਃ㚌㧚ዊఽ᳇▤ᡰ༎ᕷᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦ 2005 ߇੃ఽ༎ᕷߩᴦ≮⃻႐ߦਈ߃ߚ߽ߩ㧙╙ 15 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળߢߩࠕࡦࠤ࡯
࠻⺞ᩏ⚿ᨐࠃࠅ㧙㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦116㧙123.
33㧕 ㄭ⮮⋥ታ㧚㘩‛ߦኻߔࠆ఺∉ᔕ╵ߩ⇣Ᏹߣ㘩‛ࠕ࡟࡞ࠡ࡯㧘ዊఽౝ⑼ 2007 ᐕ㧧39 Ꮞ㧦545㧙548.
34㧕 ㄭ⮮⋥ታ㧘᪀ේᗲ⟤㧚ࠕ࠽ࡈࠖ࡜ࠠࠪ࡯㧘ዊఽ⑼⸻≮ 2007 ᐕ㧧70 Ꮞ(Ⴧೀภ)㧦111㧙112.
35㧕 ㄭ⮮⋥ታ㧚ㆮવሶ⸻ᢿ㧘⛱ว⥃ᐥ 2007 ᐕ㧧56 Ꮞ㧦1883㧙1890.
36㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛ᘒ↢ℂ㧘ࠕ࡟࡞ࠡ࡯ 2007 ᐕ㧧56 Ꮞ㧦439㧙444.
37㧕 ㄭ⮮⋥ታ㧚 Q&A ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩሶଏ߇༎ᕷߦߥࠄߥ޿ߚ߼ߦߪ㧫 Answer㧘 Q&A ߢࠊ߆ࠆࠕ࡟࡞
ࠡ࡯∔ᖚ 2007 ᐕ㧧3 Ꮞ㧦273㧙274㧚
38㧕 ㄭ⮮⋥ታ㧚ᐳ⺣ળ ዊఽࠕ࡟࡞ࠡ࡯ߩ QOL ⹏ଔᴺߣ⥃ᐥߦ߅ߌࠆᗧ⟵㧘Pediatric Allergy for Clinicians
2007 ᐕ㧧3 Ꮞ㧦5㧙11㧚
39㧕 ᷓየᢅᐘ㧚ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ ․ߦࠕ࠮࠻ࡦⴊᕈཌྷฯ∝ߣ㐓೎ߔߴ߈ࠨࠢࠪ࠾࡞㧙CoA㧦3㧙ࠤ࠻㉄ CoA࠻࡜ࡦࠬࡈࠚ࡜㧙࠯ᰳ៊∝ࠍਛᔃߦ㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦727㧙739.
40㧕 ᷓየᢅᐘ㧚ࡍ࠶࠻㘺⢒ⅣႺߣዊఽࠕ࡟࡞ࠡ࡯㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧356 Ꮞ㧦129㧙135.
41㧕 ㋈ᧁ໪ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚IgA ࠨࡉࠢ࡜ࠬ(IgA1, IgA2)ߩ․ᕈ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2007 ᐕ㧧
473 Ꮞ㧦652㧙657㧚
42㧕 Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚⤯Ꮺⴊࠍ↪޿ߚ಴↢ࠦࡎ࡯࠻⎇ⓥߦ
ࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⹏ଔ㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧27 Ꮞ㧦77㧙82㧚
43㧕 ㄭ⮮⋥ታ㧚㘩‛ࠕ࡟࡞ࠡ࡯ߣߘߩኻ╷㧘߰ߚ߫ 2007 ᐕ㧧71 Ꮞ㧦11㧙15.
44㧕 ㄭ⮮⋥ታ㧚࿾ၞක≮⏕଻ߩߚ߼ߩ౐ߟߩ⊒ᗐォ឵—ጘ㒂ᄢ‫ޟ‬࿾ၞක≮කቇ࠮ࡦ࠲࡯‫—┙⸳ߩޠ‬㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧4364 Ꮞ㧦80㧙85㧚
45㧕 ㄭ⮮⋥ታ㧚⮎‛ࠕ࡟࡞ࠡ࡯ߩ⸻ᢿߣᴦ≮㧘ዊఽ⑼⥃ᐥ 2007 ᐕ㧧60 Ꮞ㧦2319㧙2327㧚
46㧕 ㄭ⮮⋥ታ㧚㘩ຠߣࠕ࡟࡞ࠡ࡯㧘FOODS & FOOD INGREDIENTS JOURNAL OF JAPAN 2007 ᐕ㧧212
Ꮞ㧦997㧙1001㧚
47㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘⷏᧛޽߆ߨ㧚᳇▤ᡰ༎ᕷᖚఽߦኻߔࠆ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㧘ዊఽ⑼ 2007 ᐕ㧧48
Ꮞ㧦1981㧙1988.
48㧕 ㄭ⮮⋥ታ㧚↢૕ⷐ࿃ߣⅣႺⷐ࿃ߣߩ㑐ࠊࠅ߆ࠄ∛᳇ߩኻ╷ࠍ⠨߃ࠆ㧘ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4367 Ꮞ㧦
49㧙50.
49㧕 ᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦੃ᐜఽᦼߩ఺∉ᔕ╵ᕈߩᄌㆫߣࠕ࡟࡞ࠡ࡯∔ᖚ⊒∝㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦170㧙174. 
50㧕 ㄭ⮮⋥ታ㧚㘩ຠࠕ࡟࡞ࠡ࡯ߣߘߩᴦ≮ᚢ⇛㧘Milk Science 2008 ᐕ㧧56 Ꮞ㧦138㧙140㧚
51㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘⷏᧛޽߆ߨ㧚ዊఽ᳇▤ᡰ༎ᕷߩ࠹࡯࡜࡯ࡔࠗ࠼ක≮㧘༎ᕷ 2008 ᐕ㧧21 Ꮞ㧦40㧙
46.
52㧕 ᄢ⷏⑲ౖ㧘ട⮮ༀ৻㇢㧘ቄ ᗲ⬒㧘ᧁ᧛ ⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘⋧㚍๺૫㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧘᧩የ⽕ੱ㧘⊕Ꮉ᣽ብ㧚ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩࠗࡦࡄࠢ࠻ IL㧙18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ࡯࠴㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦63㧙70㧚
53㧕 ㄭ⮮⋥ታ㧚ߥߗࠕ࡟࡞ࠡ࡯߇Ⴧടߒߚߩ߆㧘BIO INDUSTRY 2008 ᐕ㧧25 Ꮞ㧦7㧙14.
54㧕 ㄭ⮮⋥ታ㧚✬㓸ᓟ⸥㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦464㧚
55㧕 ㄭ⮮⋥ታ㧘ችᧄᤘᱜ㧘ᄢ↰ ஜ㧚࠻ࠪ࡞㉄ࠬࡊ࡜࠲ࠬ࠻㥊⺣ ༎ᕷᴦ≮ߦ߅ߌࠆ Th2 ࠨࠗ࠻ࠞࠗࡦ㒖ኂ⮎ߩ૏⟎ߠߌ㧘PROGRESS IN MEDICINE 2008 ᐕ㧧28 Ꮞ㧦2167㧙2173.
56㧕 ㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧚ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦2㧙9.

㧙㧙

57㧕 ⑔ን ᖈ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘═ේ⾆⟤ሶ㧘ㄭ⮮⋥ታ㧚ዊఽࠗࡦࡈ࡞ࠛࡦࠩߦ߅ߌࠆ㤗㤛ḡߩലᨐߣᴦ
≮ߩㆬᛯߦߟ޿ߡߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧27 Ꮞ㧦22㧙33.
58㧕 ㄭ⮮⋥ታ㧚QOL ⺞ᩏ␿ߩ૶޿ᣇ㧘Pediatric Allergy for Clinicians 2008 ᐕ㧧4 Ꮞ㧦31㧙35.
59㧕 ᷓየᢅᐘ㧚⾰⇼ᔕ╵ ዊఽߩࠤ࠻࡯ࠪࠬ㧘 ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4329 Ꮞ㧦89㧙90㧚
60㧕 ㊄ሶ⧷㓶㧚ᶧᕈ఺∉ߩ⇣Ᏹߦࠃࠆ఺∉ਇో∝㧚ߎߎ߹ߢಽ߆ߞߡ޿ࠆ఺∉ਇో∝୥⟲㧘ዊఽ⑼⸻≮ 2008
ᐕ㧧61 Ꮞ㧦1775㧙1782㧚
61㧕 ᷓየᢅᐘ㧚IgG ࠨࡉࠢ࡜ࠬᰳ៊∝ߣ IgA ᰳ៊∝㧘ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4  ዊఽౝ⑼ 2008
ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1288㧙1293㧚
62㧕 ㊄ሶ⧷㓶㧚Ataxia-telangiectasia ߣߘߩ㘃✼∔ᖚ㧘ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4 ዊఽౝ⑼
2008 ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1314㧙1317.
✚⺑㧔᰷ᢥ㧕
1㧕 Matsui E, Kaneko H㧘Fukao T㧘Teramoto T㧘Kondo N. Tailor-made edicine and gene polymorphisms
in bronchial asthma. Int Rev Asthma. 2006;8:64-72.
2㧕 Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inher Metab Dis.
2007;30:193-197.
3㧕 Kondo N㧘Munakata M㧘Rosenwasser LJ. Round table discussion㧘tailor-made(personalized)medicine
for asthma-current situation and future vision㧚Int Rev Asthma. 2007;9:7-29.
4㧕 Kondo N. Current position of Japanese and Chinese medicine in regard to tailor-made medicine -Fromthe viewpoint of allergic disorders-. J Tradit Med. 2007;24:43-46.
5㧕 Kondo N, Matsui E, Nishimura A. A genetic classification and a tailor-made medicine in allergic
disorders. Korean J Asthma, Allergy and Clin Immunol. 2007;27:83-86.
6㧕 Mukoyama T, Nishima S, Arita M, Ito S, Urisu A, Ebisawa M, Ogura H, Kohno Y, Kondo N, Shibata R,
Hurusho M, Mayumi M, Morikawa A. Food Allergy Committee, Japanese Society of Pediatric Allergy
and Clinical Immunology Guidelines for diagnosis and management of pediatric food allergy inJapan. Allergol Int. 2007;56:349-361.
7㧕 Kondo N. From the Editorial Committee. Int Rev Asthma. 2008;10:4.
8㧕 Kondo N, Hae Sim Park, Soo Jong Hong. Round Table Discussion-clinical application of molecular
genetics of allergy. Int Rev Asthma. 2008;10:5-21.
ේ⪺㧔๺ᢥ㧕
1㧕 ⷏㑆ਃ㚌㧘ፒጊᐘ㓶㧘᫪Ꮉߺ߈㧘ⷺ↰๺ᒾ㧘ศේ㊀⟤㧘᫪Ꮉᤘᑝ㧘ᴡ㊁㓁৻㧘⷏—↰ᢅਯ㧘චሼᢥሶ㧘⋧ේ㓶ᐘ㧘❐ ◊㧘દ⮮ᶈ᣿㧘ቝℂ㗇ෘ㓶㧘ㄭ⮮⋥ታ㧘⋿ᑿశᢥ㧘ᐔኅବ↵㧘દ⮮▵ሶ㧘ᧃᑝ ⼾㧘᦭↰᣽ᒾ㧘ฎᎹ ẋ㧘ựፒ㓶ᐔ㧚ዊఽࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆࠕ࡟࡞ࠥࡦᗵ૞ߩో࿖⺞ᩏ㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇ
ળ⹹ 2006 ᐕ㧧20 Ꮞ㧦109㧙118.
2㧕 ૒‫ᧁޘ‬⡛㧘Ḵญ᣽ሶ㧘ㄭ⮮⋥ታ㧘ቝℂ㗇ෘ㓶㧘ᄢਭ଻౏⵨㧚ࠕ࡟࡞ࠡ࡯∔ᖚߩᣧᦼ੺౉(early intervention)ߩታ㓙ߣ⹏ଔ㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦3㧙20.
3㧕 ዊ㑐㆏ᄦ㧘᳗↰ᥓሶ㧘દ⮮⾆⟤ሶ㧘㐳ደ⡡৻㇢㧘ጤ↰᥏ሶ㧘ጤ↰⑲᮸㧘ㄭ⮮ን㓶㧘ᷡፉ⋿ℂሶ㧘ጊਛᣂ਽㧘⮮Ỉᥓ⟤㧚㗖ㇱ⚿ᩭᕈ࡝ࡦࡄ▵Ἳ߆ࠄ⊹⤏⣼∛ࠍ⊒∝ߒߚዊఽ଀㧘ᣣᧄዊఽ⊹⤏⑼ቇળ㔀⹹ 2006 ᐕ㧧25
Ꮞ㧦101㧙104.
4㧕 ᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘◉↰⚩ม㧘⑔ን ᖈ㧘ᓟ⮮ടኼ⟤㧘ㄭ⮮⋥ታ㧚QOL ⹏ଔߩታ଀⚫੺㧘PediatricAllergy for Clinicians 2007㧧3 Ꮞ㧦25㧙29.
5㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦1022㧙1033.
6㧕 ㄭ⮮⋥ታ㧚ዊఽක≮೙ᐲߢߩ⃻⁁ߣ໧㗴ὐ—ᄢቇዊఽ⑼ൕോක㧘ዊఽ⑼⸻≮ 2008 ᐕ㧧71 Ꮞ㧦1879㧙1881.
7㧕 ᐔᨋ⹞ሶ㧘᎑੗⌀ᄹ⟤㧘⨹Ꮉౖሶ㧘⑔ን⌀ᥓሶ㧘ጤ⿧ᶈሶ㧘ᷓየᢅᐘ㧘቟⮮ᕺ⟤ሶ㧘ኹỈᄢ␭㧘ዊ㑐㆏ᄦ㧘⑔ንᖈ㧚∛ఽ଻⢒ߦ߅ߌࠆ∝⁁ߦวࠊߖߚㆆ߮ߩᬌ⸛㧘଻⢒ߣ଻ஜ 2008 ᐕ㧧14 Ꮞ㧦46㧙49.
8㧕 ᫪↰⑲ⴕ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘ㄭ⮮ᙥ㧘᧻੗᳗ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚఺∉ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩၮ␆⊛ᬌ⸛㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦233㧙238.
9㧕 ⑔ንᖈ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘═ේ⾆⟤ሶ㧘ㄭ⮮⋥ታ㧚ዊఽࠗࡦࡈ࡞ࠛࡦࠩߦ߅ߌࠆ㤗㤛ḡߩലᨐߣᴦ≮ߩㆬᛯߦߟ޿ߡߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧27 Ꮞ㧦22㧙32㧚
10㧕 㕍ᧁ㓶੺㧘Ⴚ⟤Ⓞ㧘⊕਄ ㆆ㧘ဈ੗ᢕሶ㧘ጟᧄඳਯ㧘᧖ጊብ㧘ౝ↰㕏㧚ਛ⡊Ἳᴦ≮ᓟ 40 ᣣ⚻ߡ⊒∝ߒߚன⤑ᕈ⣺Ἳߩ 1 ଀㧘ዊఽ⑼⥃ᐥ 2008 ᐕ㧧61 Ꮞ㧦2307㧙2311㧚
11㧕 ട⮮ༀ৻㇢㧚ࡅ࠻ࡋ࡞ࡍࠬ࠙ࠗ࡞ࠬ6 ߦࠃࠆᕆᕈዊ⣖Ἳ㧘ዊఽౝ⑼ 2008 ᐕ㧧40 Ꮞ㧦586㧙588.
ේ⪺㧔᰷ᢥ㧕
1㧕 Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, Lavin MF. Regulation of the Atm promoter invivo. Genes Chromosomes Cancer. 2006;45:61-71.
IF 4.532
2㧕 Matsukuma E, Kato Z, Omoya K, Hashimoto K, Li A, Yamamoto Y, Ohnishi H, Hiranuma H, Komine
H, Kondo N. Development of fluorescence linked immunosorbent assay (FLISA) for high throughput
screening (HTS) of interferon-gamma. Allergol Int. 2006;55:49-54.
3㧕 Uehara R, Peng G, Nakamura Y, Matsuura N, Kondo N, Tada H. Human milk survey for dioxins in the㧙㧙general population in Japan.Chemosphere. 2006;62:1135-1141.
4㧕 Kaneko H, Matsui E, Shinoda S, Kawamoto N, Nakamura Y, Uehara R, Matsuura N, Morita M, Tada
H, Kondo N. Effects of dioxins on the quantitative levels of immune components in infants. Toxicol Ind
Health. 2006;22:131-136.
5㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal
beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
6㧕 Kaneko H, Matsui E, Asano T, Kato Z, Teramoto T, Aoki M, Kawamoto N, Lian LA, Kasahara K, Kondo
N. Suppression of IFN-gamma production in atopic group at the acute phase of RSV infection. Pediatr
Allergy Immunol. 2006;17:370-375.
7㧕 Kato Z, Asano T, Kondo N. Inosiplex affects the spectra of proton magnetic resonance spectroscopy insubacute sclerosing panencephalitis. J Child Neurol. 2006;21:177-178.
8㧕 Kaneko H, Isogai K, Kondo M, Hosoi K, Asano T, Funato M, Kondo N. Autologous peripheral blood
stem cell transplantation in a patient with relapsed pleuropulmonary blastoma. J Pediatr Hematol
Oncol. 2006;28:383-385.
9㧕 Teramoto T, Fukao T, Tomita Y, Terauchi Y, Hosoi K, Matsui E, Aoki M, Kondo N, Mikawa H.
Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system injapanese children with bronchial asthma. Allergol Int. 2006;55:317-320.
10㧕 Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study ofmontelukast versus theophlline added to inhaled corticosteroid in asthmatic children. Allergol Int.
2006;55:287-293.
11㧕 Kato T, Isogai K, Orii K, Kuratsubo I, Kondo N, Orii T, Suzuki Y. Portal hypertension in a patient withHunter disease. J Inherit Metab Dis. 2006;29:686.
12㧕 Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, Tsuchiya S, Takada H, Hara T, Kawamura N,
Ariga T, Kaneko H, Kondo N, Tsuge I, Yachie A, Sakiyama Y, Iwata T, Bessho F, Ohishi T, Joh K, Imai
K, Kogawa K, Shinohara M, Fujieda M, Wakiguchi H, Pasic S, Abinun M, Ochs HD, Renner ED,
Jansson A, Belohradsky BH, Metin A, Shimizu N, Mizutani S, Miyawaki T, Nonoyama S, Karasuyama
H. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved
in innate and acquired immunity. Immunity. 2006;25:745-755.
13㧕 Zhang G, Fukao T, Sakurai S, Yamada K, Michael Gibson K, Kondo N. Identification of Alu-mediated,large deletion-spanning exons 2-4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency.
Mol Genet Metab. 2006;89:222-226.
14㧕 Shiozawa K, Goda N, Shimizu T, Mizuguchi K, Kondo N, Shimozawa N, Shirakawa M, Hiroaki H. The
common phospholipid-binding activity of the N-terminal domains of PEX1 and VCP/p97. FEBS J.
2006;273:4959-4971.
15㧕 Orii KE, Lee Y, Kondo N, McKinnon PJ. Selective utilization of nonhomologous end-joining andhomologous recombination DNA repair pathways during nervous system development. Proc Natl Acad
Sci U S A. 2006;103:10017-10022.
16㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasa S, Kondo
N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children.
Pediatr Allergy Immunol. 2006;17:125-133.
17㧕 Fukao T, Sakurai S, Rolland MO, Zabot MT, Schulze A, Yamada K, Kondo N. A 6-bp deletion at the
splice donor site of the first intron resulted in aberrant splicing using a cryptic splice site within exon 1
in a patient with succinyl-CoA: 3-ketoacid CoA transferase (SCOT) deficiency. Mol Genet Metab.
2006;89:280-282.
18㧕 Sukegawa-Hayasaka K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effectof Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of
iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
19㧕 Kato Z, Saito K, Isogai K, Kondo N. Magnetic resonance imaging and spectroscopy in FCMD. J Ped
Neurol. 2006;4:261-264.
20㧕 Kato Z, Omoya K, Orii KE, Kondo N. Acute disseminated encephalomyelitis associated withenterovirus 71. Pediatr Infect Dis J. 2006;1:115-118.
21㧕 Horikoshi H, Kato Z, Masuno M, Asano T, Nagase T, Yamagishi Y, Kozawa R, Arai T, Aoki M, Teramoto
T, Omoya K, Matsumoto N, Kurotaki N, Shimokawa O, Kurosawa K, Kondo N. Neuroradiologic
findings in Sotos syndrome. J Child Neurol. 2006;21:614-618.
22㧕 Takahashi Y, Matsuda K, Kubota Y, Shimomura J, Yamasaki E, Kudo T, Fukushima K, Osaka H,
Akasaka N, Imamura A, Yamada S, Kondo N, Fujiwara T.Vaccination and infection as causative
factors in Japanese patients with rasmussen syndrome: Molecular mimicry and HLA class I. Clin Dev
Immunol. 2006;13:381-387.
23㧕 Tomatsu S, Sukegawa K, Trandafirescu GG, Gutierrez MA, Nishioka T, Yamaguchi S, Orii T, Froissart
R,Maire I, Chabas A, Cooper A, Di Natale P,Gal A, Noguchi A, Sly WS. Differences in methylation
patterns in the methylation boundary region of IDS gene in hunter syndrome patients: implications㧙㧙

IF 2.739

IF 0.731

IF 1.464

IF 2.454
IF 1.240

IF 1.278

IF 1.668

IF 19.266

IF 2.550

IF 6.791

IF 9.598

IF 2.454

IF 2.550

IF 1.668

IF 3.086

IF 1.240

for CpG hot spot mutations.Eur J Hum Genet. 2006;14:838-845.
24㧕 Tomatsu S, Montano AM, Lopez P, Trandafirescu G, Gutierrez MA, Oikawa H, Nishioka T, Vieira MB,
Orii T, Noguchi A. Determinant factors of spectrum of missense variants in mucopolysaccharidosis IVA
gene.Mol Genet Metab. 2006;89:139-149.
25㧕 Sakurai S, Fukao T, Haapalainen AM, Zhang G, Yamada S, Lilliu F, Yano S, Robinson P, Gibson MK,
Wanders RJA, Mitchell GA, Wierenga RK, Kondo N. Kinetic and Expression Analyses of Seven Novel
Mutations in Mitochondrial Acetoacetyl-CoA Thiolase (T2): Identification of a Km Mutant and an
Analysis of the Mutational Sites in the Structure. Mol Genet Metab. 2007;90:370-378.
26㧕 Kondo M, Fukao T, Shinoda S, Kawamoto N, Kaneko H, Kato Z, Matsui E, Teramoto T, Nakano T,
Kondo N. Lymphocyte responses to chymotrypsin- or trypsin V-digested E-lactoglobulin in patientswith cow’s milk allergy. Allergy Asthma Clin Immunol. 2007;3:1-9.
27㧕 Kato T, Kato Z, Kuratsubo I, Ota T, Orii T, Kondo N, Suzuki Y. Evaluation of ADL in patients withHunter disease using FIM score. Brain Develop. 2007;29:298-305.
28㧕 Ochiai T, Suzuki Y, Kato T, Shichino H, Chin M, Mugishima H, Orii T. Naturalhistory of extensive
Mongolian spots in mucopolysaccharidosis type II(Huntersyndrome): a survey amond 52 Japanesepatients. J Eur Acad Dermatol Venereol. 2007;21:1082-1085.
29㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein(ALDP/ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
30㧕 Yamada K, Fukao T, Zhang G, Sakurai S, Ruiter JPN, Wanders RJA, Kondo N. Single-basesubstitution at the last nucleotide of exon 6 (c.671G >A), resulting in the skipping of exon 6, and exons
6 and 7 in human Succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet Metab.
2007;90:291-297.
31㧕 Haapalainen A, Merilinen G, Piril P, Kondo N, Fukao T, Wierenga R. Crystallographic and kinetic
studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium andchloride ions for its structure and function. Biochemistry. 2007;46:4305-4321.
32㧕 Yamada K, Fukao T, Suzuki H, Inoue R, Kondo T, Kondo N. Vitamin K-Deficient Intracranial
Hemorrhage as the First Symptom of Cytomegalovirus Hepatitis with Cholestasis. Tohoku J Exp Med.
2007;212:335-339.
33㧕 Funato M, Kaneko H, Matsui E, Teramoto T, Kato Z, Fukao T, Okusu K, Kondo N. Refractoryosteomyelitis caused by bacille Calmette-Guerin vaccination: a case report. Diagn Microbiol Infect Dis.
2007;59:89-99.
34㧕 Kondo N, Matsui E, Nishimura A. A genetic classification and a tailor-made medicine in allergic
disorders. Korean Journal of Asthma, Allergy and Clinical Immunology. 2007;27:83-86.
35㧕 Ohya Y, Watanabe H, Kojima N. Katsunuma T, Kondo N, Akasawa A. Impact of Pediatric Asthma andtreatment on care-givers visiting specialist clinics in Japan. J Allergy Clini Immunol.
2007;119:S41-S42.
36㧕 Tomatsu S, Montano AM, Gutierrez M, Grubb JH, Oikawa H, Dung VC, Ohashi A, Nishioka T,
Yamada M, Tosaka Y, Trandafirescu GG, Orii T. Characterization and pharmacokinetic study ofrecombinant human N-acetyl galactosamine-6-sulfate sulfatase. Mol Genet Metab. 2007;91:69-78.
37㧕 Montano AM, Tomatsu S, Gottesman GS, Smith M, Orii T.International Morquio A registry:clinicalmanifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30:165-174.
38㧕 Tomatsu S, Vogler C, Montano AM, Gutierrez M, Oikawa H, Dung VC, Orii T, Noguchi N, Sly WS.
Murine model(Galnstm(C76S)slu)of MPS IVA with a missense mutation at the active site cysteineconserved among sulfatase proteins. Mol Genet Metab. 2007;91:251-258.
39㧕 Montaño AM, Sukegawa K, Kato Z, Carrozzo R, Di Natale P, Christensen E, Orii KO, Orii T, Kondo N,
Tomatsu S. Effect of 'attenuated' mutations in mucopolysaccharidosis IVA on molecular phenotypes ofN-acetylgalactosamine-6-sulfate sulfatase. J Inherit Metab Dis. 2007;30:758-767.
40㧕 Kato Z, Yamagishi A, Kondo N. Interstitial deletion of 1q42.13-q43 with Duane retraction syndrome. J
AAPOS. 2007;11:62-64.
41㧕 Kato Z, Nakamura M, Funato M, Kuwabara H, Kondo N. Accidental etizolam ingestion in a child.
Pediatr Emerg Care. 2007;23:472-473.
42㧕 Uehara R, Nakamura Y, Matsuura N, Kondo N, Tada H. Dioxins in human milk and smoking of
mothers. Chemosphere 2007;68:915-920.
43㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N. Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
44㧕 Fukao T, Zhang G, Aoki Y, Arai T, Teramoto T, Kaneko H, Sugie H, Kondo N. Identification of
Alu-mediated, large deletion-spanning introns 19-26 in PHKA2 in a patient with X-linked liver
glycogenosis (hepatic phosphorylase kinase deficiency). Mol Genet Metab. 2007;92:179-182.
45㧕 Matsuo N, Imamura A, Ito R, Sugawara K, Takahashi Y, Kondo N. The correlation between 1H-MR
spectroscopy and clinical manifestation with tuberous sclerosis complex. Neuropediatrics.

㧙㧙

IF 4.003

IF 2.550

IF 2.550

IF 1.464

IF 1.437

IF 4.451

IF 2.550

IF 3.368

IF 1.133

IF 2.448

IF 8.115

IF 2.550
IF 1.668

IF 2.550

IF 1.668
IF 0.983
IF 0.581
IF 2.739

IF 2.550

2007;38:126-129.
46㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical improvementof diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of theliterature. Pediatr Hematol Oncol. 2007;24:513-524.
47㧕 Funato M, Kaneko H, Ozeki M, Suzuki H, Orii K, Teramoto T, Fukao T, Kondo N. A positive
Donath-Landsteiner test in paroxysmal cold haemoglobinuria. Eur J Haematol. 2007;79:462.
48㧕 Aoyama Y, Asai K, Hioki K, Funato M, Kondo N, Kitajima Y. Herpes gestationis in a mother andnewborn: immunoclinical perspectives based on a weekly follow-up of the enzyme-linked
immunosorbent assay index of a bullous pemphigoid antigen noncollagenous domain. Arch Dermatol.
2007;143:1168-1172.
49㧕 Fukao T, Kursula P, Owen EP, Kondo N. Identification and characterization of a temperature-sensitive
R268H mutation in the human succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet
Metab. 2007;92:216-221.
50㧕 Fukao T, Zhang G, Rolland M-O, Zabot M-T, Guffon N, Aoki Y, Kondo N. Identification of an
Alu-mediated tandem duplication of exons 8 and 9 in a patient with mitochondrial acetoacetyl-CoA
thiolase (T2) deficiency. Mol Genet Metab. 2007;92:375-378.
51㧕 Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T,
Ruiter JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J.Genetic basis for correction of very-long-chain
acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a
genotype-based therapy. Am J Hum Genet. 2007;81:1133-1143.
52㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
53㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter: a case report. Transfus Apher Sci.
2008;38:199-201.
54㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency. Int J Mol Med. 2008;21:233-238.
55㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A novel
polymorphism in the 5-lipoxygenase gene associated with bronchial asthma in Japanese children. Int
J Mol Med. 2008;21:139-144.
56㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z, Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatric Allergy and Immunology. 2008;19:592-598.
57㧕 Yamada K, Yamamoto Y, Uchiyama A, Ito R, Aoki Y, Uchida Y Nagasawa H, Kimura H, Ichiyama T,
Fukao T, Kohno Y. A successfully treated case of neonatal herpes simplex type 1 infection complicatedby hemophagocytic lymphohistiocytosis and acute hepatic failure. Tohoku J Exp Med. 2008;214:1-5.
58㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of D1 and D2 gene expression in selective IgA deficiency. Molecular Medicine Report.
2008;1:395-399.
59㧕 Yotsumoto Y, Hasegawa Y, Fukuda S, Kobayashi H, Endo M, Fukao T, Yamaguchi S: Clinical andmolecular investigations of Japanese cases of glutaric acidemia type 2. Mol Genet Metab.
2008;94:61-67.
60㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle: A case report and review of the literature. Int J Pediatr Otorhinolaryngol Extra.
2008;3:105-108.
61㧕 Fukao T, Boneh A, Aoki Y, Kondo N. A Novel Single-Base Substitution (c.1124A>G) that Activates a
5-Base Upstream Cryptic Splice Donor Site within Exon 11 in the Human Mitochondrial
Acetoacetyl-CoA Thiolase Gene. Mol Genet Metab. 2008;94:417-421.
62㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of childhood X-linked adrenoleukodystrophy:
High risk for depression and neurosis. Brain Dev. 2008;30:477-482.
63㧕 Orii KE, Fukao T, Song X-Q, Mitchell GA, Kondo N. Liver-Specific Silencing of the Human Gene
Encoding Succinyl-CoA: 3-Ketoacid CoA Transferase. Tohoku J Exp Med. 2008;215:227-236.
64㧕 Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, Kaneko H, Kondo N, Kaisho T,
Miyawaki T. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked
agammagloblinemia. Clinical Immunology. 2008;126:148-154.
65㧕 Purevsuren J, Fukao, T, Hasegawa Y, Fukuda S, Kobayashi H, Yamaguchi S. Study of deep intronic
sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency. Mol
Genet Metab. 2008;95:46-51.
66㧕 Kato Z, Stern JN, Nakamura HK, Kuwata K, Kondo N, Strominger JL. Positioning of autoimmune
TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex. Proc Natl Acad Sci U S A.
2008;105:15523-15528.

㧙㧙

IF 1.225

IF 0.720
IF 2.163

IF 2.845

IF 2.550

IF 2.550

IF 11.092

IF 1.254

IF 0.970

IF 1.847

IF 1.847

IF 2.454

IF 1.133

IF 2.550

IF 0.851

IF 2.550
IF 1.464
IF 1.133

IF 3.551

IF 2.550

IF 9.59867㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Mol Med Reports.
2008;1:837-842.
68㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
augments NF-kappa B activity and the production of IL-12 and IFN-gamma. Allergol Int.
2008;57:331-338.
69㧕 Kimura T, Kato Z, Ohnishi H, Tochio H, Shirakawa M, Kondo N. Expression, purification andstructural analysis of human IL-18 binding protein: a potent therapeutic molecule for allergy. Allergol
Int. 2008;57:367-376.
70㧕 Montaño AM, Tomatsu S, Brusius A, Smith M, Orii T. Growth charts for patients affected with
Morquio A disease. Am J Med Genet A. 2008;146A:1286-1295.
71㧕 Tomatsu S, Montaño AM, Ohashi A, Gutierrez MA, Oikawa H, Oguma T, Dung VC, Nishioka T, Orii T,
Sly WS. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet.
2008;17:815-824.
72㧕 Montaño AM, Oikawa H, Tomatsu S, Nishioka T, Vogler C, Gutierrez MA, Oguma T, Tan Y, Grubb JH,
Dung VC, Ohashi A, Miyamoto K, Orii T, Yoneda Y, Sly WS. Acidic amino acid tag enhances response
to enzyme replacement in mucopolysaccharidosis type VII mice. Mol Genet Metab. 2008;94:178-189.
73㧕 Egawa K, Takahashi Y, Kubota Y, Kubota H, Inoue Y, Fujiwara T, Onodera O. Electroclinical featuresof epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy. Epilepsia.
2008;49:2041-2049.
74㧕 Matsukuma E, Kato Z, Orii K, Asano T, Orii K, Matsui E, Kaneko H, Kondo N. Acute mumps
cerebellitis with abnormal findings in MRI diffusion-weighted images. Eur J Pediatr.
2008;167:829-830.
75㧕 Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O-157-induced
hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication.
Pediatr Int. 2008;50:1-3.

IF 2.440

IF 7.806

IF 2.550

IF 3.569

IF 1.277

IF 0.7374㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16
㧙18 ᐕᐲ㧧83,000 ජ౞(24,000㧦30,000㧦29,000 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧘⎇ⓥಽᜂ⠪㧦᧻੗᳗ሶ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧10,600 ජ౞(3,400㧦3,800㧦3,400 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᐔጊቬብ(㜞ፒஜᐽ⑔␩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄੍㒐ធ⒳⎇ⓥ⃰㧦੍㒐ធ⒳ߩലᨐ⊛ታᣉߣ೽෻ᔕߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧260 ජ౞(100㧦80㧦80 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧧ች⣁೑↵(ንጊᄢቇᄢቇ㒮කቇ⮎ቇ⎇ⓥㇱ කቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧6,500 ජ
౞(2,300㧦2,200㧦2,000 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ᄙ↰⵨(ታ〣ᅚሶᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㘩ຠߩ቟ోᕈ㜞ᐲൻផㅴ⎇ⓥ੐ᬺ㧦࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ㧧
ᐔᚑ 15㧙18 ᐕᐲ㧧5,000 ජ౞(2,000㧦1,500㧦750㧦750 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧧㘩‛ࠕ࡟࡞ࠡ࡯ߩ∛࿃∛ᘒߩㆮવሶቇ⊛߅ࠃ߮࠲ࡦࡄࠢ⾰᭴ㅧቇ⊛⸃᣿㧧ᐔᚑ 17㧙21 ᐕᐲ㧧105,000 ජ౞(21,000㧦21,000㧦21,000㧦
21,000㧦21,000 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧧⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧧㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ߩ⥃ᐥ௝ߩ⸃᣿߅ࠃ߮ᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 17㧙21 ᐕᐲ㧧95,000 ජ౞(19,000㧦19,000㧦19,000㧦19,000㧦19,000ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦ᶏ⠧Ỉరብ(࿖┙∛㒮ᯏ᭴ ⋧ᮨේ∛㒮)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮੐ᬺ㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮ㅴዷ࡮㊀∝ൻߩ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ᴡ㊁㓁৻(ජ⪲ᄢቇᄢቇ㒮කቇ⎇ⓥ㒮 කቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮੐ᬺ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳߩ⊒∝߅ࠃ߮ᖡൻ࿃ሶߩห

㧙㧙ቯߣ⊒∝੍㒐࡮∝⁁ᖡൻ㒐ᱛߩߚ߼ߩ↢ᵴⅣႺᢛ஻ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,600 ජ౞(2,000㧦2,000㧦2,500 ජ౞)
10㧕 ⎇ⓥઍ⴫⠪㧦ᄢ↰ஜ(Ꮲ੩ᄢቇකቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮ
Ḱߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,500
ජ౞(4,000㧦4,000㧦4,500 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦ᐔጊቬብ(㜞ፒஜᐽ⑔␩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭੍㒐ធ⒳⎇ⓥ⃰㧦੍㒐ធ⒳ߩലᨐ⊛ታᣉߣ೽෻ᔕߦ㑐ߔࠆ✚ว⊛⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧150(100㧦50 ජ౞)
12㧕 ⎇ⓥઍ⴫⠪㧦㗇↲᧻ା(᧲੩⮫ⴚᄢቇ଻ஜ▤ℂ࠮ࡦ࠲㧙)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ක≮ᛛⴚ⹏ଔ✚ว⎇ⓥ੐ᬺ㧦ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼ߩኻ╷ߣߘࠇߦ઻߁ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧700(0㧦700 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ‫ࠕޟ‬࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ‫ޠ‬ᐔᚑ 19㧙21 ᐕᐲ 51,000 ජ౞(24,000㧦27,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮⋥ታ㧧⎇ⓥಽᜂ⠪㧦᧻੗᳗ሶ㧧ෘ↢ഭ௛⋭఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧5,700
ජ౞(3,000㧧2,700 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦ᄙ↰⵨(ታ〣ᅚሶᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧧ෘ↢ഭ௛⋭㘩ຠߩ቟ోᕈ㜞ᐲൻផㅴ⎇ⓥ੐ᬺ㧦࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧
1,250 ජ౞(500㧦750 ජ౞)
16㧕 ⎇ⓥઍ⴫⠪㧧ጊญᷡᰴ(ፉᩮᄢቇකቇㇱ)㧘⎇ⓥදജ⠪㧦ᷓየᢅᐘ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧦࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ
⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧700 ජ౞(400㧦300 ජ౞)
17㧕 ⎇ⓥઍ⴫⠪㧦ේኼ㇢(਻Ꮊᄢቇකቇ⎇ⓥ㒮)㧧⎇ⓥಽᜂ⠪㧦ㄭ⮮⋥ታ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ‫ޟ‬ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ‫ޠ‬ᐔᚑ 20㧙22 ᐕᐲ㧧2,000 ජ౞(2,000 ජ౞)
18㧕 ⎇ⓥઍ⴫⠪㧦ട⮮ༀ৻㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊ
ᣂⷙഃ⮎ಽሶ⥃ᐥᔕ↪߳ะߌߚࡅ࠻ဳ࡟࠮ࡊ࠲࡯ࡑ࠙ࠬߩ㐿⊒㧧ᐔᚑ 17㧙18 ᐕᐲ㧧2,700 ජ౞(1,800㧧900 ජ౞)
19㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⵨㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊᣂⷙ
ഃ⮎ಽሶ⥃ᐥᔕ↪߳ะߌߚࡅ࠻ဳ࡟࠮ࡊ࠲࡯ࡑ࠙ࠬߩ㐿⊒㧧ᐔᚑ 19 ᐕᐲ㧧1,040 ජ౞
20㧕 ⎇ⓥઍ⴫⠪㧦᧻੗᳗ሶ㧧ᢥㇱ⑼ቇ⋭⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠕ࡟࡞ࠡ࡯∔ᖚߩ∛ᘒ⸃ᨆߦၮߠ
޿ߚᣂߚߥ⸻ᢿᴺߩ⏕┙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,000 ජ౞(1,900㧦1,100 ජ౞)
21㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧᛫૕↥↢ᯏ᭴ߩ⸃᣿㧙᛫૕↥↢ਇో∝‫ ߦ․ޔ‬IgA ᰳ៊∝ࠍࡕ࠺࡞ߦߒߡ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(2,100㧦1,400 ජ౞)
22㧕 ⎇ⓥઍ⴫⠪㧦ᷓየᢅᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧧ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽሶ∛ᘒ㧙Ⱞ⊕ 3 ᰴᯏㅧᄌൻߣࠬࡊ࡜ࠗࠪࡦࠣ⇣Ᏹࠍਛᔃߦ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(1,900㧦1,600
ජ౞)23㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᑪᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝ߦ߅ߌࠆ␹⚻ᄌᕈᯏ᭴ࠍ⸃᣿ߔࠆߚ߼ߩၮ⋚⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ 3,400 ජ౞(2,000㧦1,400 ජ౞)
24㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᕡᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ࠤࡒࠞ࡞ࠪࡖࡍࡠࡦࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᴦ≮ߩၮ⋚⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(1,400㧦2,000 ජ౞)
25㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧⥄ὼ఺∉࡮₪ᓧ఺∉ࠬࠗ࠶࠴ࡦ
ࠣᯏ᭴ߩ᭴ㅧ↢‛ቇ⊛⸃ᨆߦၮߠߊ᛫ࠕ࡟࡞ࠡ࡯⮎㐿⊒㧧ᐔᚑ 17㧙19 ᐕᐲ㧧2,800 ජ౞(1,200㧦900㧦
700 ජ౞)26㧕 ⎇ⓥઍ⴫⠪㧦᧘ᗲ⬒㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ࠕࡦ࠲ࠧ࠾ࠬ࠻⵾೷㐿⊒߳ะߌߚ᭴ㅧ↢‛ቇ⊛ᡷᄌ෸߮ࠬࠢ࡝࡯࠾ࡦࠣߩ᭴▽㧧ᐔᚑ 17㧙18 ᐕᐲ㧧200 ජ౞(100㧦100 ජ౞)
27㧕 ⎇ⓥઍ⴫⠪㧦㕍ᧁ⟤ᄹሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧RS ࠙ࠖ࡞ࠬᗵᨴߩಽሶㆮવ
ቇ⊛⸃ᨆߦၮߠߊዊఽ᳇▤ᡰ༎ᕷߩᣂߚߥ੍㒐ᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,000㧦
1,400 ජ౞)28㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮ᙥ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧㘩‛ࠕ࡟࡞ࠡ࡯ߩ఺∉≮ᴺ‫ࡊࡍޔ‬
࠴࠼≮ᴺ‫ޔ‬ᷫᗵ૞≮ᴺߦࠃࠆ఺∉ኡኈ⺃ዉᯏᐨߩ⸃᣿㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,400 ජ౞(2,100㧦1,300
ජ౞)

㧙㧙

29㧕 ⎇ⓥઍ⴫⠪㧦᧻㓊⧷ᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧࠲ࡦࡄࠢ┙૕᭴ㅧߦၮߠߊᣂⷙ
ࠕ࡟࡞ࠡ࡯ᴦ≮⮎ߩࡂࠗࠬ࡞࡯ࡊ࠶࠻ࠬࠢ࡝࡯࠾ࡦࠣ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,100 ජ౞(1,800㧦1,300ජ౞)30㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ໪ሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧧ㆬᛯ⊛ IgA ᰳ៊∝ߩ∛ᘒ⸃᣿ߣ
IgA ࠨࡉࠢ࡜ࠬߩᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧1,700 ජ౞
31㧕 ⎇ⓥઍ⴫⠪㧦᛬ዬᑪᴦ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ዊ⣖ᄌᕈࠍ᧪ߔవᄤᕈㆮવሶୃᓳ⇣Ᏹ∝ߩ∛ᘒ‫ޔ‬ᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,400 ජ౞
32㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦᭴ㅧ↢‛ቇ⊛ᚻᴺߦࠃࠆ⥄ὼ఺∉෸߮ IL-18
ᯏ⢻೙ᓮߣᣂⷙ఺∉⺞▵⮎ߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧1,700 ජ౞
33㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏⑲ౖ㧧ᐔᚑ 20 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦MyD88 ࠪࠣ࠽࡞․⇣⊛㒖ኂ೷ߩ㐿⊒ߦะߌߚ⚦⢩⤑⺃ዉᕈࠕ࠳ࡊ࠲࡯ಽሶߩ࠲ࡦࡄࠢ᭴ㅧ࡮ᯏ⢻⸃ᨆ㧧250 ජ౞
34㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛⽕㧧ᐔᚑ 20 ᐕᐲ JST ࠪ࡯࠭⊒ជ⹜㛎⎇ⓥ㧦఺∉࡮ࠕ࡟࡞ࠡ࡯∔ᖚᴦ≮⮎ࠍ⋡ᜰߒߚᣂⷙࡅ࠻ࠗࡦ࠲࡯ࡠࠗࠠࡦ-18 ೙ᓮᴺߩ㐿⊒㧧2,000 ජ౞
35㧕 ⎇ⓥઍ⴫⠪:ዊ㑐㆏ᄦ㧧ᐔᚑ 20 ᐕᐲᄢቇᵴᕈൻ⚻⾌(⎇ⓥ㧦⑼⎇ណᛯᡰេ)㧧1,060 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘᦯ㇱᶈ᣿㧦ࠕ࡟࡞ࠡ࡯ߩේ࿃ߣߥࠆࡎࠬ࠻ߦ߅ߌࠆㆮવ࿃ሶߩห
ቯ‫⮎ߩߘ߮ࠃ߅ޔ‬೷ᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 17㧙18 ᐕᐲ㧧300 ජ౞(300㧦0 ජ౞)㧦ᩣᑼળ␠ࡆ࡯࡮ࠛࡓ࡮
ࠛ࡞✚ว⎇ⓥᚲ2㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦੃ᐜఽ༎ᕷߩ㐳ᦼ▤ℂߦ߅ߌࠆ࠷ࡠࡉ࠹ࡠ࡯࡞⾍ઃ⮎ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛㧧ᐔᚑ 18 ᐕᐲ㧧0 ජ౞㧦ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࡟࡞ࠡ࡯ㄦㅦࠠ࠶࠻ߦࠃࠆࠕ࡟࡞ࠥࡦ․⇣⊛ IgE
᷹ቯᴺߩ⹏ଔ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧700 ජ౞(700㧦0 ජ౞)㧦ᩣᑼળ␠ਃ⪉ൻቇࡗ࠻ࡠࡦ
4㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘ጟବ▸㧦ዊఽࠕ࡟࡞ࠡ࡯∔ᖚᖚ⠪ߩ࠹࡯࡜࡯ࡔࠗ࠼ක≮ࠍ⋡ᜰߒߚㆮવሶᄙ
ဳ⸃ᨆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧1,500 ජ౞(1,500㧦0 ජ౞)㧦ᄢ㢈⮎ຠᎿᬺᩣᑼળ␠
3㧕౒ห⎇ⓥ1㧕 ㄭ⮮⋥ታ㧦⺞Ḩᑪ᧚ߩஜᐽߦ෸߷ߔᓇ㗀⺞ᩏ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧100 ජ౞㧦ᣣᧄࠗࡦࠪࡘ࡟࡯࡚ࠪࡦᩣᑼળ␠2㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘᦯ㇱᶈ᣿㧦ࠕ࡟࡞ࠡ࡯ߩේ࿃ߣߥࠆࡎࠬ࠻ߦ߅ߌࠆㆮવ࿃ሶߩห
ቯ㧘߅ࠃ߮ߘߩ⮎೷ᴦ≮ᴺߩ⏕┙㧧ᐔᚑ 17㧙20 ᐕᐲ㧧300 ජ౞㧦ᩣᑼળ␠ࡆ࡯࡮ࠛࡓ࡮ࠛ࡞✚ว⎇ⓥᚲ
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧦వᄤᕈ఺∉ਇో∝ߩේ࿃ㆮવሶหቯ߅ࠃ߮∛ᘒᒻᚑᯏᐨߩ⸃᣿㧦ᐔᚑ 18㧙21
ᐕᐲ㧧⁛┙ⴕ᡽ᴺੱℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ㄭ⮮ᙥ㧘ਛၛᜏ㧘ട⮮᥍ᒾ㧦⚻ญ఺∉ኡኈࠍ⺃ዉߔࠆࡍࡊ࠴࠼⚵ᚑ‛෸߮ߘߩ⺞ᢛᣇᴺ(⊒᣿)(․⸵಴㗿)㧧ᐔᚑ 19 ᐕᐲ
2㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ᄢ⷏⑲ౖ㧘⊕Ꮉ᣽ብ㧘᧩የ⽕ੱ㧦ᄌ⇣ዉ౉ MyD88 Ⱞ⊕ߦࠃࠆ Toll like receptor/ Interleukin-18 ࠪࠣ࠽࡞ߩ․⇣⊛೙ᓮᴺ(⊒᣿)(࿖㓙․⸵಴㗿ਛ)㧧ᐔᚑ 20 ᐕᐲ
6㧚ቇળᵴേ
1㧕ቇળᓎຬㄭ⮮⋥ታ㧦
1㧕 ᣣᧄዊఽ⑼ቇળℂ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળᣉ⸳⹺ቯ࡮ᜰዉ⽿છක(㨪⃻࿷)4㧕 ᣣᧄዊఽ⑼ቇળኾ㐷ක(㨪⃻࿷)5㧕 ᣣᧄዊఽ⑼ቇળ዁᧪⸘↹ᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
6㧕 ᣣᧄዊఽ⑼ቇળᐢႎᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
7㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળℂ੐(㨪⃻࿷)8㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(㨪⃻࿷)9㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળℂ੐(㨪⃻࿷)㧙㧙10㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᣉ⸳⹺ቯ࡮ᜰዉක(㨪⃻࿷)11㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⹺ቯක(㨪⃻࿷)12㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ࿖㓙੤ᵹᆔຬ㐳(㨪ᐔᚑ 19 ᐕ 3 ᦬)
13㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᢎ⢒⎇ୃᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
14㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળኾ㐷ක೙ᐲᢎ⢒⎇ୃᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
15㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳࠟࠗ࠼࡜ࠗࡦኾ㐷ㇱᆔຬ(㨪⃻࿷)16㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐(㨪⃻࿷)17㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐㐳(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)18㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળᴦ≮࡮▤ℂࠟࠗ࠼࡜ࠗࡦᆔຬ(㨪⃻࿷)19㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ㘩‛ࠕ࡟࡞ࠡ࡯ᆔຬ(㨪⃻࿷)20㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)21㧕 ᣣᧄੱ㘃ㆮવቇળᣉ⸳⹺ቯ࡮ᜰዉක(㨪⃻࿷)22㧕 ᣣᧄੱ㘃ㆮવቇળ⹺ቯක(㨪⃻࿷)23㧕 ᣣᧄዊఽㆮવකቇળᐙ੐(㨪⃻࿷)24㧕 ᣣᧄㆮવሶ⸻≮ቇળ⹏⼏ຬ(㨪⃻࿷)25㧕 ᣣᧄㆮવሶ⸻≮ቇળቇⴚᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
26㧕 ᣣᧄዊఽ଻ஜදળ⹏⼏ຬ࡮ᡰㇱ㐳(㨪⃻࿷)ᷓየᢅᐘ㧦1㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄੱ㘃ㆮવቇળᜰዉක(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)㊄ሶ⧷㓶㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 ᣣᧄዊఽ␹⚻ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)᧻੗᳗ሶ㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ㄭ⮮⋥ታ㧦
1㧕 ╙ 5 ࿁ో࿖ዊఽ⑼࠴ࠚࠕࡑࡦද⼏ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)
3㧕 ╙ 241 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂)
4㧕 ╙ 19 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂)
5㧕 ╙ 21 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 21 ᐕ 6 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ㄭ⮮⋥ታ㧦
1㧕 Journal of Investigational Allergology & Clinical Immunology:✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹;✬㓸ᆔຬ㐳(㨪⃻࿷)3㧕 ࠕ࡟࡞ࠡ࡯ߩ㗔ၞ;✬㓸㘈໧(㨪⃻࿷)
4㧕 International Review of Asthma:✬㓸ᆔຬ(㨪⃻࿷)㧙㧙5㧕 Allergy From the Nose to the Lung ⹹: Editorial Board(✬㓸ᐙ੐)(㨪⃻࿷)6㧕 ࠕ࡟࡞ࠡࠕ㧧✬㓸ᆔຬ㐳(㨪⃻࿷)7㧕 Pediatric Allergy for Clinicians: 㘈໧(㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 Journal of Pediatric Neurology :Editorial Board(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ㄭ⮮⋥ታ㧦
1㧕 26th Symposium of the Collegium Internationale Allergologicum(2006.05, Malta, Molecular
Mechanism of Th1㨯Th2 Imbalance and Hygiene Hypothesis; Ṷ⠪)2㧕 KAAACI-WAO Joint Congress 2006 & the 9th WPAS(2006.11㧘㖧࿖㧘࠰࠙࡞㧘‫ޟ‬Genetic factors andenvironmental factors in allergy‫ޠ‬Ṷ⠪㧘ᐳ㐳)
3㧕 ╙ 109 ࿁ᣣᧄዊఽ⑼ቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘㊄ᴛ㧘ಽ㊁೎ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬᳇▤ᡰ༎ᕷߩ⊒∝੍㒐‫ޠ‬Ṷ⠪)
4㧕 ╙ 18 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 7‫ޟ‬ฦ਎ઍߢ߽༎ᕷ∝⁁ߦߤ߁ኻᔕߔࠆ߆‫ޠ‬Ṷ⠪)
5㧕 ╙ 23 ࿁๺ṽක⮎ቇળᄢળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠ṶΤ‫࠼ࠗࡔ࡯࠳࡯ࠝޟ‬ක≮ߦ߅ߌࠆ๺ṽක⮎ቇߩ૏⟎ߠߌ –ࠕ࡟࡞ࠡ࡯ߩⷞὐ߆ࠄ-‫ޠ‬Ṷ⠪)
6㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ 10‫ࠆߌ߅ߦ∝⊒࡯ࠡ࡞࡟ࠕޟ‬ㆮવሶ
ߣⅣႺ‫ޠ‬Ṷ⠪)7㧕 ╙ 4 ࿁᳇㆏∔ᖚኻ╷࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘઄บ㧘․೎⻠Ṷ‫ޟ‬᳇▤ᡰ༎ᕷߩࠝ࡯࠳࡯ࡔࠗ࠼⸻≮㐿⊒ —QOL ะ਄ࠍ߼ߑߒߡ࡯‫ޠ‬Ṷ⠪)8㧕 ╙ 2 ࿁ Osaka IPOD Allergy Seminar(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫࡝࡞࠽࡚ࠪ࡯࡟ࠬࡦ࡜࠻ޟ‬ࠨ࡯࠴ߦ߽ߣߠߊࠕ࡟࡞ࠡ࡯⸻≮ߣߘߩ㐿⊒‫ޠ‬Ṷ⠪)9㧕 ╙ 2 ࿁ዊఽ᳇▤ᡰ༎ᕷ⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ዊఽ᳇▤ᡰ༎ᕷߩࠟࠗ࠼࡜ࠗࡦ 2005
ࠍ޿߆ߦᵴ↪ዷ㐿ߔࠆ߆ -⑳ߪߎ߁⠨߃ࠆ-‫ޠ‬Ṷ⠪)10㧕 ╙ 43 ࿁ጘ㒂⋵ౝ⑼කળࡊࡠࠣ࡜ࡓ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࠍ≮⸻࡯ࠡ࡞࡟ࠕߩࠄ߆ࠇߎޟ‬⠨߃ࠆ-ᚑੱ࡮ዊఽࠍߎ߃ߡ-‫ޠ‬Ṷ⠪)11㧕 ╙ 2 ࿁㐳ፒዊఽ⊹߰⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘㐳ፒ㧘․೎⻠Ṷ‫࠼ࠗࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ක≮ߣ
21 ਎ဳࡐࠬ࠻ࠥࡁࡓ‫ޠ‬Ṷ⠪)12㧕 ╙ 11 ࿁ၔ᧲࿾඙ዊఽࠕ࡟࡞ࠡ࡯ᙣ⹤ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠ṶΥ‫࡯ࠡ࡞࡟ࠕޟ‬ᖚఽߩ QOL
ߣߘߩะ਄ࠍ߼ߑߒߡ࡯ㆮવߣⅣႺߩⷞὐ߆ࠄ࡯‫ޠ‬Ṷ⠪)
13㧕 ╙ 16 ࿁࿖㓙༎ᕷቇળᣣᧄർࠕࠫࠕㇱળ(ᐔᚑ 18 ᐕ 4 ᦬㧘᧲੩㧘ࡒ࡯࠻ࠩࡊࡠࡈࠚ࠶ࠨ࡯3 ᐳ㐳)14㧕 ╙ 14 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 18 ᐕ 4 ᦬㧘㜞⍮㧘࠮࠶࡚ࠪࡦ 2 ᐳ㐳)15㧕 ╙ 235 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)16㧕 ╙ 15 ࿁ Airway Club in Sendai(ᐔᚑ 18 ᐕ 9 ᦬㧘઄บ㧘ળ㐳⻠Ṷ ᐳ㐳)17㧕 ╙ 15 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 18 ᐕ 10 ᦬㧘␹ᚭ㧘࠮࠶࡚ࠪࡦΤ ᐳ㐳)18㧕 ╙ 38 ࿁ᣣᧄዊఽᗵᨴ∝ቇળᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 11 ᦬㧘㜞⍮㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯11 ᐳ㐳)19㧕 ╙ 43 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ 1‫∉఺⤑☼ޟ‬㧦఺∉ߣࠕ࡟࡞ࠡ
࡯ߩធὐ‫ޠ‬ᐳ㐳)20㧕 ᐔᚑ 18 ᐕᐲᣣᧄ⊹⤏⑼ቇળ೨ታ❣⎇ୃ⻠⠌ળ(ᐔᚑ 19 ᐕ 1 ᦬㧘᧲੩㧘‫ޟ‬వᄤᕈ఺∉ਇో∝୥⟲‫ޠ‬Ṷ
⠪)21㧕 ╙ 15 ࿁ዊఽ⥃ᐥ⮎ℂ࡮ࠕ࡟࡞ࠡ࡯࡮఺∉⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 2 2010 ᐕߩࠕ࡟࡞ࠡ࡯ᴦ≮ᚢ⇛‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯ᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 14 ࿁ᄢ㒋ዊఽ⑼කળ∛⸻ㅪ៤ᙣ⺣ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ࠗ࠼ක≮ࠍߤߩࠃ߁ߦዷ㐿ߔࠆ߆‫ޠ‬Ṷ⠪)
23㧕 US-Japan Asthma Summit 2007(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩㧘‫ޟ‬ᣣᧄߩ੃ᐜఽ༎ᕷࠍขࠅᏎߊ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)24㧕 ╙ 110 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ 4 ᐳ㐳)
25㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળਛ࿖ᡰㇱ ᐢፉቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫߅ߦ࡯ࠡ࡞࡟ࠕޟ‬ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)26㧕 ╙ 7 ࿁༎ᕷ Early Intervention ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘⻠Ṷ‫࡯࡜࡯࠹ࠆߌ߅ߦ࡯ࠡ࡞࡟ࠕޟ‬㧙㧙ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)27㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫࡯ࠡ࡞࡟ࠕ‛⮎ޟ‬ߩ⃻⁁ߣኻ╷ ዊఽ⑼ߦ߅ߌࠆ⮎‛ࠕ࡟࡞ࠡ࡯ߩ⃻⁁ߣኻ╷‫ޠ‬Ṷ⠪)28㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 8‫ޟ‬༎ᕷᱫ࠯ࡠࠍ⋡ᜰߒߚᴦ≮ᚢ⇛ —᳇▤ᡰ༎ᕷߩᴦ≮⋡ᮡߩ㆐ᚑߦะߌߡ‫ޠ‬ᐳ㐳)29㧕 ╙ 17 ࿁࿖㓙༎ᕷቇળᣣᧄർࠕࠫࠕㇱળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫∝⊒࡯ࠡ࡞࡟ࠕޟ‬ㆮવሶߣⅣႺߩ㑐ࠊࠅ‫ޠ‬Ṷ⠪)30㧕 ╙ 27 ࿁౐↲ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 19 ᐕ 8 ᦬㧘੩ㇺ㧘Ϊ‫ޟ‬Ⴧᖡᦼߩ∛ᘒ‫ޠ‬ᐳ㐳)31㧕 ᐔᚑ 19 ᐕᐲᣣᧄ㈼ㄘ⑼ቇࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㘩ຠࠕ࡟࡞ࠡ࡯ߣߘߩᴦ
≮ᚢ⇛‫ޠ‬Ṷ⠪)32㧕 ᾢᧄ⋵ዊఽ⑼කળ⻠Ṷળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫࠼ࠗࡔ࡯࡜࡯࠹ߩ࡯ࠡ࡞࡟ࠕޟ‬ක≮ߩᣂዷ㐿ߣታ〣‫ޠ‬Ṷ⠪)33㧕 ╙ 17 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 19 ᐕ 10 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦΣ ᐳ㐳)34㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘‫ޟ‬ጘ㒂ᄢቇߦᣂ⸳ߐࠇߚ࿾ၞක
≮කቇ࠮ࡦ࠲࡯ߩ࡙࠾࡯ࠢߥ᭴ㅧߣᓎഀ‫ޠ‬Ṷ⠪)35㧕 ╙ 241 ࿁ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)36㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠗࡉ࠾ࡦࠣࠪࡦࡐࠫ࠙ࡓ 4‫ࠕޟ‬࠻ࡇ࡯ᕈ⊹⤏Ἳ̆߆ࠁߺߣว૬∝߳ߩࠕࡊࡠ࡯࠴߆ࠄ̆‫ޠ‬ᐳ㐳)37㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ᄢળቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 2(English
session)ࠕ࠻ࡇ࡯∔ᖚߣ⮎೷ㆊᢅ∝ߦ߅ߌࠆ Pharmacogenomics‫ޟ‬Pharmacogenomics in treatment
of atopic disease and drug hypersensitivity‫ޠ‬มળ)38㧕 The World Allergy Organization̉
s 20th World Allergy Congress (WAC) (ᐔᚑ 19 ᐕ 12 ᦬㧘Bangkok㧘࿖㓙ቇળࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Symposium -Genetics- Implications for Asthma and Allergy‫ޠ‬ᐳ㐳)39㧕 The World Allergy Organization’s 20th World Allergy Congress (WAC) (ᐔᚑ 19 ᐕ 12 ᦬㧘Bangkok㧘࿖㓙ቇળࠪࡦࡐࠫ࠙ࡓ,᜗ᓙ⻠Ṷ‫ޟ‬Symposium –Genetic Evaluation of Allergic Diseases andAsthma –Japanese session: Genetic variations of interleukin 12 signaling and other cytokine
genes in allergy and asthma‫ޠ‬Ṷ⠪)40㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ✚ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 7‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴‫ޠ‬ᐳ㐳)41㧕 ╙ 16 ࿁ዊఽ⥃ᐥ⮎ℂ࡮ࠕ࡟࡞ࠡг࡮఺∉⎇ⓥળ(ᐔᚑ 20 ᐕ 1 ᦬㧘⑔ጟ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯2 ᐳ㐳)42㧕 ╙ 30 ࿁ችၔ⋵කᏧળቇᩞ଻ஜ⎇ୃળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ችၔ㧘‫ޟ‬ዊఽߩࠕ࡟࡞ࠡ࡯ߣߘߩኻ╷ ᦨㄭߩㅴᱠ߽฽߼ߡ‫ޠ‬Ṷ⠪)43㧕 ╙ 8 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᐳ㐳)44㧕 ╙ 9 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘ᐳ㐳)45㧕 ╙ 11 ࿁ൕോකㇱળቇⴚ⎇ୃળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘ၮ⺞⻠Ṷ‫ޟ‬ጘ㒂ᄢቇߩขࠅ⚵ߺ‫ޠ‬㧘Ṷ⠪)46㧕 ╙ 5 ࿁ጘ㒂⋵ዊఽ⑼කળ⻠Ṷળ㨪ࠕ࡟࡞ࠡ࡯࠮ࡒ࠽࡯㨪(ᐔᚑ 20 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ ᐳ㐳)47㧕 ╙ 5 ࿁ዊఽ᳇㆏ࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⑔ጟ㧘࠮࠶࡚ࠪࡦΦ ᐳ㐳)48㧕 ╙ 61 ࿁⥃ᐥࠕ࡟࡞ࠡ࡯⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋㧘․೎⻠ṶΤ‫ߩ≮⸻ߩ࡯ࠡ࡞࡟ࠕޟ‬ᣂዷ㐿ߣታ〣‫ޠ‬Ṷ⠪)
49㧕 The 1st Asthma Meeting in Tokyo(ᐔᚑ 20 ᐕ 5 ᦬㧘᧲੩㧘Session2 (English) ᐳ㐳)50㧕 ╙ 20 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 9‫∔࡯ࠡ࡞࡟ࠕޟ‬ᖚߩㆮવሶߣಽሶ↢‛ቇ‫ޠ‬ᐳ㐳)51㧕 ╙ 3 ࿁ጘ㒂ዊఽࠕ࡟࡞ࠡ࡯࡮༎ᕷ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ࡓ࠭࡝ࡦࠕࠖ࠺ࠞ࡯ࠨޟ‬ࠍมࠆಽሶᤨ⸘ߣߘߩశ૏⋧೙ᓮ‫ޠ‬Ṷ⠪)52㧕 ╙ 20 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯1‫߅ߦ࡯ࠡ࡞࡟ࠕޟ‬ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼ක≮ߩ㐿⊒ߣታ〣‫ޠ‬Ṷ⠪)53㧕 ╙ 18 ࿁ ࿖ 㓙 ༎ ᕷ ቇ ળ ᣣ ᧄ ർ ࠕ ࠫ ࠕ ㇱ ળ ( ᐔ ᚑ 20 ᐕ 7 ᦬ 㧘 ᄢ 㒋 , Meet-the-professor 2‫ޟ‬Understanding combination therapy for asthma‫ޠ‬Chair)54㧕 ╙ 11 ࿁ Forum on Allergy in Nagoya(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ ਎⹤ੱ)55㧕 ╙ 40 ࿁ᣣᧄዊఽᗵᨴ∝ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ ᐳ㐳)56㧕 23rd International Scientific Forum(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘Lecture 3‫ޟ‬Food Allergy ofChildhoos-Pathogenesis and Strategy of Management‫ޠ‬Ṷ⠪)57㧕 ╙ 58 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ ᐳ㐳)㧙㧙58㧕 ╙ 4 ࿁㑐⷏༎ᕷ࡮COPD ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫ޟ‬ዊఽ᳇▤ᡰ༎ᕷߩ․ᓽߣኻᔕ㨪ᚑੱ༎ᕷߣߩ㆑޿ࠍ฽߼ߡ㨪‫ޠ‬Ṷ⠪)59㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫∛࡯ࠡ࡞࡟ࠕޟ‬ᘒߩಽሶ↢‛ቇ⊛⸃᣿‫ޠ‬ᐳ㐳)60㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒࠮ࡒ࠽࡯8 ᐳ㐳)ᷓየᢅᐘ㧦
1㧕 The 10th International congress of inborn errors of metabolism(2006.09, Chiba, Mutation updateof human mitochondrial acetoacetyl-CoA thiolase (T2) deficiency; Ṷ⠪)2㧕 The 10th International congress of inborn errors of metabolism(2006.09, Chiba, Mutation updateof succinyl-CoA:3-ketoacid CoA transferase deficiency; Ṷ⠪)3㧕 ╙ 11 ࿁ᐢፉవᄤઍ⻢⇣Ᏹ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ
⠪)
4㧕 ╙ 7 ࿁᧲ർઍ⻢⇣Ᏹ∝ᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘઄บ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ⠪)
5㧕 ╙ 10 ࿁ጘ㒂ࡊ࡜ࠗࡑ࡝࡯ࠤࠕࠞࡦࡈࠔ࡜ࡦࠬ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐⴊ♧㧘㜞ࠕࡦࡕ࠾ࠕⴊ∝㧘ઍ⻢ᕈࠕࠪ࠼࡯ࠪࠬ‫ޠ‬Ṷ⠪)6㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism.(2008.09,‫ޟ‬CpG
islands around exon 1 in succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene were
hypomethylated even in human and mouse hepatic tissues where SCOT gene expression wascompletely suppressed‫ޠ‬Ṷ⠪)7㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism.(2008.09,‫ޟ‬A
novel single-base substitution(c.1124A>G)that activates 5-base upstream cryptic splice donorsite within exon 11 in the human mitochondrial acetoacetyl-CoA thiolase gene‫ޠ‬Ṷ⠪)8㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㆮવሶߣ∛᳇‫ޠ‬Ṷ⠪)9㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 10‫ߩࡦࠥ࡞࡟ࠕޟ‬ᗧ⟵ߣߘߩᄙ᭽ߥᯏ⢻‫ޠ‬Ṷ⠪)㊄ሶ⧷㓶㧦
1㧕 ╙ 18 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘‫ޟ‬᛫૕↥↢ਇో∝ߩ⥃ᐥ⚻ㆊߣ∛ᘒߩᄙ᭽ᕈ‫ޠ‬Ṷ⠪)
2㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ✚ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘‫ߩ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬ၮ␆⊛⸃ᨆߦၮߠߊᣂ
ⷙᴦ≮ᴺߩ㐿⊒‫ޠ‬Ṷ⠪)
3㧕 ╙ 43 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 1‫ߩ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬ၮ␆⊛⸃ᨆߣ఺∉ኡኈ⺃ዉߦࠃࠆᣂⷙᴦ≮ᴺ‫ޠ‬Ṷ⠪)4㧕 Pathogenesis of primary antibody deficiency Symposium for PID in Asia Riken RCAI(2008,12
Yokohama, Ṷ⠪)
5㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4 ‫ޟ‬㘩‛ࠕ࡟࡞ࠡ࡯
⸻≮ߩᣂߒ޿ዷ㐿.‐੃ࠕ࡟࡞ࠡ࡯ߦ߅ߌࠆ⚻ญ఺∉ኡኈ⺃ዉ㘩ຠߩ૞ᚑ‫ޠ‬Ṷ⠪)ട⮮ༀ৻㇢㧦
1㧕 ╙ 58 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ᦼቇⴚᄢળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 17‫⥄ޟ‬Ꮖ఺∉∔ᖚ T ⚦⢩ࠪࠣ࠽࡞વ㆐ᯏ᭴⸃᣿ߦะߌߚ TCR/peptide/HLA ⶄว૕࠲ࡦࡄࠢ┙૕᭴ㅧ⸃ᨆ‫ޠ‬Ṷ⠪)
2㧕 ╙ 38 ࿁ᣣᧄ఺∉ቇળ✚ળ࡮ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘੩ㇺ㧘Symposium 12‫ޟ‬Structural basis of
signaling via MyD88‫ޠ‬Ṷ⠪)᧻੗᳗ሶ㧦
1㧕 ╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 18 ᐕ 11 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 12‫ߦ∝⊒ޟ‬෸߷ߔ࠙ࠗ࡞ࠬᗵᨴ
ߩᓇ㗀ߣ⢝ౝ࿃ሶ‫ޠ‬Ṷ⠪)
2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬࿾ၞߩዊఽ
ක≮ߣዊఽ଻ஜ‫ޠ‬ᐳ㐳)㧙㧙Ꮉᧄ⟤ᄹሶ㧦1㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬Უ੃ᩕ㙃ߣࠕ࡟࡞ࠡ࡯
∔ᖚ⊒∝ߣߩ㑐ㅪߦߟ޿ߡ‫ޠ‬Ṷ⠪)
ᄢ⷏⑲ౖ㧦
1㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 7‫ޟ‬ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩ⥃ᐥ߳ߩࠗࡦࡄࠢ࠻ IL-18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ
࡯࠴‫ޠ‬Ṷ⠪)Ꮉᧄౖ↢㧦
1㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬಴↢ࠦࡎ࡯࠻⎇ⓥߦࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝ߦ㑐ࠊࠆ࿃ሶߩᬌ⸛‫ޠ‬Ṷ⠪)ฬ↰ආ೑㧦
1㧕 ╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4‫⥄ޟ‬ὼ఺∉♽⚦⢩ౝࠕ࠳ࡊ࠲࡯ಽሶߩ᭴ㅧ↢‛ቇ⊛ᯏ⢻⸃ᨆߣ⥃ᐥᔕ↪߳ߩዷᦸ‫ޠ‬Ṷ⠪)᫪↰⑲ⴕ㧦
1㧕 ╙ 57 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ᄢળቇળ⑺ቄቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 12‫ޟ‬ᄢ⼺ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ p34 ߩ࠲ࡦࡄࠢ᭴ㅧߩ⸃᣿ߣ⥃ᐥᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 1‫∉఺ޟ‬ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩ᭴ㅧ⸃᣿‫ޠ‬Ṷ⠪)ᧁ᧛⽕㧦
1㧕 Joint Singapore Paediatric Congress & APAPARI Meeting 2008(2008.10, ‫ ޟ‬Expression,
Purification and Structural Analysis of Human IL-18 Binding Protein: A Potent Therapeutic
Molecule for Allergy‫ޠ‬Ṷ⠪ )ᓼ⷗ືม㧦1㧕 Joint Singapore Paediatric Congress & APAPARI Meeting 2008(2008.10㧘
‫ޟ‬Molecular Analyses
Of Interaction Between Myd88-Adaptor- Like And The Other TIR Proteins In Toll-Like Receptor
Signaling‫ޠ‬Ṷ⠪ )2㧕 ╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩‫ޟ‬Molecular analyses of protein-protein
interactions of intra-cellular signaling in innate immunity‫ޠ‬Ṷ⠪ )ਅỈિⴕ㧦1㧕 ╙ 48 ࿁ᣣᧄዊఽ␹⚻ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ᶆ቟㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ㆮવᕈ␹⚻╭∔ᖚߩ⸻ᢿ࡮ᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)2㧕 10th International Congress of Inborn Errors of Metabolism(2006.09, Chiba, ࿖㓙ቇળၮ⺞⻠Ṷ㧘‫ޟ‬Molecular and clinical aspects of peroxisomal disease‫ޠ‬Ṷ⠪)3㧕 10th International Congress of Inborn Errors of Metabolism(2006.09, Chiba,‫ޟ‬A second case of
PEX14 deficiency with prolonged survival and renal tubular dysfunction‫ޠ‬Ṷ⠪)
4㧕 ╙ 49 ࿁ᣣᧄవᄤઍ⻢⇣Ᏹቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊᒻ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯
ߩㅧⴊᐙ⚦⢩⒖ᬀ≮ᴺߩ⃻⁁ߣ໧㗴ὐ∔ᖚߩస᦯ߦะߌߡ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᛬ዬᑪᴦ㧦᫪᳗ᄺ઀ળ⎇ⓥᅑബ㊄(ᐔᚑ 18 ᐕᐲ)
2㧕 ⥵ᚭ㆏ᓼ㧦᫪᳗ᄺ઀ળ⎇ⓥᅑബ㊄(ᐔᚑ 19 ᐕᐲ)
3㧕 ᓼ⷗ືม: Young Investigator Award (╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ)(ᐔᚑ 19 ᐕᐲ)
4㧕 ㊄ሶ⧷㓶㧦╙ 9 ࿁ዊఽකቇᎹ㊁⾨ ዊఽၮ␆කቇಽ㊁ ዊఽߩ㔍ᴦᕈࠕ࡟࡞ࠡ࡯࡮఺∉∔ᖚߩ∛ᘒ⸃ᨆߣᣂⷙᴦ≮ᴺߩ㐿⊒(ᐔᚑ 20 ᐕᐲ)㧙㧙9㧚␠ળᵴേㄭ⮮⋥ታ㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળℂ੐(㨪⃻࿷)2㧕 ో࿖කቇㇱ㐳∛㒮㐳ળ⼏Ᏹછℂ੐(ᐔᚑ 18㨪19 ᐕᐲ)
3㧕 ⷏ᣣᧄක⑼ቇ↢૕⢒ㅪ⋖೽ળ㐳(ᐔᚑ 18 ᐕᐲ)
4㧕 ᣣᧄቇⴚᝄ⥝ળ․೎⎇ⓥຬ╬ክᩏᆔຬળኾ㐷ᆔຬ෸߮࿖㓙੐ᬺᆔຬળᦠ㕙ክᩏᆔຬ(ᐔᚑ 17 ᐕ㨪19ᐕᐲ)
5㧕 ⽷࿅ᴺੱකቇᢎ⢒ᝄ⥝⽷࿅⹏⼏ຬ(ᐔᚑ 19 ᐕᐲ)
6㧕 ⽷࿅ᴺੱᲣሶஜᐽදળዊఽකቇ⎇ⓥഥᚑክᩏળክᩏຬ(ᐔᚑ 17㨪19 ᐕᐲ)
7㧕 ጘ㒂⋵ዊఽ଻ஜදળળ㐳(㨪⃻࿷)8㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ᆔຬળ੍㒐ធ⒳ㇱળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
9㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ኻ╷ᆔຬળࠛࠗ࠭ኻ╷ㇱળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
10㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷ᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
11㧕 ጘ㒂⋵࿾ၞක≮᡽╷ද⼏ળᆔຬ(ᐔᚑ 19 ᐕᐲ)
12㧕 ጘ㒂⋵࿾ၞක≮᡽╷ද⼏ળಽ⑼ળㇱળ㐳(ᐔᚑ 19 ᐕᐲ)
13㧕 ጘ㒂⋵කᏧળ੍㒐ធ⒳ᆔຬળᆔຬ(㨪ᐔᚑ 19 ᐕᐲ)
14㧕 ጘ㒂⋵කᏧળൕോකㇱળቇⴚᆔຬળ㘈໧(㨪ᐔᚑ 19 ᐕᐲ)
15㧕 ጘ㒂Ꮢ੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏᆔຬળᆔຬ(㨪⃻࿷)
16㧕 ⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺጘ㒂࡮ᄢ၂࿾ၞߦ߅ߌࠆᧄㇱળ⼏ᆔຬ(ᐔᚑ 18ᐕᐲ)17㧕 ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળℂ੐㐳(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)ᷓየᢅᐘ㧦1㧕 ጘ㒂⋵ዊఽ଻ஜදળᏱછℂ੐(㨪⃻࿷)2㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)3㧕 ጘ㒂Ꮢ଻⢒ᚲఽ┬ߩஜᐽࠍ⠨߃ࠆળᆔຬ(ᆔຬ㐳)(㨪⃻࿷)4㧕 ጘ㒂⋵ዊఽᢇᕆක≮ද⼏ળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)㊄ሶ⧷㓶㧦1㧕 ጘ㒂࿾ၞዊఽᢇᕆක≮૕೙ㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)ട⮮ༀ৻㇢㧦
1㧕 ࡏࠬ࠻ࡦ✚㗔੐㙚ᣂဳࠗࡦࡈ࡞ࠛࡦࠩኻ╷ supervisor(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ࡏࠬ࠻ࡦ✚㗔੐㙚ਥ௅ᣂဳࠗࡦࡈ࡞ࠛࡦࠩኻ╷⻠Ṷળ⻠Ꮷ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)᧻੗᳗ሶ㧦1㧕 ⊒㆐㓚ኂߩᣧᦼ⊒⷗ߦ߻ߌߚ੃ᐜఽஜ⸻ᬌ⸛ᆔຬ(ᐔᚑ 20 ᐕᐲ)
2㧕 ጘ㒂⋵ኅᐸᢎ⢒ផㅴᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ஜ㧘⿒Ỉᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦205㧙207(2006 ᐕ 3 ᦬)
2㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦208㧙210(2006 ᐕ 3 ᦬)
3㧕 ᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ߅ࠃ߮ዊఽ∛ᘒߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫
⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 2 ಽౠ(ㄭ⮮⃰)㧦226㧙228(2006 ᐕ 3 ᦬)
4㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ஜ㧘⿒Ỉᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2006 ᐕ 3 ᦬)㧙㧙

5㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹㧙࡜㧙ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙7(2006 ᐕ 3 ᦬)
6㧕 ᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ߅ࠃ߮ዊఽ∛ᘒߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫
⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦37㧙39(2006 ᐕ 3 ᦬)
7㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛╬ߦࠃࠆࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߩේ࿃‛⾰(ࠕ࡟࡞ࠥࡦ)ߩ⏕ቯ㧘੍㒐࡮੍⍮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ 㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(ᶏ⠧Ỉ⃰)㧦90㧙92(2006 ᐕ 3 ᦬)
8㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ✚᜝⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
9㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦఺∉ࠕ࡟࡞ࠡ࡯ߦଥࠊࠆ⢝ౝ࡮⢝ᄖ࿃ሶߩหቯߦ㑐ߔࠆ⎇ⓥ RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(᫪Ꮉ⃰)㧦41㧙43(2006 ᐕ 3 ᦬)
10㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(᫪Ꮉ⃰)㧦9㧙17(2006 ᐕ 3 ᦬)
11㧕 ㄭ⮮⋥ታ㧘㕍ᧁ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧦RS ࠙ࠗ࡞ࠬᗵᨴ߇ࠕ࡟࡞ࠡ࡯⊒∝ߦ෸߷ߔᓇ㗀߅ࠃ߮⤯Ꮺⴊࠍ↪޿ߚࠕ࡟࡞ࠡ࡯∔ᖚߩ੍⍮࡮੍㒐ᴺߩ⏕┙㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ
௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(᫪Ꮉ⃰)㧦12㧙
16(2006 ᐕ 3 ᦬)
12㧕 ᛬ዬᑪᴦ㧘ᷓየᢅᐘ, ㊄ሶ⧷㓶, ㄭ⮮⋥ታ㧦Ataxia telangiectasia(Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝)ߩ∛ᘒߦ㑐ߔಽሶ↢‛ቇ⊛⸃ᨆ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦49㧙51(2006 ᐕ 3 ᦬)
13㧕 ㄭ⮮⋥ታ, Ꮉᧄౖ↢, ᧻੗᳗ሶ, ㊄ሶ⧷㓶㧦Უ੃ਛߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߣ఺∉ᯏ⢻,ࠕ࡟࡞ࠡ࡯ߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᄙ↰⃰)㧦77㧙79(2006ᐕ 3 ᦬)
14㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇකቇㇱ ዊఽ⑼ߦ߅ߌࠆࠕ࡟࡞ࠡ࡯⸻≮ㅪ៤㧦ࠕ࡟࡞ࠡ࡯⸻≮ᣉ⸳੐଀㓸 ᐔ
ᚑ 18 ᐕ 10 ᦬ෘ↢ഭ௛⑼ቇ⎇ⓥ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ⃰(㗇↲⃰)㧦210(2006 ᐕ 10 ᦬)
15㧕 ട⮮ༀ৻㇢㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߦ߅ߌࠆ࠹࡯࡜࡯ࡔࠗ࠼੍㒐࡮ᴦ≮ᴺ㐿⊒ߩߚ߼ߩ HLA ┙૕᭴ㅧߦၮߠ޿ߚࡍࡊ࠴࠼ࡐ࡝ࡑ㧙ഃ⮎ߩ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળᐔᚑ 17 ᐕ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐ᬺႎ๔ᦠ(ㄭ⮮⃰)㧦14㧙19(2006 ᐕ 3 ᦬)
16㧕 ᄢ⷏⑲ౖ㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળ㧦ᐔᚑ 17 ᐕ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐
ᬺႎ๔ᦠ(ㄭ⮮⃰)㧦87㧙103(2006 ᐕ 3 ᦬)
17㧕 ㄭ⮮⋥ታ㧘⥵ᚭ㆏ᓼ㧘⏷⽴శᴦ㧘㊁ਛਁ␭ሶ㧘㕙ኅஜᄥ㇢㧘ኹᧄ⾆⧷㧘᧻੗᳗ሶ㧘᛬ዬᑪᴦ㧘Ꮉᧄౖ↢㧘ട⮮ༀ৻㇢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧦Ꮐ⣊㛽ߦ⊒∝ߒߚ BCG 㛽㜑Ἳߩ৻଀IFN㧙J⚻〝ߩ⸃ᨆࠍ฽߼ߡ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࠻࡝࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ
੐ᬺ ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦105㧙107(2006 ᐕ 3 ᦬)
18㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ(ች⣁⃰)㧦6(2007 ᐕ 1 ᦬)
19㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳
㓸(ㄭ⮮⃰)㧦1㧙3(2007 ᐕ 2 ᦬)
20㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ᄢ⷏⑲ౖ㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦4(2007 ᐕ 2 ᦬)㧙㧙21㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ‫߮ࠃ߅ޔ‬ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦11(2007 ᐕ 2 ᦬)
22㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦125(2007 ᐕ 2 ᦬)
23㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦143(2007 ᐕ 2 ᦬)
24㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2007 ᐕ 3 ᦬)
25㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ
࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙8(2007 ᐕ 3 ᦬)
26㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ‫߮ࠃ߅ޔ‬ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦39㧙41(2007 ᐕ 3 ᦬)
27㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘⊕Ꮉᄥ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦1㧙4(2007 ᐕ 3 ᦬)
28㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ࠹࡯࡜࡯ࡔ
ࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦5㧙9(2007 ᐕ 3 ᦬)
29㧕 ᧻੗᳗ሶ㧦ㆮવሶᖱႎߩ✂⟜⊛⸃ᨆ㧘߅ࠃ߮ዊఽ༎ᕷߦ߅ߌࠆࡠࠗࠦ࠻࡝ࠛࡦฃኈ૕ᜟ᛫⮎ߩᴦ≮෻ᔕᕈ੍᷹ㆮવሶ࿃ሶߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮㐿⊒㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦53㧙59(2007 ᐕ 3 ᦬)30㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)
31㧕 ㄭ⮮⋥ታ㧘Ꮉᧄౖ↢㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧦Უ੃ਛߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߣ఺∉ᯏ⢻㧘ࠕ࡟࡞ࠡ࡯
ߦ㑐ߔࠆᬌ⸛ ࠳ࠗࠝࠠࠪࡦߩ੃ᐜఽ߳ߩᓇ㗀ߘߩઁߩᳪᨴታᘒߩ⸃᣿ߦ㑐ߔࠆ⎇ⓥ ․ߦᲣ੃ਛ
ߩ࠳ࠗࠝࠠࠪࡦ㘃Ớᐲߩ⚻ᐕ⊛ᄌൻߣᐜఽ⊒⢒⊒㆐ߦ෸߷ߔᓇ㗀㧦ᐔᚑ 16 ᐕᐲ㧙18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㘩ຠߩ቟ᔃ࡮቟ో⏕଻ផㅴ⎇ⓥ੐ᬺ ✚ว⎇ⓥႎ๔ᦠ(ᄙ↰⃰)㧦43㧙46(2007ᐕ 3 ᦬)
32㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔
ᦠ(ᄢ↰⃰)㧦20㧙24(2007 ᐕ 3 ᦬)
33㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦9㧙11(2007 ᐕ 3 ᦬)
34㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᴡ㊁⃰)㧦20㧙22(2007 ᐕ 4 ᦬)
35㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ
⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ⊒ⴕ ╙ 1 ಽౠ(ㄭ⮮⃰)㧦177㧙
180(2007 ᐕ 3 ᦬)
36㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩ∛࿃ㆮવሶ࡮∛ᘒ࡮ᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⸃᣿ߣ

㧙㧙࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙߅ࠃ߮ഃ⮎ߩᬌ⸛㧦ᐔᚑ 18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ╙ 1 ಽౠ(ㄭ⮮⃰)㧦181㧙184(2007 ᐕ 3 ᦬)
37㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᶏ⠧Ỉ⃰)㧦161㧙163(2007 ᐕ 3 ᦬)
38㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫․ޔ‬ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᴡ㊁⃰)㧦210㧙212(2007 ᐕ 3 ᦬)
39㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᄢ↰⃰)㧦302
㧙306(2007 ᐕ 3 ᦬)
40㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘ᷓየᢅᐘ㧦఺∉ᯏ⢻ૐਅࠍ᦭ߔࠆዊఽߦኻߔࠆ੍㒐ធ⒳ߩᬌ⸛(╙ 3 ႎ)఺∉⛽ᜬߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 18 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦85㧙87(2007 ᐕ 4 ᦬)
41㧕 ᧘ ᗲ⬒㧘ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺ⏕┙ߩߚ߼ߩ᭴ㅧ↢‛ቇ⊛ഃ⮎ߦ㑐ߔࠆ⎇ⓥ㧦⽷࿅ᴺੱᣣᧄ੍㒐කቇදળ ᐔᚑ 18 ᐕᐲ఺∉ࠕ࡟࡞ࠡ࡯
∔ᖚ੍㒐࡮ᴦ≮⎇ⓥផㅴ੐ᬺ(⧯ᚻ⎇ⓥ⠪⢒ᚑᵴ↪੐ᬺ)⎇ⓥႎ๔ᦠ(ㄭ⮮⃰)㧦42㧙45(2007 ᐕ 7 ᦬)
42㧕 Ohnishi H㧘Tochio H㧘Hiroaki H㧘Kato Z㧘Kondo N㧘Shirakawa M㧦Deposition㧦Protein Data
Bank ⊓㍳㧦Accession number㧦2z5v ‘Solution structure of the TIR domain of human MyD88’
Date㧦(2007㧙07㧙19)43㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩᴦ≮෻ᔕᕈ੍᷹࿃ሶߩ⏕┙෸߮࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮ᴺߩ⏕┙ߦ㑐ߔࠆ
⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺࡄࡦࡈ࡟࠶
࠻(ㄭ⮮⃰)㧦15㧙16(2007 ᐕ 8 ᦬)
44㧕 ㄭ⮮⋥ታ㧘⑺ጊ৻↵㧘ᄢ↰ ஜ㧘⿒Ỉ ᤩ㧘ጊญᖝ㇢㧘ᶏ⠧Ỉరብ㧘⮮Ỉ㓉ᄦ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻߦ㑐ߔࠆ⎇ⓥ㧚ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦165㧙
167(2008 ᐕ 1 ᦬)
45㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯ߩㆮવⷐ࿃࡮ⅣႺⷐ࿃ߩ⾰ߣ㊂ߩ⹏ଔᴺߩ⏕┙ߣ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟ
ࠗ࠼࡜ࠗࡦߩ⏕┙‫✚߮ࠃ߅ޔ‬᜝㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ㄭ⮮⃰)㧦168(2008 ᐕ 2 ᦬)
46㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦98(2008 ᐕ 2 ᦬)
47㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ༎ᕷ QOL ⎇ⓥߩ✚᜝ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼
ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(㗇↲⃰)㧦73(2008 ᐕ 2 ᦬)48㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ᄢ⷏⑲ౖ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ‫ߦ․ޔ‬Უ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦8(2008 ᐕ 2 ᦬)
49㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ዊఽ᳇▤ᡰ༎ᕷߩᣧᦼ⸻ᢿ࡮ᣧᦼᴦ≮ߩᜰ㊎ߩ૞ᚑߣ⹏ଔ߅ࠃ߮᳇▤ᡰ༎ᕷߦ㑐ㅪߔࠆㆮવሶ⸃ᨆ ࠕ࡟࡞ࠡ࡯∔ᖚߩ⥄Ꮖ▤ℂߣ୘೎ൻක≮ࠍ⋡ᜰߒߚᣧᦼ⸻ᢿၮḰߣᣧᦼᴦ≮ᴺߩ⏕┙෸߮ߘߩ᦭ലᕈߣ᦭ኂ੐⽎ߩ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᄢ↰⃰)㧦204(2008 ᐕ 2 ᦬)
50㧕 ㄭ⮮⋥ታ㧦ࠕ࡟࡞ࠡ࡯ߩ࠹࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙ߣታ↪ൻ㧦ᐔᚑ 19 ᐕᐲ ෘ↢
ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ╙ 3 ಽౠ(ㄭ⮮⃰)㧦359
㧙362(2008 ᐕ 3 ᦬)
51㧕 ㄭ⮮⋥ታ㧘ട⮮ༀ৻㇢㧘ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߩㆮવⷐ࿃࡮ⅣႺⷐ࿃ߩ⾰ߣ㊂ߩ⹏ଔᴺߩ⏕┙ߣ࠹㧙㧙࡯࡜࡯ࡔࠗ࠼ᴦ≮▤ℂࠟࠗ࠼࡜ࠗࡦߩ⏕┙㧘߅ࠃ߮✚᜝㧦ᐔᚑ 19 ᐕᐲ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ╙ 3 ಽౠ(ㄭ⮮⃰)㧦363㧙365(2008 ᐕ 3 ᦬)
52㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ᳇▤ᡰ༎ᕷ⎇ⓥߩ✚᜝㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 1 ಽౠ(㗇↲⃰)㧦
496㧙498(2008 ᐕ 3 ᦬)
53㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᶏ⠧Ỉ⃰)㧦154㧙156(2008 ᐕ 3 ᦬)
54㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᄢ⷏⑲ౖ㧘᫪↰⑲ⴕ㧦ࠕ࠻ࡇ㧙ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽ
ߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ
੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᴡ㊁⃰)㧦200㧙202(2008 ᐕ 3 ᦬)
55㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ዊఽ᳇▤ᡰ༎ᕷߩᣧᦼ⸻ᢿ࡮ᣧᦼᴦ≮ߩᜰ㊎ߩ૞ᚑߣ⹏ଔ߅ࠃ߮᳇▤ᡰ༎ᕷߦ㑐ߔࠆㆮવሶ⸃ᨆ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ
੐ᬺ ಽᜂ⎇ⓥႎ๔ᦠ ╙ 2 ಽౠ(ᄢ↰⃰)㧦309㧙311(2008 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ㄭ⮮⋥ታ㧦વᨴᕈ⤥∘∐(ߣ߮߭)߳ߩᣂߚߥࠕࡊࡠ࡯࠴‫߭߮ߣޟ‬ᴦ≮‫ࠍ⁁⃻ߩޠ‬⠨߃ࠆ㧦Acuatim
Forum in Gifu ᐳ⺣ળ 6(2006 ᐕ 1 ᦬ 1 ᣣ)
2㧕 ㋈ᧁᐽਯ㧦ጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯(ో࿖౒ห೑↪ᣉ⸳)࡮කቇᢎ⢒ડ↹㐿⊒ቶ㧦කቇᢎ⢒ 37㧦54㧙55(2006 ᐕ 1 ᦬ 1 ᣣ)
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧦‐੃࡮ᄢ⼺ࠕ࡟࡞ࠡ࡯‫ޟ‬㘩ߴߡᴦߔ‫ޠ‬㘩ຠ㐿⊒߳㧦ᦺᣣᣂ⡞(2006 ᐕ 1 ᦬ 13
ᣣ)4㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ㧘කቇㇱ㐳ㄭ⮮ᢎ᝼㧦ጘ㒂ᣂ⡞(2006 ᐕ 1 ᦬ 20 ᣣ)
5㧕 ㄭ⮮⋥ታ㧦ᬌᩏߢ⊒∝੍੍᷹㒐ߦലᨐ㧦⺒ᄁᣂ⡞(2006 ᐕ 2 ᦬ 9 ᣣ)
6㧕 ㄭ⮮⋥ታ㧦ߎߣߒߪߤ߁ߥࠆ㧫⧎☳∝ኻ╷ᦨ೨✢ ᣂ㞲⚵㧦ࠃߺ߁ࠅ࠹࡟ࡆ࠾ࡘ࡯ࠬࠬࠢ࡜ࡦࡉ࡞
(2006 ᐕ 2 ᦬ 24 ᣣ)
7㧕 ㄭ⮮⋥ታ㧦╙ 6 ࿁㘩‛ࠕ࡟࡞ࠡ࡯⎇ⓥળ ࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߦ㑐ߔࠆ⎇ⓥᚑᨐ 㨪‐੃ࠕ࡟࡞ࠡ࡯㨪㉄⚛ಣℂࠍߒߚ‐੃ࡍࡊ࠴࠼ߦࠃࠅ఺∉ኡኈࠍ⺃ዉ㧦Medical Tribune(2006 ᐕ 3 ᦬ 23 ᣣ)
8㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯૕⾰ࠍㆮવሶߢ್ቯ㧦ਛ੩࠹࡟ࡆ࠾ࡘ࡯ࠬࡊ࡜ࠬ 1(2006 ᐕ 3 ᦬
28 ᣣ)
9㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯⚛࿃ߩㆮવሶᬌᩏࠠ࠶࠻ߩ㐿⊒ጘ㒂ᄢቇዊఽ∛ᘒቇ⎇ⓥࡊࡠࠫࠚࠢ࠻⚫੺㧦ጘᄢߩ޿߱߈(2006 ᐕ 4 ᦬ 1 ᣣ)
10㧕 ᷓየᢅᐘ㧦⎇ⓥቶ߆ࠄ㧦ጘ㒂ᣂ⡞(2006 ᐕ 4 ᦬ 4 ᣣ)
11㧕 ኹᧄ⾆⧷㧦ዊఽߗࠎߘߊᴦ≮ᴺࠍ⸃⺑㧦ᦺᣣᣂ⡞(2006 ᐕ 9 ᦬ 25 ᣣ)
12㧕 ㊄ሶ⧷㓶㧦ᢇᕆක≮ߦ߽ᓇ㗀 ஍࿷㧘࿾ၞᩰᏅ⸃ᶖ߇⺖㗴㧦⺒ᄁᣂ⡞(2006 ᐕ 11 ᦬ 8 ᣣ)
13㧕 ㄭ⮮⋥ታ㧦⚵❱࿑㧦ጘ㒂ᄢቇవ┵ഃ⮎⎇ⓥ࠮ࡦ࠲࡯ࡄࡦࡈ࡟࠶࠻(2006 ᐕ 12 ᦬)
14㧕 ㄭ⮮⋥ታ㧦කቇㇱߩ⃻⁁ߦߟ޿ߡ㧦ጘ㒂කቇળ㙚ߛࠃࠅ 82㧘3㧙5(2007 ᐕ 1 ᦬ 1 ᣣ)
15㧕 ㄭ⮮⋥ታ㧦ㇺᏒ஍࿷ ో࿖ࡢ࡯ࠬ࠻ 5 ૏㧦ጘ㒂  ᦺᣣᣂ⡞(2007 ᐕ 1 ᦬ 1 ᣣ)
16㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦ߎߎ߹ߢࠊ߆ߞߚ⧎☳∝⎇ⓥᦨ೨✢㧦NHK ࠨࠗࠛࡦࠬ ZERO(2007 ᐕ 2 ᦬
13 ᣣ)
17㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢߣㅪ៤㧘࿾ၞක≮ᡷༀ㧦ጘ㒂  ጘ㒂ᣂ⡞(2007 ᐕ 2 ᦬ 16 ᣣ)
18㧕 ㄭ⮮⋥ታ㧦㜞ጊߩකᏧਇ⿷ᢇ߃㧦ጘ㒂  ጘ㒂ᣂ⡞(2007 ᐕ 2 ᦬ 17 ᣣ)
19㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧦‫ޟ‬ᕆჇߔࠆࠕ࡟࡞ࠡ࡯ࠍస᦯ߖࠃ㨪⧎☳∝࡮ߗࠎᕷ ᴦ≮ᦨ೨✢㨪‫ޠ‬㧦NHK ࠢ
ࡠ࡯࠭ࠕ࠶ࡊ⃻ઍ(2007 ᐕ 3 ᦬ 8 ᣣ)
20㧕 ㄭ⮮⋥ታ㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯⸳⟎㧦ጘ㒂  ⺒ᄁᣂ⡞(2007 ᐕ 4 ᦬ 25 ᣣ)
21㧕 ㄭ⮮⋥ታ㧦࿾ၞߩකᏧਇ⿷⸃ᶖࠍ ጘ㒂ᄢකቇㇱ ో࿖ೋ ࠮ࡦ࠲࡯㐿⸳㧦ጘ㒂  ਛᣣᣂ⡞(2007ᐕ 4 ᦬ 25 ᣣ)
22㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ㧘කቇ࠮ࡦ࠲࡯ᆎേ‫ޟ‬࿾ၞක≮ࠍᡰ߃ࠆ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬ 25 ᣣ)
23㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇකቇㇱ කᏧਇ⿷⸃᳿ߩಾࠅᧅ㧦ਛ੩࠹࡟ࡆ ࡝ࠕ࡞࠲ࠗࡓ(2007 ᐕ 4 ᦬ 25 ᣣ)
24㧕 ㄭ⮮⋥ታ㧦කᏧਇ⿷⸃᳿ߦක≮࠮ࡦ࠲࡯⸳⟎㧦ጘ㒂᡼ㅍ ᄕ߇ߚደ࠹㧍(2007 ᐕ 4 ᦬ 25 ᣣ)
25㧕 ㄭ⮮⋥ታ㧦⋵࿾ၞක≮ኻ╷ද߇ೋળว㧦ጘ㒂ᣂ⡞(2007 ᐕ 4 ᦬ 27 ᣣ)
26㧕 ㄭ⮮⋥ታ㧦੐ᬺߩ⁁ᴫ ࡒ࡟࠾ࠕࡓ⸥ᔨ⾨ ᦨఝ⑲⎇ⓥ⾨㧦⽷࿅ᴺੱ᫪᳗ᄺ઀ળ ⸳┙ 50 ๟ᐕ⸥ᔨ⹹ 50 ᐕߩ޽ࠁߺ㧘20㧙21(2007 ᐕ 6 ᦬)㧙㧙27㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢ,࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎㧦ᢥᢎᣂ⡞(2007 ᐕ 6 ᦬ 13 ᣣ)
28㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࠍ⸳⟎㧦ᢥᢎ࠾ࡘ࡯ࠬ(2007 ᐕ 6 ᦬ 18 ᣣ)
29㧕 ㄭ⮮⋥ታ㧦කᏧਇ⿷ ⃻႐ߩദജ↢߆ߔ᡽╷ࠍ㧦ਛᣣᣂ⡞(2007 ᐕ 7 ᦬ 9 ᣣ)
30㧕 ኹᧄ⾆⧷㧦ࠕ࡟࡞ࠡ࡯ߣߘߩኻᔕ㧦᧲੩ TBS ࡜ࠫࠝ(2007 ᐕ 8 ᦬ 20㨪24 ᣣ)
31㧕 ㄭ⮮⋥ታ㧦ሶߤ߽ߩஜᐽ ࠹࡯ࡑߦ⻠Ṷ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 12 ᣣ)
32㧕 ㊄ሶ⧷㓶㧦ዊఽᄛ㑆ක≮⠨߃ࠆ කᏧ㧘⋴⼔Ꮷࠄ߇⃻⁁ႎ๔㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 12 ᣣ)
33㧕 ㄭ⮮⋥ታ㧦࿾ၞක≮⏕଻߳⺞ᩏ⎇ⓥ කᏧ㙃ᚑ㧘૕೙ࠍᢛ஻㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 18 ᣣ)
34㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢቇߦ⻠ᐳ㐿⸳ ⋵߇ነ㒝㊄ ࿾ၞߩ૕೙ࠍ⎇ⓥ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 18 ᣣ)
35㧕 ㄭ⮮⋥ታ㧦࿾ၞᨒផ⮈౉⹜ࠍ⺑᣿ ᧪ᐕᐲታᣉߩጘ㒂ᄢቇකቇㇱ㧦ਛᣣᣂ⡞(2007 ᐕ 11 ᦬ 6 ᣣ)
36㧕 ㄭ⮮⋥ታ㧦“ო”⿥߃ੱ᧚߿ࠅߊࠅ කᏧ⏕଻ᦨ೨✢ ਄㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 13 ᣣ)
37㧕 ㄭ⮮⋥ታ㧦ጘ㒂ᄢ‫ޔ‬කቇㇱ࿾ၞᨒផ⮈౉⹜⺑᣿ળࠍ㐿௅㧦ᢥᢎㅦႎ(2007 ᐕ 12 ᦬ 14 ᣣ)
38㧕 ㄭ⮮⋥ታ㧦⃻⁁ᛂ㐿߳ᜰዉකᵷ㆜ කᏧ⏕଻ᦨ೨✢ ਅ㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 15 ᣣ)
39㧕 ㄭ⮮⋥ታ㧦කᏧ⏕଻ߩ㆏ࠍᮨ⚝ ጘ㒂ᄢቇߢࠪࡦࡐࠫ࠙ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 12 ᦬ 16 ᣣ)
40㧕 ᧻੗᳗ሶ㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ੍㒐ߦะߌߚ⢝ౝ࡮⢝ᄖ࿃ሶߩ⸃᣿㧦╙ 56 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળ⑺ቄቇⴚᄢળ Medical Tribune㧚40㧘16(2007 ᐕ 1 ᦬ 4 ᣣ)
41㧕 Ꮉᧄౖ↢㧦̆ࠕ࡟࡞ࠡ࡯∔ᖚߣㆮવሶᄙဳ̆ LTC4S A-444C ߦᄌ⇣ࠍᜬߟ⟲ߢ᳇▤ᡰ༎ᕷߩ᦭∛₸㜞޿㧦╙ 19 ࿁ᣣᧄࠕ࡟࡞ࠡ࡯ቇળᤐቄ⥃ᐥᄢળ․㓸 Medical Tribune㧚2㧘104(2007 ᐕ 7 ᦬ 19
ᣣ)42㧕 ㄭ⮮⋥ታ㧦↢ᵴⅣႺ〯߹߃⸻ᢿ ๮ࠍߟߥߋ࡮ጘ㒂ߩක≮⃻႐߆ࠄ㧦ጘ㒂  ጘ㒂ᣂ⡞(2008 ᐕ 1
᦬ 4 ᣣ)
43㧕 ㄭ⮮⋥ታ㧦ၮ␆කቇ⎇ⓥ㒮↢ߦᅑቇ㊄㧦ጘ㒂  ጘ㒂ᣂ⡞(2008 ᐕ 1 ᦬ 8 ᣣ)
44㧕 ㄭ⮮⋥ታ㧦ၮ␆කቇ⎇ⓥ⠪ᷫዋߦᱤᱛ߼ ጘᄢ߇ኾ᡹㒮↢ߦᅑቇ㊄㧦ጘ㒂  ਛᣣᣂ⡞(2008 ᐕ 1
᦬ 8 ᣣ)
45㧕 ㄭ⮮⋥ታ㧘ᄢ⷏⑲ౖ㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩಽሶ↢‛ቇ ̆⥃ᐥߦ⽸₂ߔࠆᦨㄭߩ⎇ⓥᚑᨐߣㆮવሶᄙ
ဳ̆㧦Medical Tribune㧚41㧘31(2008 ᐕ 2 ᦬ 7 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ✚ว⊛ߦߪߘࠇߥࠅߩ⹏ଔߪߢ߈ࠆ‫੹ޕ‬ᓟ߽ᒁ߈⛯߈⎇ⓥᚑᨐߣᬺ❣ߩᦝߥࠆ⛽ᜬ㧘ะ਄߇ᦸ߹ࠇࠆ‫ޕ‬ᰴ਎ઍࠍᜂ߁⧯ᚻ⎇ⓥ⠪㧘⧯ᚻዊఽ⑼කߩ⢒ᚑߦജࠍ౉ࠇߡ޿ࠆߎߣߪ⹏ଔߦ୯ߔࠆ‫ߦࠄߐޕ‬ᒝൻߒߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᦨᄢߩ໧㗴ὐߪ⎇ⓥቶߩࠬࡍ࡯ࠬ߇⁜ዊߢ޽ߞߚ߇ 2004 ᐕ 4 ᦬ߩකቇㇱ⒖ォ⛔วߦࠃࠅ✭๺ߐࠇߚ‫ޕ‬ᄢቇ㒮ߩ౉ቇߪᲤᐕ 4㨪5 ੱߢ㧘ዊఽ∛ᘒቇߩᄢቇ㒮↢ߪోቇᐕ޽ࠊߖߡᏱߦ 20 ੱ೨ᓟߢ޽ࠆ‫ోޕ‬㗔ၞࠍࠞࡃ࡯ߔࠆዊఽ⑼ߩ⥃ᐥ߆ࠄࠊ߈಴ࠆ⇼໧ߣ࠹࡯ࡑߩోߡߦ⌕ᚻߔࠆߎߣߪ࿎㔍ߢ޽ࠆ߇㧘ࠕ࡟࡞ࠡ࡯࡮఺∉࡮ઍ⻢ߦട߃ߡⅣႺ߿ᗵᨴߣㆮવሶߩࠃ߁ߥᣂߚߥࡊࡠࠫࠚࠢ࠻ࠍ┙ߜ਄ߍߡㅴ߼ߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸ⃻࿷ߩ࠹࡯ࡑߣᣇะᕈߩᦝߥࠆలታߣ᜛ᄢ‫ߦࠄߐޕ‬㧘ߎࠇࠄߩᚑᨐࠍක≮ߦ⋥ធ⊛ߦᔕ↪ߔࠆ㧔࠻࡜㧔࿑ 1㧕ߣోኈ㧔㧔࿑ 2㧕ߣᣂ⡞ႎ㆏㧔࿑ 3㧕ࠍࡦࠬ࡟࡯࡚ࠪ࠽࡞࡝ࠨ࡯࠴㧕‫⃻ޕ‬࿷߹ߢߩ⎇ⓥߩਥߥᵹࠇ㧔࿑␜ߔࠆ‫̌ޕ‬࿾⃿ߣ࿾ၞߦะߌߚఝࠇߚකቇ⎇ⓥ⠪ߣࠃࠅࠃ޿කᏧߩ⢒ᚑߣታ〣̍ࠍ⋡ᮡߦߒߡ޿ࠆ‫ޕ‬

㧙㧙

㧙㧙

㧙㧙

㧔8㧕∛ᘒᖱႎ⸃ᨆකቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕࡝ࡐⰮ⊕ઍ⻢ߣേ⣂⎬ൻࠦ࡟ࠬ࠹ࡠ࡯࡞ૐਅ⮎ߢ޽ࠆ HMGCoA reductase 㒖ኂ೷ߢ޽ࠆ޿ࠊࠁࠆࠬ࠲࠴ࡦ♽⮎೷ߩ೽૞↪ߢ޽ࠆᮮ⚉╭Ⲣ⸃∝ߣㆮવሶᄙဳߣߩ㑐ㅪᕈߦߟ޿ߡᬌ⸛ߒ㧘ߐࠄߦ೽૞↪⊒∝ᯏᐨߩ⸃᣿‫ޕ‬
2㧕ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆ
⒳‫∔ޘ‬ᖚߦ߅ߌࠆⴊᷡࠍ⸃ᨆߒ㧘∛ᘒࠍ෻ᤋߔࠆᣂߒ޿ࡑ࡯ࠞ࡯ࠍ⷗޿಴ߒหቯߔࠆ‫ޕ‬
3㧕⢄Ἳ⊒∝ᯏᐨ
CH-B㧔B ဳᘟᕈ⢄Ἳ㧕ߦ߅ߌࠆ Impaired CTL proligeration ߩᯏᐨߩ⸃᣿㧘෸߮ IDO ߩ⢄Ἳ⊒∝ߦ߅ߌࠆᓎഀ‫ޕ‬
4㧕⢄⚦⢩ࠕࡐ࠻࡯ࠪࠬ߅ࠃ߮✢⛽ൻᯏᐨߦߟ޿ߡ
േ‛ࡕ࠺࡞ࠍ↪޿ߡ㧘ಽሶ↢‛ቇ⊛⷗࿾߆ࠄࠕࡐ࠻࡯ࠪࠬ߅ࠃ߮✢⛽ൻࠍ⹏ଔ‫ޕ‬
5㧕ᔃ╭⚦⢩ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯
ࠝ࡯࠻ࡈࠔࠫ࡯ߩᓎഀߣᔃᯏ⢻ߦਈ߃ࠆᓇ㗀ࠍ⛘㘩߅ࠃ߮ᔃ╭᪪Ⴇࡕ࠺࡞ࠍ↪޿ߡᬌ⸛‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦

ᷡፉ ḩ
દ⮮ᒄᐽ
ᄢỈ㓁੺
㊄᫪ኡల

Mitsuru Seishima
Hiroyasu Ito
Yousuke Osawa
Hiromitsu Kanamori3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷡፉ ḩ㧘᦯ㇱ㜞ᐘ㧘㗇⮮㚅❱㧚࡝ࡐⰮ⊕ߣߘߩಽ↹㧦ਛ੗೑ᤘ✬㓸㧚‫ޟ‬ᬌᩏ୯ߩߺ߆ߚ‫́ޠ‬㧘᧲੩㧦ਛᄖකቇ␠㧧2006 ᐕ㧦173㧙176㧚
2㧕 ᷡፉ ḩ㧘㜞ᯅ㚅ᄹሶ, ᦯ㇱ㜞ᐘ㧚p(a)㧦ਛ੗೑ᤘ✬㓸㧚́‫ޟ‬ᬌᩏ୯ߩߺ߆ߚ‫́ޠ‬㧘᧲੩㧦ਛᄖකቇ␠㧧2006ᐕ㧦177㧙179.
3㧕 ᷡፉ ḩ㧘Ꮭ૒శᵗ, 㜞ᯅ㚅ᄹሶ㧚Lp(a)㧦ਛ੗೑ᤘ✬㓸.́ࠕࡐⰮ⊕ߣߘߩಽ↹́㧘᧲੩㧦ਛᄖකቇ␠㧧2006
ᐕ㧦187㧙189.
4㧕 ᷡፉ ḩ㧘ⁿ⁚ ᷕ㧚ਛේ৻ᒾ✬㧚‫ޟ‬ᮡḰ⥃ᐥᬌᩏකቇ ╙ 3 ‫ޠ‬㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙180.
5㧕 Ỉ᧛ᴦ᮸㧚ਃ㡞ᑝ❥✬㧚ᓸ↢‛ฦ⺰‫ޟ‬Microbial Handbook‫ޠ‬, 㔚ㅢࠨ࠼࡜࡯࡮ࠕࡦ࠼࡮߳ࡀࠪ࡯ᩣᑼળ␠㧧2007 ᐕ㧦5㧙76.
6㧕 ᷡፉ ḩ㧘ᰞᨋ㇚ਯ੺㧚ᾢဈ৻ᚑ⋙ୃ㧚࡝ࡐⰮ⊕ ߶߆ 12 㗄⋡㧘⥃ᐥᬌᩏ㗄⋡ㄉౖ㧘᧲੩㧦කᱤ⮎಴ ᩣᑼળ␠㧧2008 ᐕ㧦237㧙245.
7㧕 ㊄᫪ኡల㧘ᷡፉ ḩ㧚ᔃᯏ⢻ᬌᩏ㧦Ꮟ ౖਯ⋙ୃ㧚✕ᕆኻಣࠟࠗ࠼ࡉ࠶ࠢ㧘㊄⧐ၴ㧧2008 ᐕ㧦163㧙165.
8㧕 ㊄᫪ኡల㧘ᷡፉ ḩ㧚ᔃࠛࠦ࡯㧦Ꮟ ౖਯ⋙ୃ㧚✕ᕆኻಣࠟࠗ࠼ࡉ࠶ࠢ㧘㊄⧐ၴ㧧2008 ᐕ㧦166㧙167.
9㧕 ┻᧛ᱜ↵㧘ᷡፉ ḩ㧚⣲≌ࡑ࡯ࠞ࡯㧦ਅ᧦ᢥᱞ✬㓸㧚ࡔ࠺ࠖࠞ࡞ࡁ࡯࠻‫ޟ‬ᬌᩏߩၮᧄ‫ޠ‬㧘⷏᧛ᦠᐫ㧧2008ᐕ㧦59㧙65.
10㧕 Ỉ᧛ᴦ᮸㧚ᄢቇᬌᩏ⑼ቇኾ᡹ᓸ↢‛ቇᢎຬᙣ⺣ળ✬㧚૕⴫ㇱᗵᨴ∝‫ࠬࡦࠛࠗࠨ࡞ࠞࠖ࠺ࡔޟ‬ᓸ↢‛ᬌᩏቇ‫ޠ‬㧘ㄭઍ಴ 㧧2008 ᐕ㧦269㧙277.
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ⮮၂⧷༹㧘ᢧ⮮㇌᣿㧚࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢㉂⚛ߩ⠡⸶ᓟୃ㘼㧘ᔅ㗇ࠕࡒࡁ㉄⎇ⓥ 2006 ᐕ㧧176 Ꮞ㧦20
㧙26.
2㧕 ᄥ↰ᶈᢅ㧚ᬌᩏઃടଔ୯ᖱႎߩឭଏ㧘ᬌᩏߣᛛⴚ 2007 ᐕ㧧35 Ꮞ㧦479㧙480㧚
3㧕 ┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧚㑐▵࡝࠙ࡑ࠴ᬌᩏ࡮⸻≮ߩᣂዷ㐿㧘Medical Technology 2008 ᐕ㧧36 Ꮞ㧦27㧙30.
4㧕 ᤊ 㓷ੱ㧚⥃ᐥᬌᩏ Yearbook 2008 ৻⥸ᬌᩏ✬㧘⥃ᐥ∛ℂ࡟ࡆࡘ࡯․㓸 2008 ᐕ㧧140 ภ㧦167㧙169.
5㧕 ᄢỈ㓁੺㧘ᧃᰴ ᷕ㧘Ⴆ↰⦟ᒾ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢙▤⚿⚤ߦࠃࠅ⺃ዉߐࠇߚᘟᕈ⢄㓚ኂࡑ࠙ࠬࡕ࠺
࡞ߦ߅ߌࠆࠕࡐ࠻࡯ࠪࠬ₪ᓧᯏᐨ㧘Minophagen medical review 2008 ᐕ㧧53㧦123㧙125.
6㧕 ᷡፉ ḩ㧚․㓸 ․ቯஜ⸻೙ᐲ ․ቯஜ⸻ߦ߆߆ࠊࠆᬌᩏߣᗧ⟵㧘ஜᐽ㘩ຠ▤ℂ჻⹺ቯදળળႎ 2008 ᐕ㧧
3 Ꮞ㧦11㧙20.
✚⺑㧔᰷ᢥ㧕
1㧕 Osawa Y, Nagaki M. Cyclooxygenase-2: its paradoxical roles in liver inflammation and fibrosis.

㧙㧙Hepatol Res. 2008;38:772-774.
ේ⪺㧔๺ᢥ㧕
1㧕 Ꮉἑ᥍⟤㧘೨↰ ቇ㧘ᵢ੗ବᄦ㧘๺↰ਭᵏ㧘ർፉᐽ㓶㧘ᷡፉ ḩ㧚ᔃᜉᄌേ߆ࠄߺߚోりᕈᒝ⊹∝ߩ⥄ᓞ␹⚻ᯏ⢻㧘⥃ᐥ∛ℂ 2006 ᐕ㧧54 Ꮞ㧦325㧙328.
2㧕 Ꮉἑ᥍⟤㧘ᣧᎹᕶᳯ㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘ᷡፉ ḩ㧚╭ࠫࠬ࠻ࡠࡈࠖ࡯ᖚ⠪ߦ߅ߌࠆᔃቶᕈᦼᄖ෼❗ߩ㊀∝ᐲಽ㘃ߣฦ⒳ࡄ࡜ࡔ࡯࠲ᬌᩏ⚿ᨐߩ㑐ଥᬌ⸛㧘කቇᬌᩏ 2006 ᐕ㧧55 Ꮞ㧦639㧙643.
3㧕 ᄢᯅ⪲ᵤᏗ㧘ᄥ↰ᶈᢅ㧘ฎ↰િⴕ㧘⍹ጊߣߒሶ㧘᦯ㇱ㜞ᐘ㧘㐳ደ᣽ᐘ㧘ਣᧄ㓷ᄦ㧘೨↰ᖗม㧘┻᧛ᱜ↵㧘ᷡፉ ḩ㧚࡝ࠦࡦࡆ࠽ࡦ࠻ TP ᛫ේࠍ↪޿ߚ᪢Ქᬌᩏߩᬌ⸛ ́ᣣ┙ 7170 ᒻಽᨆⵝ⟎߳ߩᔕ↪㧘ක≮ߣᬌᩏᯏེ࡮⹜⮎ 2006 ᐕ㧧29 Ꮞ㧦603㧙607.
4㧕 ᄥ↰ᶈᢅ㧘┻᧛ᱜ↵㧘ฎ↰િⴕ㧘ਛየ⌀ℂ㧘ዊᳰ♿ሶ㧘᦯ㇱ㜞ᐘ㧘ᢧ⮮ᄢテ㧘⑺ጊ⋿Ẵ㧘ᷡፉ ḩ㧚㜞ᗵᐲൻቇ⊒శ㉂⚛఺∉᷹ቯᴺߦࠃࠆ interleukin-8 (IL-8) ᷹ቯߩ⥃ᐥ⊛᦭↪ᕈߦߟ޿ߡ㧘කቇߣ⮎ቇ 2006ᐕ㧧55 Ꮞ㧦437㧙442.
5㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚᛫૕⺃ዉࡑ࠙ࠬ㑐▵Ἳࡕ࠺࡞ߦ߅ߌࠆࠨࠗ࠻ࠞࠗ
ࡦߩᄌേ㧘ਛㇱ࡝࠙ࡑ࠴ 2006 ᐕ㧧37 Ꮞ㧦8㧙9.
6㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴⤒㑐▵ਛߩ᛫
CCP ᛫૕᷹ቯߩᗧ⟵㧘⥃ᐥ࡝࠙ࡑ࠴ 2006 ᐕ㧧18 Ꮞ㧦158㧙162.
7㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚⤒㑐▵ᶧਛߩ Cartilage Oligomeric Matrix ProteinỚᐲߩ᷹ቯ㧘ਛㇱ࡝࠙ࡑ࠴ 2006 ᐕ㧧37 Ꮞ㧦76㧙77.
8㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡟࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߣ቟ోᕈ㧘᦭ലᕈߦ㑐ߔࠆᬌ⸛㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦923㧙924㧚
9㧕 ᧻ᯅᑧᄈ㧘౎ᐈ๺ᙗ㧘ᳰ੉↱㚅㧘᪀ේ⑲ᰴ㧘┻᧛ᱜ↵㧘᧛਄໪㓶㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚-Dࠣ࡞ࠞࡦ୯
ࠍᜰᮡߣߒߚᷓ࿷ᕈ⌀⩶∝ߦኻߔࠆࡒࠞࡈࠔࡦࠡࡦߩ᦭ലᕈߩᬌ⸛㧘ᣣ㓸ਛක⹹ 2007 ᐕ㧧14 Ꮞ㧦77㧙
80㧚
10㧕 ᧻Ꮉᵗሶ㧘ችㇱ㜞ౖ㧘Ỉ᧛ᴦ᮸㧘Ყཅ⟤਽ሶ㧘ጊᩮ⺈ਭ㧘ᶆᐩᗲሶ㧘㆙⮮㓉৻㧚⍴ᦼ㑆(6 ᤨ㑆)೨ၭ㙃ߒߚ
Haemophilis influenzae ࠍ⹜㛎ኻ⽎ߣߔࠆో⥄േ⚦⩶ᬌᩏⵝ⟎࡜ࠗࠨࠬߢߩ⮎೷ᗵฃᕈ⹜㛎ߩㆡᱜൻ㧙ⶄᢙᣉ⸳ߢߩ౒ห⹏ଔ㧘⥃ᐥ∛ℂ 2007 ᐕ㧧55 Ꮞ㧦611㧙618㧚
11㧕 ᦯ㇱ㜞ᐘ㧘┻᧛ᱜ↵㧘ട⮮ೣᑝ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘೨↰ᖗม㧘દ⮮ᒄᐽ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㜞ಽ
ሶ㊂ࠕ࠺ࠖࡐࡀࠢ࠴ࡦ᷹ቯߦ㑐ߔࠆၮ␆⊛ᬌ⸛㧘ක≮ߣᬌᩏᯏེ࡮⹜⮎ 2007 ᐕ㧧30 Ꮞ㧦499㧙503.
12㧕 ૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ TNF- ࠍᮡ⊛ߣߒߚ↢‛ቇ⊛⵾೷ᴦ≮㧘Biotherapy 2007 ᐕ㧧21 Ꮞ㧦176㧙180㧚
13㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧚ࠨࠗ࠻ࠞࠗࡦỚᐲ߆ࠄߺߚ㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ
ࠗࡦࡈ࡝ࠠࠪࡑࡉߩ⥃ᐥലᨐ㧘ਛㇱᢛἴ⹹ 2007 ᐕ㧧50 Ꮞ㧦633㧙634㧚
14㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪᔒ㧘ⷺ↰ ᕡ㧘┻᧛ᱜ↵㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡞࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߣ᦭ലᕈ‫ޔ‬቟ోᕈߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴ቇળ 2007 ᐕ㧧38 Ꮞ㧦24㧙25㧚
15㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘ᢪ⮮㇌᣿㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠛ࠲ࡀ࡞࠮ࡊ࠻ߩᛩਈ࿁ᢙ
ߩᬌ⸛㧘⥃ᐥ࡝࠙ࡑ࠴ቇળ 2007 ᐕ㧧19 Ꮞ㧦164㧙169㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J,
Takikawa O, Seishima M, Markey SP. Nitration and inactivation of IDO by peroxynitrite. J Immunol.
2006;176:372-379.
2㧕 Zhu Y, Saito K, Murakami Y, Asano M, Iwakura Y, Seishima M. Early increase in mRNA levels ofpro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global
ischemia. Neurosci Lett. 2006;393:122-126.
3㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasaki S,
and Kondo N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic
children. Pediatr Allergy and Immunol. 2006;17:125-133.
4㧕 Fujigaki H, Saito K, Fujigaki S, Takemura M, Sudo K, Ishiguro H, Seishima M. The signal transducer
and activator of trenscription 1 and interferon regulatory factor 1 are not essential for the inductionof indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein
kinase and nuclear factor-B pathways, and synergistic effect of several proinflammatory cytokines. J
Biochem. 2006;139:655-662.
5㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita M, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor factor receptor 2(sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma.
Eur J Haematol. 2006;77:217-225.
6㧕 Cen X, Nitta A, Ohya S, Zhao Y, Ozawa N, Mouri A, Ibi D, Wang L, Suzuki M, Saito K, Ito Y, Kawagoe
T, Noda Y, Ito Y, Furukawa S, Nabeshima T. An analogue of dipeptide-like structure of FK506
increases GDNF expression through CREB activated by Hsp90/Akt signaling pathway. J Neurosci.
2006;26:3335-3344.
7㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Shen L, Noda Y, Furukawa S,
Nabeshima T. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha㧙㧙

IF 6.068

IF 2.085

IF 2.454

IF 2.020

IF 2.163

IF 7.490

protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry.
2007;61:890-901.
8㧕 Li Y, Takemura G, Okada H, Miyata S, Kanamori H, Maruyama R, Esaki M, Li L, Ogino A, Ohno T,
Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. ANG II type 1A receptor signaling
causes unfavorable scar dynamics in the postinfarct heart. Am J Physiol Heart Circ Physiol.
2007;292:946-953.
9㧕 Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Esaki M, Kanamori H, Li L,Ogino A, Ohno T,
Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Molecular signaling mediated byangiotensin II type 1A receptor blockade leading to attenuation of renal dysfunction-associated heart
failure. J Card Fail. 2007;13:155-62.
10㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Shen L, Noda Y, Furukawa S,
Nabeshima T. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alphaprotects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry.
2007;61:890-901.
11㧕 Kanamori H, Takemura G, Li Y, Okada H, Maruyama R, Aoyama T, Miyata S, Esaki M, Ogino A,
Nakagawa M, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara H. Inhibition of Fas-associatedapoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricularremodeling by olmesartan. Am J Physiol Heart Circ Physiol. 2007;292:2184-2194.
12㧕 Li L, Takemura G, Li Y, Miyata S, Esaki M, Okada H, Kanamori H, Ogino A, Maruyama R, Nakagawa
M, Minatoguchi S, Fujiwara T, Fujiwara H. Granulocyte colony-stimulating factor improves left
ventricular function of doxorubicin-induced cardiomyopathy. Lab Invest. 2007;87:440-455.
13㧕 Takahashi K, Saito K, Masuda J, Fujigaki S, Takemura M, Ito H, Seishima M.Changes in neuronalprotein expression in LP-BM5-infected mice. Neurosci Lett. 2007;422:114-118.
14㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N.Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
15㧕 Niwa M, Nitta A, Yamada Y, Nakajima A, Saito K, Seishima M, Noda Y, Nabeshima T. Tumor necrosis
factor-alpha and its inducer inhibit morphine-induced, Rewarding effects and sensitization. Biol
Psychiatry. 2007;62:658-668.
16㧕 Ogino A, Takemura G, Kanamori H, Okada H, Maruyama R, Miyata S, Esaki M, Nakagawa M,
Aoyama T, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara T, Fujiwara H. Amlodipine inhibits
granulation tissue cell apoptosis through reducing calcineurin activity to attenuate postinfarction
cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:2271-2280.
17㧕 Kimura A, Sakurai T, Tanaka Y, Hozumi I, Takahashi K, Takemura M, Saito K, Seishima M, Inuzuka
T. Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patientwith white matter hyperintensities on brain MRI. Lupus. 2008;17:16-20.
18㧕 Shinohe R, Sato M, Takemura M, Shimizu K, Koishi H , Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type II collagen monoclonal antibody plus
lipopolysaccharide. Jpn J Clin Chem. 2008;37:53-62.
19㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara K, Morita H, Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARgamma and AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.
20㧕 Sakashita F, Osada S, Takemura M, Imai H, Tomita H, Nonaka K, Takahashi T, Seishima M. The
effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. Cancer ChemotherPharmacol. 2008;62:379-385.
21㧕 Maruyama R, Goto K, Takemura G, Ono K, Nagao K, Horie T, Tsujimoto A, Kanamori H, Miyata S,
Ushikoshi H, Nagashima K, Minatoguchi S, Fujiwara T, Fujiwara H. Morphological and biochemical
characterization of basal and starvation-induced autophagy in isolated adult rat cardiomyocytes. Am J
Physiol Heart Circ Physiol. 2008;295:H1599-607.
22㧕 Nakagawa M, Takemura G, Kanamori H, Goto K, Maruyama R, Tsujimoto A, Ohno T, Okada H, Ogino
A, Esaki M, Miyata S, Li L, Ushikoshi H, Aoyama T, Kawasaki M, Nagashima K, Fujiwara T,
Mintoguchi S, Fujiwara H. Mechanisms by which late coronary reperfusion mitigates post infarction
cardiac remodeling. Circ Res. 2008;103:98-106.
23㧕 Okada H, Takemura G, Li Y, Ohno T, Li L, Maruyama R, Esaki M, Miyata S, Kanamori H, Ogino A,
Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. Effect of a long-term treatment with a low dose
granulocyte colony-stimulating factor on post-infarction process in the heart. J Cell Mol Med.
2008;12:98-106.
24㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.
25㧕 Chousa M, Ito H, Saito K, Takahashi K, Takemura M, Takahashi T, Tomita E, Seishima M. The
measurement of serum ceruloplasmin is useful for diagnostic differentiation of immune
thrombocytopenic purpura. Clin Chim Acta. 2008;389:132-138.
26㧕 Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T,㧙㧙

IF 8.456

IF 3.973

IF 3.067

IF 8.456

IF 3.973

IF 4.479
IF 2.085

IF 8.456

IF 3.973

IF 2.248

IF 1.823

IF 2.568

IF 3.973

IF 9.721

IF 6.807
IF 2.218

IF 2.601

Kakumu S, Seishima M. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific
CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol.
2008;20:869-879.
IF 3.290
27㧕 Sudo K, Yamada Y, Saito K, Shimizu S, Ohashi H, Kato T, Moriwaki H, Ito H, Seishima M. TNF-alphaand IL-6 signals from the bone marrow derived cells are necessary for normal murine liver
regeneration. Biochim Biophys Acta. 2008;1782:671-679.
IF 4.0414㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᷡፉ ḩ㧘⎇ⓥಽᜂ⠪㧦ᢪ⮮㇌᣿㧘๺↰ਭᵏ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧
14,400 ජ౞(5,500㧦5,200㧦3,700 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᢪ⮮㇌᣿㧧ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦఺∉ᕈ␹⚻∔ᖚߦ߅ߌࠆᣂߚߥ఺∉೙ᓮ࿃ሶߣߒߡߩ Indoleamine-2,3-dioxygenase ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦┻᧛ᱜ↵㧘⎇ⓥಽᜂ⠪㧦ᷡፉ ḩ㧘ᢪ⮮㇌᣿, ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣㆮવሶᬌᩏࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧧ᐔᚑ 18㧙
19 ᐕᐲ㧧3,500 ජ౞(1,800㧦1,700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢỈ㓁੺㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⢄㓚ኂߦ߅ߌࠆࠬࡈࠖࡦࠧ⢽⾰ࠪࠣ࠽࡞ߩ⢄⚦⢩ߩ↢ᱫ᳿ቯᯏᐨߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(1,800㧦1,500 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦દ⮮ᒄᐽ㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦⢄⚦⢩㓚ኂߦ߅ߌࠆ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢೙ᓮߩ⸃᣿ߣ⢄∔ᖚ߳ߩᴦ≮ᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,050 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦㊄᫪ኡల㧧ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦ᚑ૕ᔃ╭ߦ߅ߌࠆࠝ࡯࠻ࡈࠔࠫ࡯ߩᯏ⢻⊛ߥࠄ߮ߦᒻᘒቇ⊛ᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧1,050 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᷡፉ ḩ, ᢪ⮮㇌᣿㧦ᰴ਎ઍ⥃ᐥᬌᩏᖱႎࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞㧦ᩣᑼળ␠ࠛࠗࠕࡦ࠼࠹ࠖ࡯
2㧕 ᢪ⮮㇌᣿: ᣂⷙ㐿⊒࠺ࡃࠗࠬࠍ↪޿ߚ⥃ᐥࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧100 ජ౞:᧲࡟ᩣᑼળ␠
3㧕 ᷡፉ ḩ㧦ࡉࠪ࡜ࡒࡦߩ૞↪ᯏᐨ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧1,819 ජ౞㧦ෳᄤ⵾⮎ࢃ
4㧕 ᷡፉ ḩ, દ⮮ᒄᐽ㧦࠽ࡁࡇࠕ D ࠳ࠗࡑ࡯⹜⮎߅ࠃ߮ࠦࠕࠣࡇࠕ Fig ⹜⮎ߩၮ␆⊛ᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧180 ජ౞㧦╙৻ൻቇ⮎ຠࢃ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡፉ ḩ㧦
1㧕 ᣣᧄ⥃ᐥᬌᩏකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥൻቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᬌᩏ⥄േൻቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄേ⣂⎬ൻቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥಽሶකቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇⴚផㅴൻᆔຬ(㨪⃻࿷)7㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇળ⾨ᆔຬ(㨪⃻࿷)8㧕 ో࿖࿖┙ᄢቇ∛㒮ᬌᩏㇱળ⼏ᐙ੐(᧲ᶏ࡮ർ㒽ࡉࡠ࠶ࠢ)(㨪ᐔᚑ 18 ᐕ)
9㧕 ᣣᧄ⥃ᐥᬌᩏකቇળቇળ⾨ᆔຬ(㨪⃻࿷)10㧕 ᣣᧄ⥃ᐥൻቇળ࿖㓙੤ᵹᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)㧙㧙

2㧕ቇળ㐿௅ߥߒ
3㧕ቇⴚ㔀⹹ᷡፉ ḩ㧦
1㧕 ක≮ߣᬌᩏᯏེ࡮⹜⮎㧧✬㓸ᆔຬ(㨪ᐔᚑ 18 ᐕ)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡፉ ḩ㧦
1㧕 ౏⋉ା⸤⥃ᐥᬌᩏකቇ⎇ⓥᝄ⥝ၮ㊄ ᐔᚑ 18 ᐕᐲዊ㈬੗ᦸ⾨ฃ⾨⸥ᔨ⻠Ṷળ(2007 ᐕ 2 ᦬㧘᧲੩㧘⸥ᔨ⻠Ṷ‫↢ߩ⊕Ⱞࡐ࡝ࡐࠕޟ‬ℂ⊛ᯏ⢻ߣ∔ᖚߣߩ㑐ࠊࠅ‫ޠ‬Ṷ⠪)
2㧕 ஜᐽ㘩ຠ▤ℂ჻ળਛㇱᡰㇱ⸳┙✚ળ(2007 ᐕ 10 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ߣࡓ࡯ࡠ࠼ࡦࠪࠢ࠶࡝ࡏ࠲ࡔޟ‬㘩↢ᵴ‫ޠ‬Ṷ⠪)દ⮮ᒄᐽ㧦
1㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(2006 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃㨯Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴‫ࠆࠃߦࡦࠪࠠ࠻࠼ࡦࠛ́ޠ‬๭ๆེਇోࡑ࠙ࠬࡕ࠺࡞ߩ㐿⊒‫́ޠ‬Ṷ⠪)2㧕 ஜᐽ㘩ຠ▤ℂ჻ળ ਛㇱᡰㇱ⸳┙⸥ᔨࠪࡦࡐࠫ࠙ࡓ(Ꮢ᳃౏㐿⻠ᐳ)(2007 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ ޟ‬㘩ߩ቟ో࡮቟ᔃߪ቞ࠄࠇߡ޿ࠆ߆㧫‫ޠ‬㧙‫ޟ‬ஜᐽ㘩ຠߩഞ⟋‫⥃ޠ‬ᐥකߩ┙႐߆ࠄஜᐽ㘩ຠࠍ⠨߃ࠆ㧙Ṷ⠪)
ᢪ⮮㇌᣿㧦1㧕 The 11th Meeting of International society for Tryptophan research(2006.06, Tokyo, Physiologicalsignificances of tryptophan-kynurenine pathway metabolism. In CNS Opening remark: What is
the new in the kynurenine pathway in CNS.–In the past, present and future; Speaker)
2㧕 The 6th Korea-Japan Gerontologist Joint Meeting(2006.06, Korea, Oxidative stress,
inflammation and aging: The physiological significance of cerebral indoleamine-2,3-dioxygenase
following transient cerebral ischemia in gerbil; Speaker)
3㧕 ᣣᧄ⥃ᐥൻቇળ᧲ᶏർ㒽ᡰㇱ✚ળ(2006 ᐕ 6 ᦬, ฬฎደᏒ, ࠪࡦࡐࠫ࠙ࡓ‫∛ޟ‬ᘒࠍᝒ߃ࠆ⥃ᐥൻቇᬌᩏߩ New Marker TNF- ߣߘߩ㑐ㅪಽሶࠍ࠲࡯ࠥ࠶࠻ߣߒߚ⥃ᐥࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆ‫ޠ‬Ṷ⠪)4㧕 Recent advances in kynurenine pathway metabolism in CNS. ISTRY 2006, (2006.07, Tokyo,
Significance of IDO in CNS : Inhibition of increased indoleamine-2, 3-dioxygenase activity
exacerbates neuronal cell death in various CNS disorders; Panelist)5㧕 ╙ 1 ࿁⥃ᐥᬌᩏቇᢎ⢒ቇળ(2006 ᐕ 8 ᦬, ᧲੩, ࠪࡦࡐࠫ࠙ࡓ ⥃ᐥᬌᩏᛛᏧᢎ⢒‫߇⑳ޟ‬ᱠ޿ߡ᧪ߚ
㆏ : ⥃ᐥᬌᩏᛛᏧᢎ⢒ߩℂᗐ௝‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 દ⮮ᒄᐽ㧘቟⮮㊂ၮ㧘⍹Ꮉື਽㧘ਛጊବᙗ㧘⼱ญ స㧘ᢧ⮮㇌᣿㧘੗ᑫ㆏ᄦ㧘᫪⣁ਭ㓉㧘ฦോિ৻㧘ᷡፉ ḩ㧦The 5th JSH Single Topic Conference Young Investigator Award (ᐔᚑ 18 ᐕᐲ)
2㧕 ᷡፉ ḩ㧦ዊ㈬੗ᦸ⾨ฃ⾨(ᐔᚑ 19 ᐕᐲ)
3㧕 દ⮮ᒄᐽ㧘ጤᧄ⋥᮸㧘㜞ᯅ㚅ᄹሶ㧘቟⮮㊂ၮ㧘⍹Ꮉື਽㧘ᢧ⮮㇌᣿㧘┻᧛ᱜ↵㧘੗ᑫ㆏ᄦ㧘᫪⣁ਭ㓉㧘ᷡፉ ḩ㧦The 6th JSH Single Topic Conference Best Poster Award (ᐔᚑ 19 ᐕᐲ)
4㧕 ᷰㆺᕡᄦ㧘᫪↰✍ሶ㧘ቝ㊁↱㉿ሶ㧘ᨋ ᕶሶ㧘ᵻ㊁㤗⴩㧘Ꮉἑ᥍⟤㧘ട⮮⟵ᒄ㧘᧻ጟᢅ↵㧘દ⮮ᒄᐽ㧘ᷡፉ ḩ㧦╙ 33 ࿁ᣣᧄ⿥㖸ᵄᬌᩏቇળ YIA(Young Investigator’s Award)ఝ⑲⾨(ᐔᚑ 20 ᐕᐲ)
5㧕 ㊄᫪ኡల㧘┻᧛రਃ㧘ਣጊ⇐⟤㧘ᓟ⮮๺ሶ㧘᧘ 㦖⯥㧘ᷡፉ ḩ㧘Ḋญା਽㧘⮮ේਭ⟵㧦╙ 12 ࿁ᣣᧄᔃਇోቇⴚ㓸ળ YIA(Young Investigator’s Award)ఝ⑲⾨(ᐔᚑ 20 ᐕᐲ)
6㧕 ㊄᫪ኡల㧘┻᧛రਃ㧘Ꮉญᥓೣ㧘┻ጊବᤘ㧘Ꮉ᧛৻ᄥ㧘ᓟ⮮๺ሶ㧘᧘ 㦖⯥㧘⮮ේਭ⟵㧘ᷡፉ ḩ㧘Ḋญା਽㧦╙ 30 ࿁ᔃ╭↢ᬌ⎇ⓥળ⧯ᚻᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
1㧕 ጘ㒂⋵♖ᐲ▤ℂኾ㐷ᆔຬ(ጘ㒂⋵)(㨪⃻࿷)2㧕 ጘ㒂Ꮢ♖ᐲ▤ℂኾ㐷ᆔຬ(ጘ㒂Ꮢ)(㨪⃻࿷)㧙㧙3㧕 ጘ㒂⋵කᏧળ⥃ᐥᬌᩏ♖ᐲ▤ℂᆔຬળᆔຬ(ጘ㒂⋵කᏧળ)(㨪⃻࿷)4㧕 ⥃ᐥᬌᩏᛛᏧ⹜㛎ᆔຬળᆔຬ㐳(ෘ↢ഭ௛⋭)(㨪ᐔᚑ 19 ᐕ 6 ᦬)
5㧕 ⸻ᢿᛛⴚ⎇ⓥផㅴᆔຬળᆔຬ(⽷࿅ᴺੱጘ㒂⋵౏ⴐⴡ↢࠮ࡦ࠲࡯)(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᷡፉ ḩ㧘ᢪ⮮㇌᣿㧘๺↰ਭᵏ㧦2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧘๺↰ਭᵏ㧦2 ᰴర࠽ࡁ LC/MS ࠍ↪޿ߚ⥄Ꮖ఺∉∔ᖚߩ∛ᘒ⸃ᨆࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
3㧕 ๺↰ਭᵏ㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧘┻᧛ᱜ↵㧦ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣ
ㆮવሶᬌᩏࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⎇ⓥᚑᨐ
ႎ๔ᦠ(2006 ᐕ 3 ᦬)
4㧕 ┻᧛ᱜ↵㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧦ࠬ࠲࠴ࡦߦࠃࠆᮮ⚉╭Ⲣ⸃⊒∝ߩࡔࠞ࠾࠭ࡓߩ⸃᣿ߣㆮવሶᬌᩏ
ࠍ↪޿ߚ੍᷹ᴺߩ⏕┙㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⎇ⓥᚑᨐႎ๔ᦠ(2007ᐕ 3 ᦬)
11㧚ႎ㆏
1㧕 ᷡፉ ḩ㧦੺⼔⡯ຬߩࠬ࠻࡟ࠬᢙ୯ൻ㧦ጘ㒂ᣂ⡞(2006 ᐕ 2 ᦬ 24 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥᬺ❣ߪᓟඨߦߥߞߡዋߒࡍ࡯ࠬࠕ࠶ࡊߒߚᗵ߇޽ࠅ㧘૗ߣ߆੍ቯߒߡ޿ߚ⋡ᮡࠍࠢ࡝ࠕߒߚߣᕁ
ࠊࠇࠆ‫ޕ‬ᄖㇱ⾗㊄ߦߟ޿ߡߪ⑼ቇ⎇ⓥ⾌ࠍਛᔃߦ߽߁ዋߒ₪ᓧߔࠆࠃ߁ദജߒߥߌࠇ߫ߥࠄߥ޿߇㧘ቇ
ⴚ⾨ߩฃ⾨߽޽ࠅ㧘ో૕⊛ߦߪ⋡ᮡߦ㆐ߒߚߣ⹏ଔߒ߁ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷ዋੱᢙߩߚ߼㧘㒮↢ߩ⏕଻ߣหᤨߦ޿߆ߦല₸⊛ߥ⎇ⓥࡊࡠ࠻ࠦ࡯࡞ࠍߚߡࠆ߆߇㊀ⷐߥ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ⎇ⓥౝኈߪᄙጘߦࠊߚࠆ߇㧘ߥࠆߴߊઁ⻠ᐳ߅ࠃ߮ઁᣉ⸳ߣߩ౒ห⎇ⓥࠍⓍᭂ⊛ߦⴕ޿㧘ല₸⊛ߥ⎇ⓥࠍ⋡ᜰߒߚ޿‫ޕ‬㧙㧙